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Abstract
Intensity Modulated Radiotherapy (IMRT) and proton therapy are the state-of-art
external radiotherapy modalities. To make the most of such precise delivery, accurate
knowledge of the patient anatomy and biology during treatment is necessary, as unac-
counted variations can compromise the outcome of the treatment. Treatment modification
to account for deviations from the planning stage is a framework known as adaptive ra-
diotherapy (ART).
To fully utilise the information extracted from different modalities and/or at different
time-points it is required to accurately align the imaging data. In this work the feasibility
of cone-beam computed tomography (CBCT) and deformable image registration (DIR)
for ART was evaluated in the context of head and neck (HN) and lung malignancies, and
for IMRT and proton therapy applications. This included the geometric validation of de-
formations for multiple DIR algorithms, estimating the uncertainty in dose recalculation
of a CBCT-based deformed CT (dCT), and the uncertainty in dose summation resulting
from the properties of the underlying deformations. The dCT method was shown to be a
good interim solution to repeat CT and a superior alternative to simpler direct usage of
CBCT for dose calculation; proton therapy treatments were more sensitive to registration
errors than IMRT. The ability to co-register multimodal and multitemporal data of the
HN was also explored; the results found were promising and the limitations of current
algorithms and data acquisition protocols were identified.
The use of novel artificial cancer masses as a novel platform for the study of imag-
ing during radiotherapy was explored in this study. The artificial cancer mass model
was extended to generate magnetic resonance imaging (MRI)-friendly samples. The tu-
moroids were imageable in standard T1 and T2 MRI acquisitions, and the relaxometric
properties were measured. The main limitation of the current tumour model was the
poor reproducibility and controllability of the properties of the samples.
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Chapter 1
Introduction
Living is worthwhile if one can
contribute in some small way to this
endless chain of progress.
Paul Dirac
1.1 Contextualisation of the research project
Radiation therapy stands for the medical use of ionising radiation as part of cancer
treatment. Radiotherapy works by damaging the genetic material of cancerous cells [1].
The treatment is devised such that the prescribed dose is delivered to the tumour while
minimising the dose to the surrounding healthy tissues, and delivered over multiple and
smaller doses over a period time (fractionation) to minimise the negative side effects of
the treatments. Intensity modulated radiation therapy (IMRT) [2, 3] and proton therapy
[4] are the state-of-art external radiotherapy modalities. IMRT and proton therapy deliver
very precise dose maps that minimise the dose to healthy tissues, and therefore the risks
of secondary effects. To make the most of such precise delivery it becomes crucial to
have accurate knowledge of the patient anatomy, biology, and tumour response during
treatment, as unaccounted variations can compromise the outcome of the treatment. A
typical radiotherapy treatment starts with the acquisition of a computed tomography
(CT) scan, which is used to plan an individualised treatment for the patient. CT is the
universal imaging modality in radiotherapy due to its good image quality, volumetric
information, and how it correlates with the dose deposited during the actual treatment.
Thus, a radiotherapy treatment is planned on a “snapshot” of the patient, but is actually
delivered daily over several weeks, based on the (not always correct) premise that the
anatomy is unchanged since the planning stage. During treatment delivery the patient
positioning is verified with image guidance techniques. Image-guided radiation therapy
(IGRT) is a useful tool that can detect and correct random and systematic change errors
Introduction
that occur during treatment delivery [5, 6]. Several imaging techniques can be used, such
as in-room CT, cone-beam CT (CBCT), magnetic resonance imaging (MRI), ultrasound
or planar X-rays. Each technique is associated with costs in terms of machine time and
patient imaging dose [7]. By combining different and complementary medical imaging
modalities it becomes possible to closely monitor the patient’s physical and biological
responses throughout the treatment course. This information can then be used to rapidly
modify the treatment to take in consideration any changes that could impact the final
outcome. This framework is known as adaptive radiation therapy (ART) [8].
1.2 Research question and aims
Even though different imaging modalities provide additional and complementary
information of the patient, their further introduction in the radiotherapy pathway is still
limited by several reasons. Two of the major challenges in modern radiotherapy are
how to combine the information that different imaging modalities at different time points
provide in a comprehensive way, and how to use all this information in the best possible
way to improve patient outcome.
The answer these questions, this project focuses on two main aims:
1. Development of in-house tools to facilitate the integration of different imaging
modalities into ART workflows for clinical investigation. This aim is broken down
into the following technical objectives:
• Investigate and optimise the use of deformable image registration (DIR) for
the alignment of CT, CBCT and MRI images, in the context of head and neck
(HN) and/or lung malignancies.
• Proposing and applying methodologies to validate the use of DIR for the clin-
ical applications of contour propagation, dose recalculation and summation.
• Implementation of the ART workflows as prototype in a research platform tool.
2. Development an in vitro tumour model (tumoroid) that can be used for multimodal
and sequential imaging studies, and therefore act as a test subject that provides pre-
clinical evidence of the benefits of incorporating additional imaging information in
radiotherapy. This objective is broken down into the following technical objectives:
• Design specifications and procedure development to achieve MRI-friendly
samples.
• Design of the experimental setup of pre-clinical MRI sessions of the tumoroids.
• Preliminary characterisation of the relaxometric properties of the tumoroids.
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1.3 My contribution to this work
This research project is in the field of Medical Physics, particularly IGRT and ART, and
is part of a collaboration effort across various and interdisciplinary research groups. The
following institutions and departments were involved in this collaboration:
• Proton and Advanced RadioTherapy Group, Department of Medical Physics &
Biomedical Engineering, London, United Kingdom (UK)
• Centre of Medical Image Computing (CMIC), Department of Medical Physics &
Biomedical Engineering and Department of Computer Science, University College
London (UCL), London, UK
• Radiotherapy Physics Department, University College London Hospital (UCLH),
London, UK
• Radiotherapy Department, UCLH, London, UK
• Centre for Advanced Biomedical Imaging (CABI), UCL, London, UK
• Division of Surgery and Interventional Science, UCL, London, UK
• Ion Beam Applications, SA (IBA), Louvain-la-Neuve, Belgium
• Department of Radiation Oncology, Hospital of the University Pennsylvania (HUP),
United States of America (USA)
The different areas of research are listed below, along with my particular contribution
to each one:
Clinical needs in radiotherapy: I was part-time based at the Radiotherapy Physics and
Radiotherapy departments at UCLH from the beginning of this project to understand the
clinical needs of HN and lung patients. This included observing the clinical IMRT treat-
ment pathway, learning about how to use two treatment planning systems (Eclipse and
RayStation) for ART applications, and practical sessions on proton treatment planning.
During the time I completed my research project in UCLH multimodal imaging was
not used in ART applications, so to fill gaps in knowledge due to lack of in-house expertise,
I attended the “Multimodal imaging towards individualized RT treatments” SUMMER
consortium summer school in Delft, The Netherlands (July 2014).
Proton beam therapy centres are currently being developed at UCLH and The Christie
(Manchester), and will start treating patients from 2018. Therefore, this is still a growing
area in the UK and the expertise is still very limited. To further specialise in this area, I
attended the NPL PPRIG Proton Workshop in London, UK (March 2014). This workshop
was very valuable to learn about the different areas of research in proton therapy, and
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was an unique opportunity to understand the need of image guidance in proton therapy
directly from experts in the field.
I was also responsible for organising a visit to the Centre of Protonthérapie d’Orsay
(Orsay, France) to establish research links with this institution (December 2014).
Finally, I have spent 6 months at Roberts Proton Center at the HUP (Philadelphia,
USA) in collaboration with IBA (April to September 2015). I had a privileged role in the
development and evaluation of the world’s first CBCT system for adaptive lung proton
therapy. During my stay I also participated in several clinical activities, including proton
therapy patient specific and machine quality assurance.
Computational medical imaging tools: NiftK was the main research tool used in this
project, and it was developed by computer scientists at CMIC; NiftyReg is the open-source
DIR tool available as part of the NifTK project. My work is in the interface between theo-
retical/technical developments and clinical usage, and my contributions include applying
technologies developed by computer scientists to clinical applications, modifying outputs
to a language that can be interpreted by the treatment planning system (TPS) available
clinically, implementing an accessible framework that will spark the clinicians’ interest,
providing validation protocols that answer their concerns, and highlighting the benefits
of translating this new technology to the clinic. As part of this process, I was also closely
involved in testing cutting-edge improvements of the software tools, identifying and
reporting malfunctioning of the code, and assessing its performance and relevance for
different applications.
In the context of my placement at the University of Pennsylvania, I was invited to IBA
headquarters (Louvain-la-Neuve, Belgium) where I stayed for a week (March 2015) and
was introduced to the iMagX project. I was trained to be competent in the in-house DIR
tools developed at IBA (REGGUI), which I independently used and further developed
during the whole placement.
Tissue Engineering: I was part-time based at the UCL Division of Surgery and Inter-
ventional Sciences from September to November (2013) to be trained on the basics of
cell culture techniques and tissue engineering. I learnt the protocol for the production of
the artificial tumour model, and identified the limitations of the model for multimodal
and sequential imaging. I worked very closely with Tong Long (Division of Surgery and
Interventional Sciences, UCL) to design a tridimensional (3D) phantom more adequate
for such applications. The samples used in the experimental work of this thesis were
manufactured by my colleague, but the sample optimisation and imaging experiments
were designed by me.
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Pre-clinical imaging: I was responsible for setting a collaboration link with CABI to
access their pre-clinical MRI scanner for experimental sessions. Dr. Bernard Siow was
the responsible for the scanner and for the optimisation of the acquisitions during the
experiments. I was responsible for designing and preparing the experimental setup, was
trained to independently operate the MRI scanner, and analysed the resulting imaging
data.
1.4 Novelty of this work
Research efforts are being focused in developing reliable workflows to incorporate
additional imaging as part of the clinical radiotherapy pathway. Several aspects of the
work presented in this thesis are novel:
• While the concept of using CBCT and DIR for ART for HN patients itself was first
investigated by Yang et al. [9] and Peroni et al. [10], this was the first time the
uncertainties associated with dose calculations and dose warping were reported.
Particularly, in the context of proton therapy this was, simultaneously with the work
of Landry et al. [11, 12], one of the first studies assessing the clinical implications of
CBCT and DIR based dose calculations.
• This thesis reports the first clinical use of on-board CBCT for adaptive proton therapy
for lung cancer. This included the proposition of a novel adaptive therapy workflow,
based on a fast decision online followed by a more careful oﬄine review. This
workflow was benchmarked both in terms of clinical indicators generated, and on
the uncertainties associated with the approximations used.
• On a more technical aspect, several points of this work were novel. Different
gold-standards for the validation of CT-to-CBCT registration were proposed. Addi-
tionally, NiftyReg had not been previously validated in the HN region for different
image modalities (CT, CBCT, and MRI), or validated specifically for ART appli-
cations. A new method to deal with missing image information for CBCT dose
calculations was proposed, which was adequate for the HN region. Finally, a cor-
rection method was employed to deal with the limitations of deformable registration
regarding non-deformable changes the thoracic region.
• The idea of developing a tumour model tailored for MRI is novel, and so is the
tumour model engineered toward this application. This was the first attempt to
acquire images of the artificial cancer masses on pre-clinical MRI system and to
quantify its relaxometric properties.
The work presented in this thesis resulted in the following peer-reviewed journal
papers:
• (In preparation) C. Veiga, G. Janssens, T. Baudier, L. Hotoiu, S. Brousmiche, J. R.
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McClelland, C.-L. Teng, L. Yin, G. Royle, and B.-K. K. Teo, “The accuracy of CBCT
and deformable registration for adaptive lung proton therapy” (2016).
• C. Veiga, G. Janssens, C.-L. Teng, T. Baudier, L. Hotoiu, J. R. McClelland, G. Royle,
L. Lin, L. Yin, J. Metz, T. D. Solberg, Z. Tochner, C. B. Simone II, J. McDonough, and
B.-K. K. Teo, “First clinical investigation of CBCT and deformable registration for
adaptive proton therapy of lung cancer,” Int. J. Radiat. Oncol. Biol. Phys. 95(1)
549-559 (2016).
• C. Veiga, J. Alshaikhi, R. Amos, A. M. Lourenço, M. Modat, S. Ourselin, G. Royle,
and J. R. McClelland, “CBCT and deformable registration based “dose of the day”
calculations for adaptive proton therapy,” Int. J. Particle Ther. 2(2) 404-414 (2015).
• C. Veiga, A. Lourenço, S. Moinuddin, M. van Herk, M. Modat, S. Ourselin, D.
D’Souza, G. Royle, and J. R. McClelland, “Toward adaptive radiotherapy for head
and neck patients: uncertainties in dose warping due to the choice of deformable
registration algorithm,” Med. Phys. 42(2) 760-769 (2015).
• C. Veiga, J. McClelland, S. Moinuddin, A. Lourenço, K. Ricketts, J. Annkah, M.
Modat, S. Ourselin, D. D’Souza, and G. Royle, “Toward adaptive radiotherapy
for head and neck patients: feasibility study on using CT-to-CBCT deformable
registration for “dose of the day” calculations,” Med. Phys. 41 031703 (2014).
1.5 Impact of this work
The work conducted was truly collaborative and multidisciplinary; thus it had impact
beyond the content explicitly exhibited in this thesis:
Clinical tools for DIR: The tools developed throughout this project were implemented
in a friendly way in clinical research settings, and are currently being used at the De-
partment of Radiotherapy Physics (UCLH) and Radiation Oncology (HUP) to monitor
patients that may benefit from treatment adaptation.
Adaptive lung therapy for photon therapy: Following the studies performed on the
context of HN malignancies for photon/proton therapy at UCLH and for lung at HUP, I
collaborated with Alison Cole (Department of Radiotherapy Physics, UCLH) to extend
the work performed on HN to lung malignancies in the context of photon therapy at
UCLH. This work resulted in the following output:
• A. J. Cole, J. R. McClelland, C. Veiga, U. Johnson, D. D’Souza, and M. Bidmead,
“Toward adaptive radiotherapy for lung patients: Feasibility study on deforming
planning CT to CBCT to assess the impact of anatomical changes on dosimetry,”
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Proceedings of the 18th International Conference on the Use of Computers in Ra-
diotherapy (London, UK, 2016).
Range verification for eye proton therapy based on proton-induced x-ray emissions
from implanted metal markers: Due to my computational skills and expertise of proton
therapy, I was part of a team consisting of members from UCL and Centro de Adroterapia e
Applicazioni Nucleari Avanzate (CATANA) proton source at the Istituto Nazionale Fisica
Nuclear - Laboratori Nazionali del Sud (INFN-LNS) (Catania, Italy), which operated to
collect experimental data in April 2013 [13].
Validation of clinical acceptability of an atlas-based segmentation algorithm for the
delineation of organs at risk in head and neck cancer: I collaborated with Albert
Duanc (CMIC, UCL) to facilitate the transfer of data between NifTK and the clinical
systems for validation of automatic segmentation in the HN, and provided expertise into
the validation of the application for clinical use. This work resulted in the following
output:
• A. K. Hoang Duc, G. Eminowicz, J. McClelland, M. Modat, M. J. Cardoso, A. F.
Mendelson, C. Veiga, T. Kadir, D. D’Souza, and S. Ourselin, “Validation of clinical
acceptability of an atlas-based segmentation algorithm for the delineation of organs
at risk in head and neck cancer,” Med. Phys. 42(9) 5027-5034 (2015).
Synthesising CT from MRI data: I collaborated closely with Dr. Albert Duanc (CMIC,
UCL) on a synthetic CT project based on atlas registration, and ran preliminary analysis
on the clinical performance of the method [14]. The preliminary results obtained were
promising, and therefore a collaboration group was formed with the Institute of Cancer
Research, that within the MRI-linear accelerator (LINAC) project was developing treat-
ment planning on MRI. I provided expertise in the optimisation of DIR for registrations
of images of the HN region, and how to clinically validate the dose calculations. This
work resulted in the following output:
• N. Burgos, M. J. Cardoso, F. Guerreiro, C. Veiga, M. Modat, S. Ourselin, J. Mc-
Clelland, A.-C. Knopf, S. Punwani, D. Atkinson, S. R. Arridge, B. F. Hutton, and
S. Ourselin, “Robust CT Synthesis for Radiotherapy Planning: Application to the
Head & Neck Region”, Proceedings of the 18th International Conference on Medical
Image Computing and Computer Assisted Intervention (Munich, Germany, 2015).
Six degrees-of-freedom couch quality assurance in clinical settings: I provided exper-
tise in image registration and research/commercial system integration to generate syn-
thetic rotated phantoms for quality assurance of the new six degrees-of-freedom couch at
the Radiotherapy department, UCLH. This is now being used clinically.
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Development of oxide contrast agents: The tools developed to quantify the relaxomet-
ric properties of the tumour models from the data extracted from the pre-clinical magnetic
resonance (MR) system at CABI were modified for other application. This project was
conducted by Nicholas Hobson and Xian Weng Jiang (School of Pharmacy, UCL) and
consisted of developing oxide contrast-agents for cancer detection and drug delivery.
This work resulted in the following outputs:
• (In preparation) N. Hobson, X. Weng-Jiang, C. Veiga, B. Siow, M. Ashford, N. T.
K. Thanh, A. Schätzlein, and I. Uchegbu, “Design and synthesis of self-assembling
polymeric iron oxide nanoparticle theranostics for applications in cancer diagnostics
and cancer therapy,” ACS Nano (2016).
• (In preparation) X. Weng-Jiang, N. Hobson, C. Veiga, B. Siow, N. T. K. Thanh, A.
Schätzlein, and I. Uchegbu, “Aqueous in-flow synthesis of superparamagnetic iron
oxide nanoparticles for dual T1/T2-weighted magnetic resonance imaging,” ACS
Nano (2016).
1.6 Structure of this thesis
The current chapter consisted of a brief introduction to the research context where this
thesis is inserted, detailing the research questions, novelty and personal contribution to
the work. The structure of the remaining of the thesis resulted from grouping its contents
in two major lines of research, described and justified in the following paragraphs.
The first line of research of this thesis, consisting of chapters 2 to 7, presents very
focused and coherent studies into the same common global topic of the use and validation
of DIR in ART applications. This research line was motivated by clinical needs from the
Radiotherapy Department at UCLH. Chapter 2 introduces the theoretical concepts of
cancer radiobiology, image registration, and the clinical problems tackled in this context.
It also includes all the preliminary work conducted regarding the optimisation of DIR,
and the identification of strategies for its validation for clinical applications. Building
on this introduction, the following chapters evaluate the use of image registration for
different and sequential applications. Chapter 3 is focused on the use of DIR for contour
propagation and “dose of the day” calculations for HN malignancies and in the context
of IMRT treatments. Then, this work was extended to the study of dose warping and
summation in chapter 4, and to proton therapy in chapter 5. The work of these three
chapters builds up the expertise that culminates in chapter 6, where a clinical adaptive
therapy workflow based on CBCT and DIR was implemented, thoroughly validated
and clinically investigated in the context of lung proton therapy. Finally, in chapter 7
preliminary work on co-registration of multimodal (CT and MR) imaging was reported.
The focus on MRI instead of CBCT on this chapter creates a bridge with the work presented
in the following chapter.
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The second line of research consists of the final chapter (chapter 8), in which the
development of an in vitro artificial cancer mass (ACM) for multimodal and multitemporal
imaging experiments was investigated. The methods and materials used in this chapter
differ substantially from those used in the previous chapters (i.e., computational methods
and patient data versus experimental methods and in vitro data). In the previous chapters,
two of the major technical difficulties found while conducting the studies presented was
the limitations of the readily available clinical data (both in acquisition protocols and size
of the cohorts), and the difficulties in defining ideal gold-standards for DIR validation
based on patient models. Those two points are the reason why this study is presented at
the end of this thesis, and in conjunction with excellent collaboration links with the UCL
Division of Surgery, constitute the motivation behind the use of controllable in vitro data.
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Chapter 2
The role of deformable image
registration in adaptive radiotherapy
I learned very early the difference
between knowing the name of
something and knowing something.
Richard Feynman
This chapter introduces the role of image registration in ART and NifTK, the main
software tool used in the project. The word described here allowed to identify strategies
for the validation of DIR for radiotherapy applications, as well as developing of the tools
needed for its in-house clinical translation.
The work in this chapter resulted in the following outputs:
• C. Veiga, J. McClelland, S. Moinuddin, K. Ricketts, M. Modat, S. Ourselin, D. D’
Souza, and G. Royle, “Towards adaptive radiotherapy for head and neck patients:
validation of an in-house deformable registration algorithm,” J. Phys.: Conf. Ser.
489 012083 (2014).
• S. Moinuddin, P. Davies, R. Bodey, C. Veiga, R. Mendes, D. D’Souza, G. Royle and
I. Rosenberg, “Adaptive re-planning for H/N IMRT: How to choose when to do it!”
IPEM: Adaptive radiotherapy (Leeds, United Kingdom, 2013).
• C. Veiga, J. McClelland, S. Moinuddin, K. Ricketts, D. D’Souza, and G. Royle,
“Deformable registrations for head and neck cancer adaptive radiotherapy”, Im-
age Guidance and Multimodal Dose Planning in Radiation Therapy Workshop of
the 15th International Conference on Medical Image Computing and Computer
Assisted Intervention (Nice, France, 2012).
The role of DIR in ART
Figure 2.1: Direct and indirect actions of radiation [1].
2.1 An introduction to cancer radiobiology
Cancer begins when a cell breaks free from the normal restraints on cell division
and begins to follow its own agenda for proliferation [15]. In order to fully understand
cancer treatment using radiotherapy, an understanding of the biology of the tumour
microenvironment and biological effects of radiation is necessary.
The biological effects of radiation result principally from damage to the deoxyribonu-
cleic acid (DNA), which is the critical target in radiotherapy. The radiation is known to
interact in two distinct pathways: (1) direct action, i.e., the radiation interacts directly
with the DNA molecule, and (2) indirect action, i.e., the radiation interacts with the water
inside the cell producing free radicals that interact with the DNA (Figure 2.1). About two-
thirds of the biological damage caused by x-rays results from indirect action. The timeline
of physical/chemical and biological effects are of very different orders of magnitude. The
physics of the absorption process is 10−15s; the chemistry takes 10−5s for the reactions
between DNA and free radicals; the biology takes hours, days or months for cell killing
[1]. In radiobiology, cell death is defined as the process that leads to permanent loss of
reproductive capacity which includes several mechanisms. The most common process in
radiotherapy is mitotic death, but other mechanisms such as apoptosis, autophagy, necro-
sis, and senescence are also possible responses [16]. The prevalence of each mechanism
differs between different types of normal and tumour cells.
The tumour microenvironment consists of the cancer cells, normal cells, structural
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support given by the extracellular matrix (ECM) and secreted soluble factors that regulate
the growth and signalling between cells. Hence, the complexity of the in vivo system
causes a non linear relationship between physical dose and biological effect. The biological
consequences of DNA damage are complex and influenced by pathways within the
DNA damage response system, which determines the likelihood of the cells dying after
irradiation and the type of cell death that occurs. Depending on the severity of the damage
caused by a single irradiation, this damage may be irreversible and irreparable, leading
to cell death (i.e., lethal damage). However, if the damage is not lethal the cells have
mechanisms of DNA repair and may be able to recover for sublethal damage. Tumour
cells are known to have lost the ability of repair damage, and thus are in general more
sensitive to irradiation than normal tissue. Moreover, biological effects that are not related
with direct dose delivery also occur, as irradiated cells signal nearby unirradiated cells
that also exhibit response to radiation (bystander effect) [17].
Several factors are known to influence the radiosensitivity of human cells (i.e., the
biological outcome will differ when the same physical dose is delivered):
• Cell cycle: cells are more sensitive to radiation depending on the phase of their cell
cycle (Figure 2.2) [18]. Between cell cycle phases checkpoints exist, such that dam-
aged normal cells stop progressing through the cycle to attempt to repair damage.
Abnormalities in the genetic material of cancer cells interfere with the repair mech-
anisms, and the cells progress to mitosis anyway leading to mitotic catastrophe. In
general, cells are more sensitive to radiation during the mitotic phase as repair is
not possible at this point.
• Oxygenation: aerobic cells are generally more radiosensitive than hypoxic cells;
• Proliferation: the higher the rate of proliferation, the greater the radiosensitivity;
• Differentiation: undifferentiated cells are more radiosensitive than differentiated
cells.
Therefore, and considering the biological mechanisms of dose response, two param-
eters are of utmost importance when devising a radiotherapy treatment: dose rate and
fractionation. Radiation-induced cell death is directly proportional to dose rate. How-
ever, both normal and tumour cells show this increased radiosensitivity, hence high dose
rates are rarely used to improve radiotherapy outcome. Dose is then delivered in fractions
for the following reasons: (1) it allows for re-oxygenation of previously hypoxic tumour
areas (Figure 2.3), (2) permits the redistribution of cells in the cell cycle, increasing the
proportion of cancer cells in more radiosensitive phases of the cell cycle on the next radio-
therapy fraction; and (3) normal cells exhibited higher rates of repair than tumour cells,
and hence are given time to recover from radiation damage and repopulate. The schemes
of fractionation used in the clinic are based on empirical data and convenience [1, 19].
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Figure 2.2: (a) Cell cycle phases: gap 0 (G0), gap I (G1), synthesis (S), gap II (G2) and mitosis (M). (b)
Variation of radiosensitivity with the phase of the cells in the cell cycle [18].
Figure 2.3: Tumours contain a mixture of aerated and hypoxic cells. Irradiation kills a greater fraction of
aerated than hypoxic cells, leaving mostly hypoxic cells surviving. Given time reoxygenation occurs, and
the distribution of aerated/hypoxic cells returns to pre-irradiation state. This allows to successfully target
previously radioresistant hypoxic cells. Adapted from [1].
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Figure 2.4: Key items of any image registration algorithm: transformation model, similarity metric,
optimisation method and validation protocol [20].
2.2 An introduction to image registration
The ability to fully utilise the information extracted from images acquired with different
modalities and/or at different time-points relies on the accuracy to align the multiple
sources of information. Image registration is the process of aligning different sets of
data into a single coordinate system. It can be used to find the corresponding anatomical,
biological or functional locations between two or more images. Depending on the specific
application, it can be divided based on if the subject is the same or not for the different
images (intra-subject or inter-subject registration), or by taking in consideration if the
images being registered are of the same modality or not (monomodal or multimodal
registration).
The key items of an image registration algorithm are summarised in Figure 2.4, and
will be discussed in further detail in the following sections.
2.2.1 Transformation Model
Image registration results in a mathematical transformation T that maps every point
in a source (or floating) image to the corresponding point in a target (or reference) image.
T : (x, y, z)→ (x′, y′, z′) (2.1)
There are several transformation models, ranging from quite simple, like rigid and
affine transformations, to more complex, like deformable transformations.
A rigid transformation in three dimensions involves the rotation and translation in
the three different Cartesian axes. An affine transformation combines rigid alignment
with scaling and shearing. Rigid and affine transformations are usually applied in the
registration of anatomical structures like the brain and bones. However, when significant
deformation is expected, like in soft tissue, such simple transformations do not properly
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characterise the deformation of the tissue. In situations like this non-rigid (or deformable)
transformations are used. There are a plethora of DIR algorithms available in the liter-
ature, which can be divided into parametric methods (B-splines [21], linear elastic finite
element method [22], etc.) and nonparametric methods (viscous fluid [23], Demons [24],
etc.).
Free-form deformations (FFDs) are a popular type of DIR algorithm. The basic idea
is to deform an object by deforming the space around it, that is, by manipulating a
3D parallelepiped lattice containing the object. This manipulated lattice determines a
deformation function that specifies a new position for each point in the object [25]. The
original FFD scheme was based on trivariate Bernstein polynomials [26], but tri-variate B-
splines tensor products are used nowadays [25, 27]. The use of FFD based on B-splines was
first proposed by Rueckert et al. for the registration of contrast-enhanced breast MRI [21].
Spline-based transformations are based on the assumption that a set of corresponding
control points (CPs) can be identified in the source and target images. At the CP position
the spline-based transformations interpolate or approximate the displacements, which are
necessary to map the location of the CP in the target image to its corresponding counterpart
in the source image. Between CPs, they provide a smoothly varying displacement field.
The local control properties of B-splines make them computationally efficient even for a
large number of CPs, and the continuity of the transformation is guaranteed when any
CPs are moved [28], as only the local neighbourhood of that CP is affected [21].
To define a B-spline based FFD, the domain of the image volume is defined as Ω =
{(x, y, z)|0 ≤ x < X, 0 ≤ y < Y, 0 ≤ z < Z}, and Φ is a nx × ny × nz mesh of control points φi, j,k
with spacing δ. Then, the FFD can be written as a 3D tensor of the unidimensional (1D)
cubic B-splines.
Tlocal =
3∑
l=0
3∑
m=0
3∑
n=0
Bl(u)Bm(v)Bn(w)φi+l, j+m,k+n (2.2)
where i = bx/δxc − 1, j = by/δyc − 1, k = bz/δzc − 1, u = x/δx − bx/δxc, v = y/δy − by/δyc,
w = z/δz − bz/δzc and Bl is the lth basis function of the B-spline [25, 27].
B0(u) = (1 − u)3/6 (2.3a)
B1(u) = (3u3 − 6u2 + 4)/6 (2.3b)
B2(u) = (−3u3 + 3u2 + 3u + 1)/6 (2.3c)
B3(u) = u3/6 (2.3d)
2.2.2 Similarity metric
The registration looks to find correspondences of voxel intensities in the field-of-view
(FoV) of the images, and the algorithm will maximise some measure of similarity. The
similarity metric measures globally or locally the degree of alignment between the images
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registered (i.e., how well the images are matched to each other). For monomodal regis-
trations, images of similar histogram content are registered by establishing a relationship
between pixel intensities, while for multimodal registrations the assessment of pixel sim-
ilarities is replaced by the likelihood of a pixel position being occupied [29]. Some of the
most popular measures of similarity are described below:
• Sum of the squared differences (SSD)
SSD =
1
N
N∑
i
(A(i) − B(i))2 (2.4)
where N is the number of voxels in the region of overlap.
• Normalised cross correlation (NCC)
NCC =
∑
(A(i) − A¯)(B(i) − B¯)√∑
(A(i) − A¯)2 ∑(B(i) − B¯)2 (2.5)
where A¯ and B¯ are the average intensities of the two images.
• Normalised mutual information (NMI), which is based on the information content,
or entropy, of the images:
NMI(A,B) =
H(A) + H(B)
H(A,B)
(2.6)
The entropy H(A) of an image A is:
H(A) = −
∑
a∈A
p(a) log p(a) (2.7)
where p(a) is the probability that a voxel in image A has intensity a. The joint entropy
H(A,B) of the overlapping region of images A and B is
H(A,B) = −
∑
a∈A
∑
b∈B
p(a, b) log p(a, b) (2.8)
where p(a, b) is the joint probability that a voxel in the overlapping region of A and
B has values a and b.
Both SSD and NCC assume that both image modalities have the same intensity char-
acteristics. If the images are correctly aligned, the different between them should be zero
except for the noise produced. Such measures can be calculated globally (i.e., over the
whole common FoV) or localised (i.e., over a specified neighbourhood of the pixel). An
example of such a measure is the localised normalised cross correlation (LNCC).
NMI is based on the notion of the marginal and joint probability distributions of the
two images, and therefore is adequate for multimodal applications. It can be estimated
by using histograms whose bins count the frequency of occurrence (or co-occurrence) of
intensities. Dividing these frequencies by the total number of voxels yields the estimate
of the probability of that intensity.
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2.2.3 Optimisation
Optimisation in image registration aims at (1) maximising the similarity of the images
and (2) minimising the cost associated with particular transforms. Thus, a cost function
is defined as the sum of the measure of similarity and constrains, added to stop the
registrations from being ill-posed (i.e., having no unique or stable of solution). The
constraints act as a regularisation of the transformation.
In clinical applications, it is commonly accepted that the local deformation of soft tissue
should be characterised by a smooth transformation. A B-spline FFD can be constrained
to be smooth by introducing a 3D penalty term that regularises the transformation. A
popular constrain is the bending energy penalty term (BE) [21]:
BE =
∫ ∫ ∫
Ω
(∂2T∂x2
)2
+
(
∂2T
∂y2
)2
+
(
∂2T
∂z2
)2
+ 2
(∂2T∂xy
)2
+
(
∂2T
∂xz
)2
+
(
∂2T
∂yz
)2
Other penalty terms can be used to constrain the registrations, such as the logarithm
of the Jacobian determinant penalty term (JL):
JL =
1
n
∑
| log (det(∇T)| (2.9)
The Jacobian determinant has an important physical meaning: det(Jac)=1 means that
there is no volume change, while det(Jac)<1 is a compression and det(Jac)>1 an expansion.
Negative det(Jac) is in general unwanted since it means that the pixel disappears (a
process also known as folding). JL penalises the regions where the algorithm tries to do
extreme contractions or expansions, and enforces one-to-one mapping in the resulting
transformation.
The cost function is maximised using an optimisation algorithm. Popular choices of
algorithms are the gradient descend and conjugate gradient methods. Such algorithms
require the gradient of the cost function, so faster implementations are possible when this
can be calculated analytically.
2.2.4 Symmetry, inverse-consistency and diffeomorphisms
In image registration at least two input images are necessary, the source and the target
images, and the result is a transformation (Ts→t) that can be used to deform the source
image (s) onto the target image (t). Therefore if Ts→t exists, the transformation in the
opposite direction (Tt→s), which can be used to deform the target image onto the source
image, can also be defined. The majority of the research and commercial registration
algorithms are unidirectional, which means they only optimise and generate the forward
transformation (Ts→t) and do not consider the transformation in the opposite direction
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(Tt→s). For applications where Tt→s is also required one can simply use a unidirectional
algorithm twice, by switching the roles of the source and the target images, numerically
estimate the inverse of Ts→t, or use bidirectional algorithms that optimise Ts→t and Tt→s
simultaneously.
In clinical applications, DIR can be used to model the spatial anatomical mapping
between time points, therefore physically plausible transformations may be desirable for
applications where the underlying deformation is important. Two concepts are associ-
ated with physically plausible deformations: inverse-consistency and symmetry. Inverse-
consistent registrations try to ensure that Tt→s is the mathematical inverse of Ts→t (i.e.,
Tt→s = T−1s→t). Symmetric registration means that identical transformations are obtained
when the roles of source and target images are switched: if the source image becomes
the target (t′, such that t′ = s), and the target is now the source (s′, such that s′ = t),
a symmetric algorithm will ensure that Tt′→s′=Ts→t and Ts′→t′=Tt→s. The two concepts
are usually intertwined in the literature, but are not equal as a symmetric algorithm is
not necessarily inverse-consistent (i.e., Ts′→t′ is not guaranteed to be T−1t′→s′), and vice-
versa. The differences between symmetry and inverse-consistency are more clear when
considering unidirectional algorithms, since most bidirectional algorithms that aim to
guarantee inverse-consistency are also symmetric. For example, when performing two
unidirectional registrations, one in each direction, the resulting transformations are sym-
metric but not inverse-consistent (switching the source and target results in the same the
transformations on opposite directions). If Tt→s is obtained by numerically estimating the
inverse of the final registration result (Ts→t) the transformations are inverse-consistent,
but are not symmetric (estimating the inverse of the opposite transformation does not
produce the same result as running the unidirectional registration in that direction).
Another commonly stated requirement for DIR is to have diffeomorphic transfor-
mations, i.e., deformations that are invertible, differentiable and whose inverse is also
differentiable [30]. Diffeomorphic transformations maintain the topology and guarantee
that connected subregions of an image remain connected, neighbourhood relationships
between structures are preserved, and surfaces are mapped to surfaces [31]. A diffeomor-
phic transformation implies invertibility in the sense that T−1 is defined. However not all
diffeomorphic registration algorithms explicitly generate T−1.
In recent years advanced and complex registration algorithms have been developed
to be symmetric, inverse-consistent and diffeomorphic. One approach consists in using
the inverse-consistency error (ICE) to create a inverse-consistency penalty term (IC) [31]:
IC =
∑
x∀R
||TFw(TBw(x))||2 +
∑
x∀F
||TBw(TFw(x))||2 (2.10)
While this encourages inverse-consistency, it can reduce the ability to recover large
and complex deformations, and the forward and backward transformations are only
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approximate inverses to each other [32]. A better, but less add-hoc, approach is to use
a stationary velocity field to parametrise the transformation [33]. In large deformation
models the displacement field u is generated via a time dependent velocity field,
u(x, y, z, 1) =
∫ 1
0
v(u(x, y, z, t))dt (2.11)
with u(x, y, z, 0) = (x, y, z). This can be used to generate the deformation field in either
the forward or backward direction, and these are guaranteed to be exact inverses of each
other (subject to methodological approximation and numerical precision). The resulting
transformation provides a smooth one-to-one (invertible) mapping.
2.2.5 Evaluation and validation of deformable image registration
Evaluation and validation are two steps of major importance to image registration;
however, this is not incorporated as part of the software tools and in-house strategies are
necessary. Evaluation and validation are necessary to quantify the performance and to
show the suitability of the algorithms for the desired medical application. There are many
criteria to take in consideration for the evaluation and validation of an image registration
technique. These can involve the following and more [20]:
• technical criteria: is the technique fast, robust, accurate and reliable?
• application criteria: is the technique user-friendly and useful for daily clinical prac-
tice?
• legal criteria: does the technique have potential to be used in commercial systems?
2.2.6 In-house software: NifTK
NifTK software was developed by CMIC, at the Department of Medical Physics &
Bioengineering of UCL (http://cmic.cs.ucl.ac.uk/home/software). The software is an on-
going project, with regular updates and new functionalities being implemented, and
contains several tools for image registration and visualisation. It combines a set of different
toolkits, including the open-source NiftyReg for rigid and deformable registration (Table
2.1), and a viewer (NiftyView).
The affine registration implemented in NiftyReg uses a Block Matching-based ap-
proach [34]. The default DIR is a standard unidirectional graphics processing unit (GPU)
implementation of the popular B-spline FFD algorithm using NMI as similarity measure
[21]. The major differences from the original work by Rueckert et al. are in the calculation
of the gradient and joint histogram, introduction of other penalty terms, and the GPU
implementation, which make the code faster and more robust [35]. Recently more so-
phisticated (bidirectional, symmetric and inverse-consistent) implementations have been
incorporated in the software. An inverse-consistent symmetric [36] and a stationary
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Table 2.1: Functionalities implemented in NiftyReg.
Command Tools implemented
reg_aladin Rigid/affine registration algorithm
reg_f3d Deformable image registration algorithm
reg_jacobian Computation of the Jacobian matrix, Jacobian determinant and logarithm
of the jacobian determinant of a deformation field
reg_resample Resampling of images after applying input transformations
reg_transform Conversion between control points and deformation/displacement fields
Composition of transformations
Inversion of affine transformations and deformation fields
Update the header of an image to incorporate affine transformation
velocity field transformation model implementations [37] became more recently freely
available. NiftyReg also features a numerical estimation of the inverse of a deformation
vector field (DVF), which uses an iterative method to estimate each vector of the inverse
DVF independently using the simplex algorithm. It is similar to other published imple-
mentations [38, 39] but was independently developed and implemented by Dr Marcel
van Herk (Netherlands Cancer Institute) for this particular project. This algorithm was
also implemented in the GPU.
The different algorithms implemented in NiftyReg have similar implementations with
different underlying desirable properties. While in the standard and symmetric imple-
mentations the transformation at the CPs are directly optimised, in the stationary velocity
fields the control points are used to parametrise a stationary velocity field, from which
the final transformation is computed through exponentiation.
NiftyReg allows its users the flexibility of defining the parameters of the DIR algorithm.
This allows to fully customise the registrations to the particularities of the datasets and
application. Table 2.2 describes the most relevant parameters the user is free to tune when
performing DIR. SSD, NMI and LNCC are available as similarity measures; BE, JL and IC
are some of the available penalty terms.
2.2.6.1 Data transfer between NifTK and clinical systems
Clinical imaging datasets are formatted in the form of Digital imaging in communi-
cations in medicine (DICOM). DICOM is a standard protocol to handle, store, print and
transmit information in medical imaging and it includes a file format definition (.dcm
extension) [40]. A DICOM file saves not only the pixel matrix that forms the actual image,
but also information that uniquely defines its origin (i.e., scanner, institution, operator,
patient information).
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Table 2.2: Deformable image registration parameters that the user can specify in NiftyReg.
Flag Definition
Inputs and outputs
-ref Filename of the reference image
-flo Filename of the floating image
-cpp Filename of the output control point grid
-res Filename of the resampled image (registration result)
-rmask
-fmask Filenames of the mask image in the reference/floating space
-aff Filename which contains an input affine transformation
Input image options
–rLwTh
–fLwTh Lower threshold to apply to the reference/floating image
–rUpTh
–fUpTh Upper threshold to apply to the reference/floating image
B-Spline options
-sx
-sy
-sz Grid spacing at highest resolution level along the x/y/z axes
-sym Use the symmetric implementation of the B-Spline algorithm*
-vel Use the diffeomorphic implementation of the B-Spline algorithm*
Regularisation options
-be Weight of the bending energy penalty term
-jl Weight of the logarithm of the Jacobian determinant penalty term
-ic Weight of the inverse-consistency penalty term*
Similarity measures
–rbn Number of bin to use for the reference/floating image histogram
–fbn (normalised mutual information is the default similarity measure).
–lncc Define localised normalised cross correlation as similarity measure,
and the standard deviation of the Gaussian kernel*
–ssd Define sum of the squared differences as similarity measure
Optimisation options
-maxit Maximum number of iterations per level
-ln Number of resolution levels
-lp Number of the first resolution levels that will be performed
* These parameters were only implemented until more recent versions
of the software became available and therefore were not fully investigated until
chapters 4 and 5.
54
The role of image registration in image guidance and adaptive radiotherapy
NifTK uses as default Nifti format to communicate data, a simplified imaging format
developed for research purposes. It is therefore necessary to convert DICOM to Nifti to
use the registration package, and NiftyView had the tools necessary for this. The opposite
conversion, Nifti to DICOM is more complex as DICOM stores more of information than
Nifti, and was not available in the NifTK package. As an auxiliary and necessary step
for this project, I wrote MATLAB code to convert images, structures and doses from Nifti
to DICOM format that were compatible with the UCLH clinical TPS. This technical work
proved to be very useful to other projects I contributed to outside the scope of this thesis.
2.2.7 Other registration algorithms
Even though most of the work conducted in this thesis used NiftyReg as DIR tool,
in chapter 6 other DIR softwares were also investigated: REGGUI and the commercial
version of DIR in RayStation (RaySearch, Stockholm, SE) TPS. The REGGUI DIR package
uses a diffeomorphic Morphons algorithm, a nonparametric method using a phase-based
approach. The principle of the method is to match transitions (between dark and bright
zones) by looking locally at the spatial oscillations in intensities. This method uses
Gaussian smoothing as regularisation of the displacement field and additive accumulation
during the iterative process [41]. The DIR algorithm in RayStation 4.5 is hybrid free-
form registration that uses a multi-resolution approach and an intensity based similarity
measure.
2.3 The role of image registration in image guidance and adap-
tive radiotherapy
One of the main challenges in clinical radiotherapy is to position the patient in every
fraction of the treatment exactly as he was imaged for planning, and make sure he stays
in that position during the beam-on time. The steeper the dose gradients, the more
important it becomes to precisely position the patient and its internal anatomy [42]. The
clinical consequences of inaccuracy include both potential underdosage of the target
volumes (resulting in increased risk of tumour recurrence) and potential overdosage of
normal tissues (resulting in increased risk of complications) [43]. Setup errors, inter- and
intra-fraction organ motion/deformation should be characterised, controlled, and taken
into account [44]. IGRT is a useful tool that can detect and correct random and systematic
errors that occur during treatment delivery.
The current paradigm of a radiotherapy treatment starts with the acquisition of a CT
scan, which is used to plan individualised treatment for the patient. The treatment is then
delivered in many fractions over several weeks, based on the premise that the anatomy
is unchanged since the planning stage. However, it is well known that patient’s anatomy
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can vary within a fraction, with swallowing and respiratory motion [45], and from fraction
to fraction, with changes in bladder/bowel filling and tumour shrinkage [46]. The concept
of ART was first suggested by Yan et al., and can be described as a closed-loop feedback
process that suggests a change of paradigm in radiotherapy [8]: the stationary anatomy
is replaced by a variable anatomy, by utilising daily imaging in the radiotherapy process
[47].
ART is a very broad subject and full clinical implementation requires further devel-
opments in computational power, image guidance, dose verification and plan adaptation
[47, 48]. Repetitive and daily imaging plays a vital role in ART, and the information
retrievable depends on the systems available in the clinic. Of all the systems available,
CBCT is an increasingly popular in-room imaging method that provides valuable 3D in-
formation of the patient in treatment position. The image quality of CBCT is consistently
inferior to CT in soft tissue contrast, Hounsfield unit (HU) consistency and artefacts [47,
49, 50]. For example, the CBCT values vary with the size of the imaged volume, and in
result the image intensities in the upper thorax area are in general lower than in the neck
area [11]. The lower quality of CBCT imaging limits its direct utilisation to assess the
current plan and modify it if necessary.
It is widely accepted that the future of ART depends on the use of DIR algorithms
[51–53]. DIR provides a solution for the major challenges in ART: the planning computed
tomography (pCT) can be deformed to match the daily anatomy (from in-room imaging,
such as CBCT) to calculate the dose delivered per fraction [9], the deformations can be
applied to propagate contours [10, 54], and the fraction by fraction dose maps can be
warped back to a common reference frame for summation [55, 56].
2.3.1 The clinical problem: head and neck
The definition of HN malignancies covers a heterogeneous group of cancers, which
includes paranasal and sinonasal cancer, and cancer of the salivary gland, lip, oral cavity,
pharynx and larynx [57]. The annual incidence of the cancer of the oral cavity, pharynx
and larynx is approximately 147500 in Europe. This represents 4.6% of all cancer cases,
accounting for 63400 deaths [58]. It is considered a complicated cohort to treat with
radiotherapy due to the complex geometry of the HN region, and close proximity of organ-
at-risks (OARs) such as the spinal cord, brainstem, parotid glands and optic structures.
HN is a clear example of a patient cohort known to benefit from ART, and therefore
the focus of clinical research. Several studies show that HN patient’s anatomy can change
considerably during the course of the treatment [43, 59–61], and that this results in
dosimetric changes from the original plan [46, 62–68]. It is clear that some patients
require at least one replan [46, 56, 69–73], but it is not clear which benefit the most from
ART and when is the right time for intervention.
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HN patient data was used in the initial phase of this project to explore and opti-
mise NiftyReg DIR (this chapter). Follow-up studies on the clinical applications were
investigated in chapters 3, 4, 5 and 7.
2.3.2 The clinical problem: lung
Lung cancer is the leading cause of cancer-related death in the USA and worldwide.
There are two major types of lung cancers: small cell lung cancer and the more predomi-
nant non small cell lung cancer. In 2015, the National Cancer Institute estimated 220000
new cases and 158000 deaths for both men and women in the United States, with a 5-year
survival rate of only 17.4% [74].
The overall low survival rate of lung cancer led to new treatments that aimed to
improve local and locoregional controls, such as radiation dose escalation [75, 76]. How-
ever, when delivering higher dose with curative intent, both the dose delivered and
the expected tissue toxicity must be considered, with lung itself often being the most
dose-limiting organ at risk [77–79]. To limit risks of radiation-induced injuries to normal
tissues such as lungs, heart, oesophagus and cord, higher tumour doses are not always
achievable [80].
Intra-fractional changes are the most researched aspect of lung tumours [81–83]. In
lung radiotherapy several planning and delivery strategies have been developed to con-
sider and reduce the effects of motion. Four-dimensional (4D)-CT is acquired with the
patient free-breathing, and the planning is conducted on an average CT resulting from
all the phases of the 4D-CT. The gross tumour volume (GTV) then is delineated on all
the frames and the planning GTV consists of the union of all motion phases, which after
expanded by the margin for suspected microscopic disease forms the internal clinical
tumour volume (iCTV). In some cases, the intensity of the target in the average-CT is
replaced by the maximum intensity projection (MIP), i.e., the voxel of greatest value from
all corresponding voxels over the respiratory cycle. During delivery several approaches
are suggested to mitigate or compensate for the effects of motion, such as breath-hold,
jet-ventilation, gating, and beam tracking. However other inter-fractional changes dur-
ing the course of radiotherapy may also affect the dose delivered to target and healthy
tissues [84, 85]. These factors include, but are not limited to, changes in tumour size and
position, alterations in tissue anatomy, variations in respiratory patterns, and fluctuations
in patient weight [86].
The lung cohort will be the focus of interest of chapter 6.
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2.4 Initial studies: optimisation of NiftyReg
Before clinical use, any DIR algorithm should be validated within the context of
the specifications of the desired implementation, the clinical environment (modalities,
image quality, sites) and user-defined parameters [47]. This section describes the studies
performed at the beginning of this project, to familiarise with the concepts and software
tools. It also allowed to understand the problems associated with the evaluation and
validation of DIR.
In this preliminary study a large range of NiftyReg parameters were investigated on
two HN datasets to find a set of promising parameters of DIR to use in CT-to-CBCT
studies. This process generates a deformed CT (dCT), that matches the geometry of the
CBCT. Ideally, DIR should be used automatically in clinical applications. Therefore a set
of parameters was investigated such that it gave good results (but not necessary optimal)
for each dataset by minimising the computation time and keeping acceptable values for
the similarity measures. Since high values of similarity measures do not necessarily
mean a better registration the analysis is aided with visual assessment of the registered
images and corresponding deformed grids. Additionally, analysing the deformation itself
besides the deformed image is very important to assess if the transformations are well
regularised (Figure 2.5). Understanding the underlying performance of the algorithm is
fundamental before translating DIR to clinical applications.
2.4.1 Choice of registration parameters and algorithms
Different user-defined parameters of NiftyReg were extensively studied in this section
(see Table 2.2). This included the effect of the initialisation (i.e., initial rigid alignment),
masking (i.e., ignore regions of the image during optimisation), CP grid size, penalty
terms, similarity measures and implementations of the B-spline algorithm.
Rigid only transformations were applied to describe the global alignment between
CT and CBCT, as it is an intra-subject registration. Mask usage in the rigid registration
improved the global alignment results and reduced significantly the computation time.
Ignoring the last level of resolution has no visual effect if masks are used, which reduces
the computation time even further. The rigid registrations took approximately 1 minute
to compute. The rigid registration algorithm has other parameters that can be tuned.
When the datasets are well aligned to begin with, and no large rotations are necessary,
the remaining default parameters are adequate. A rigid-only registration could not fully
capture all the changes that occur in the HN region (Figure 2.6); thus, DIR was necessary.
Regarding the deformable registration,
1. Good results were achieved when using a control point spacing (CPS) between 5 and
10 voxels. For lower values it is difficult to sufficiently constrain the registration and
the algorithm loses the ability to capture bigger deformations. It is appropriate to
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Figure 2.5: Importance of well constrained registrations. Example of (a) source and (b) target images, and
a (c) under-constrained and (d) well-constrained transformation. The under-constrained registration may
be more similar to the target image, but physically implausible deformations are occurring. For applications
where the underlying deformation is important such deformations are not adequate. Courtesy of Dr Jamie
McClelland.
Figure 2.6: Saggital slices of the CBCT, registered image and difference image between the two. The
first column refers to a rigid-only transformation, and the second to the deformable transformation. Grey
areas show where the CBCT and registered image disagree. Even though the anatomy of the head and
neck is conventionally considered rigid, a rigid-only registration cannot fully capture all the changes. A
rigid registration shows considerable disagreement in the bone and external contours alignment. Using
deformable registration the matching is improved. Near the throat there are still discrepancies due to
swallowing.
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first find the value of CPS that captures the deformation, and then tune the weight
of the penalty terms accordingly. Using voxels instead of mm to define the CPS
made the automated process more foolproof, i.e., if the resolution of datasets varied
between patients without the user realising, it could result in using more CPs than
voxels, leading to over-parametrisation of the registration.
2. The similarity measure used for CT-CBCT registration was the NMI (equation 2.6).
Tests conducted with SSD as similarity measure showed that it did not perform well
due to the intensity differences between CT and CBCT images. On a later stage of
this project, LNCC became available as well, and proved to be more appropriate
for monomodal and quasi-monomodal registrations. This similarity measure was
used in chapters 5 and 7.
3. The similarity measure used may also have specific parameters to be tuned. In the
case of NMI, the number of bins used in the joint histogram calculations is used and
was found to affect the overall results. Unexpectedly, increasing the number of bins
did not seem to increase the computation time but degraded the final registration.
It is possible that a higher binning value makes the code more sensitive to noise in
the images. Also, CBCT intensity values for the same type of tissue may vary in
different areas of the image; thus, smaller binning intervals may lead to the same
tissue being separated in different bins on different zones of the image. Considering
NMI values and visual assessment, a binning between 32 and 128 was acceptable in
all tests done. When using LNCC as measure of similarity, the user can define the
standard deviation of the Gaussian kernel used to assess the pixel’s neighbourhood.
Studies performed for the optimisation of DIR for chapters 5 and 7 suggest a value
within the interval [8, 20].
4. Values of BE within the interval [0.01, 0.10] appeared to produce acceptable results.
For these two datasets the best visual results were produced by a narrower range
([0.02, 0.06]). Low values of BE resulted in higher NMI similarity values (Figure
2.7), but visually the alignment could be incorrect .
5. In general, using JL only causes dramatic visual changes for low values of BE, where
unrealistic deformations such as folding are more likely to occur. The introduction
of this parameter smoothed the effect that other parameters changes had. Thus
values within [0.01, 0.10] seemed like a good compromise between constrain of the
transformation and stopping folding from occurring. Besides contributing to the
cost function, the use of JL prompts a folding correction scheme to the final DVF.
6. A thresholding may be advisable to remove “padding” values (voxels with intensi-
ties less than -1000 HU) and to deal with high-intensity artefacts. The thresholding
conducted showed no improvement in image alignment and computation time.
However, since the effect of threshold is similar to the effect of increasing the bin-
ning of the joint histogram, for thresholding to have a positive effect the choice of
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binning had to be adjusted properly. Further testing showed that using a threshold-
ing of [-1000 2000] combined with a smaller binning of 32 seemed to improve the
external contours and bony anatomy.
7. Reducing the maximum number of iterations reduces the computation time by
forcing the algorithm to finish before it reaches a convergence value. Overall was
a good compromise to use a maximum of 1000 iterations at, which limited the
maximum computation time to approximately 5 minutes on CT-CBCT datasets.
8. NiftyReg implements a multi-resolution approach, and the number of levels can be
defined by the user. Since the datasets were well aligned to begin with, changing
the number of levels of resolution did not bring great changes in NMI, computation
time and visual quality. Three resolution levels were appropriate for the datasets
available.
9. The choice of rigid registration parameters does have an impact in the following
deformable registration. In general, initialising the deformable registration with
a better rigid alignment reduces the time spent to reach convergence (Figure 2.8).
The final results were visually similar while overall the NMI value was slightly
improved.
10. Masking the reference image in the deformable transformation reduced the compu-
tation time to 1 minute, but made the registrations more sensitive to other parame-
ters.
11. The symmetric inverse-consistent algorithms were still in development during the
initial stage of this project. Both this and the stationary velocity fields implemen-
tations were further studied from chapter 4 onward. These two implementations
were more robust to unrealistic deformations which allowed to reduce the weight
of the regularisation terms in comparison to the default asymmetric algorithm.
2.4.2 Image pre-processing to improve registration quality
As a follow-up of the preliminary study, the impact of image pre-processing (to reduce
noise and enhance contrast) on the registration quality was investigated. Other authors
suggested that noise reduction and image contrast enhancement could improve the regis-
tration accuracy and convergence speed [55, 87, 88]. With SSD as similarity measurement
one expects pre-processing to contribute for a better registration. However with NMI
that may no longer be the case, as the registration is less sensitive to the actual intensity
values.
Lu et al. suggested the application of an “edge-preserving filter” to the CBCT image
prior to the deformable registration, to take in consideration the differences between the
modalities and to minimize their effect in the resulting transformation [55]. Conventional
denoising techniques, such as Gaussian smoothing, tend to blur the sharp boundaries
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Figure 2.7: Decreasing of the normalized mutual information (NMI) value with increasing value of the
penalty terms: bending energy (BE) and logarithm of the determinant of the Jacobian (JL).
Figure 2.8: Computation time as a function of bending energy penalty term (BE) using different initial
rigid alignments. Mask stands for initialisation where a mask was used during the rigid registration, which
resulted in better initial alignment.
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Figure 2.9: Transformation applied by gamma correction for different gamma values.
within the image. Such filter is not appropriate for DIR as loosing information at bound-
aries will degrade the registration. An anisotropic diffusion filter however attempts to
smooth very little at sharp boundaries and smooth more when no boundaries are present.
This is achieved by modifying the classic diffusion equation into the following form [89]:
∂I(x, t)
∂t
= div[g(||∇I||)∇I] (2.12)
where ∇I is the image gradient and ||∇I|| is the gradient magnitude. g(||∇I||) is the “edge-
stopping” function. In the limit where g(||∇I||) is a constant, equation (2.12), becomes the
classic diffusion equation (and a Gaussian smoothing is applied). A possible option for
the “edge-stopping” function is as follows [89]:
g(||∇I||) = e− ||∇I||
2
2k2 (2.13)
The diffusion is slowed or even stopped in the edges, where the image gradient is large
(limx→∞ g(x) = 0). The parameter k controls the sensitivity of the smoothing process. If
a small value is used, large amplitude noise may be preserved, while if a large value is
used image detail is lost.
In gamma correction the intensity values are mapped to a specified range, so that the
intensities can be better distributed on the histogram. Depending on the value of gamma
(G) the mapping can be linear or non-linear. G can take any value in the interval [0,
∞[. If G=1 the mapping is a linear transformation. However if G <1 the mapping is
weighted toward higher (brighter) output values, and if G>1 the mapping is weighted
toward lower (darker) output values (Figure 2.9).
The effects of the following pre-processing techniques in the DIR were investigated:
• Edge-preserving smoothing, using a 3D implementation based on Gerig et al. [90];
• Intensity adjustment, using MATLAB (MathWorks, Natick, MA, USA) Image En-
hancement toolbox.
The following values were tested: k={0, 50, 100, 150} and G={1.0, 1.5, 2.0}. G>1 make
a better use of the dark region of the spectrum to better differentiate soft tissues. If G>2.0
the image would get too dark and information from lower intensities was lost. The range
G=[1, 2] seems to have a good compromise between contrast and tissue information.
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Visual assessment and variation of NMI for different pre-processing processes showed
that:
• Edge-preserving filtering: Visually there were not relevant changes between using
pre-processing or not. Most of the differences were within the soft tissue region, and
therefore harder to evaluate with visual inspection. In some areas the alignment
seemed to be better, while in others the opposite occurs. Smaller values of k also
seem to be a better option, since some deformations start to appear for k=150. The
changes in NMI using edge-filtering were negligible.
• Gamma correction: While a value of G=2.0 seems to degrade the registration, a
smaller value as G=1.5 seems to improve the registration results, particularly in the
bony alignment and external contours.
Gamma correction was a viable option to improve the registrations by pre-processing
the reference image, while edge-preserving filtering had an impact on the final registration
but it was hard to quantify if there was a benefit or not using visual inspection. The pre-
processing methods studied did not seem to improve the computation time.
2.5 Optimisation of NiftyReg for CT to cone-beam CT de-
formable image registration
In section 2.4 the user-defined parameters available in NiftyReg were explored, and a
large range of parameters that provided suitable visual matching of the registrations was
found. NiftyReg DIR was found to be fairly robust as small changes in the parameters
did not cause dramatic changes in the registration results, particularly when the Jacobian
penalty term was used.
For rigid registrations the best results were achieved using a mask and ignoring the
last level of resolution. The optimal parameters found for the DIR were: BE=[0.02, 0.06],
CPS=[0.01, 0.10], 3 levels of resolution, a maximum number of 1000 iterations, a binning
of 32 for the joint histogram calculation, thresholding the intensities to the range [-1000,
2000] and a CPS between 5 and 10 voxels. Such registrations can took up to a maximum
of 5 minutes to finish; using a mask this time was reduced to less than 1 minute. Pre-
processing the CBCT image with non-linear intensity adjustment could also improve the
registrations.
In this section the aim was to narrow the large range to a single set of parameters
that performs well over all the datasets available, and identify strategies to quantitatively
evaluate and validate DIR results.
64
Optimisation of NiftyReg for CT to cone-beam CT deformable image registration
2.5.1 Methods and Materials
2.5.1.1 Patients data acquisition
Data from five HN patients that were identified as potential candidates for replanning
and referred for dosimetric assessment at UCLH was used in this study. The referral
happened when the spinal canal or brainstem was found outside their respective planning
organ at risk volume, their external contour had decreased more than 5 mm and/or the
immobilisation mask was no longer effective.
This cohort had therefore large anatomical variations, and was a challenging dataset
for DIR which contained only patients that would benefit from CBCT and DIR-based
ART.
All patients underwent IMRT with a planned dose of 65 Gy delivered in 30 daily
fractions. Patient positioning was assured by appropriate head-rest and a personalised
HN and shoulder mask.
The imaging protocol consisted of a pCT (GE Widebore 16 slice system, GE Healthcare,
Little Chalfont, UK) with contrast injection, and weekly CBCTs (On-board imaging v1.4,
Varian Medical Systems, Palo Alto, CA, USA) acquired in treatment position. The CBCTs
were acquired in half-fan mode, full rotation, 110 kVp, 20 mA, 20 ms, with a maximum
FoV of 45 cm in diameter and 16 cm in length. Imaging resolution was 0.977×0.977×2.5
mm3 and 0.879×0.879×2 mm3 for the CT and CBCT scans, respectively.
2.5.1.2 Registration settings
Four different parameter settings and/or were compared: (i) different BE (3% and 5%),
(ii) different CPS (5 and 10 voxels), (iii) pre-processing of the CBCT and, (iv) masking, giv-
ing a total of 16 registrations per dataset. The remaining parameters were kept constant,
and matched those described in section 2.5.
2.5.1.3 Contours comparison
Registrations were compared qualitatively, by visual inspection, and quantitatively,
by computation time and similarity of warped structures with a gold-standard. The
deformation field resulting from the registration can be used to map points and regions
of interest delineated in the pCT dataset to the CBCT dataset. Structures delineated in the
pCT were warped and compared with contours manually drawn by the same physician
on the CBCT. Due to the noise and low contrast inherent to CBCT imaging, it is difficult
to define points or delineate structures with confidence and consistency. The features
were chosen to be structures that could be unequivocally identified in both scans and that
gave an indication of how well the registration accounts for patient positioning errors and
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Figure 2.10: Structure set manually delineated on the CT and CBCT of each patient.
weight loss. Vertebrae C1, C4 and C7 were considered as bone landmarks for different
regions, while external body and sternocleidomastoid muscles, right sternocleidomastoid
muscle (RSCM) and left sternocleidomastoid muscle (LSCM), were chosen as surrogates
for soft tissue (Figure 2.10). The structure set was delineated in all datasets by Syed
Moinuddin (Department of Radiotherapy, UCLH).
Vertebrae C1, C4 and C7 were used because they are only subject to rigid motion
(i.e., they do not deform), and cover the length of the cervical spinal canal. External
body contour, RSCM and LSCM were used as soft tissue structures. The two muscles are
adjacent to the region that contains the neck lymph nodes. Deformation between scans
may affect their shape and position, and therefore nodal dose [91].
Considering that A and B are the set of voxels that define the volumes of the manual
and deformed features while A˜ and B˜ define the corresponding surfaces, four metrics
were used to describe the similarity between the features:
• Dice similarity coefficient (DSC), which describes the overlapping ratio between
two volumes of interest.
DSC =
2|A ∩ B|
|A| + |B| (2.14)
• Overlap index (OI) can be used as an additional measure of volume overlap to
consider one as a gold-standard, since DSC does not allow preference between two
volumes [51]. The manual contours are the gold-standard (A):
OI =
|A ∩ B|
|A| (2.15)
• Distribution of Euclidean distances between surfaces’ points, also known as the
distance transformation (DT) [54].
DT(a) = min(||a − b||), a ∈ A˜, ∀b ∈ B˜ (2.16)
The algorithm written to compute DT is signed (i.e., values can be positive or neg-
ative depending if the surface is surrounding or within the gold-standard volume).
Since DT is a distribution and not a single value, several statistical quantities can be
derived from the distribution to facilitate the analysis of the results. The statistics
are computed bi-directionally.
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• Center-of-mass (centroid) position error (CoM).
CoM = ||aCoM − bCoM|| (2.17)
The metrics presented provide complementary information about the overlap between
volumes (DSC and OI), closeness between the surfaces (DT) and spatial positioning of
the features (CoM). In this study DT results were summarised in terms of the fraction of
the DT distribution larger than a tolerance value of 2 mm (|DT|2mm).
2.5.1.4 Dosimetric analysis
Dose comparisons were performed on three patients to assess whether reduced accu-
racy but faster registrations had a noticeable effect when performing dose calculations.
Dose calculations for the IMRT plans that the patients were treated with Eclipse (Varian
Medical Systems, Palo Alto, CA, USA) External Beam TPS analytical isotropic algorithm
(AAA), using the highest available resolution (1 mm).
The comparison of dose distributions is conventionally performed using a number of
different methods:
• Dose-volume histograms (DVHs): DVHs summarise the dose distribution informa-
tion within a volume of interest (VOI). The more commonly used DVHs in practice
are the cumulative type, which are plots of volume receiving a dose greater than (or
equal to) a given dose, against dose [18].
• Dose-difference (DD): absolute difference, voxel-by-voxel, between two dose distri-
butions [92]. This quantity is very sensitive in high dose gradient regions.
• Distance to agreement (DTA): distance between a dose point in a gold-standard
dose and the nearest point in the measured dose distribution containing the same
dose value. This is equivalent to determining the shortest distance between the dose
point at the reference and the isodose surface of the evaluated dose distribution [93].
It is more suitable than DD for high dose gradient regions, but it is overly sensitive
in low-dose gradient regions.
• Gamma-index: DD and DTA alone can be insufficient, and the two methods actually
complement each other. The gamma analysis method compares a reference (Dref)
and calculated (Dcal) dose distributions using acceptance criteria [94]. It combines
two important dose comparison criteria: DTA (∆dM) and DD (∆DM). The gamma
index (γ) at each point of the dose distribution is given by:
γ(rref) = min{Γ(rcal, rref)}∀{rcal} (2.18)
where
Γ(rcal, rref) =
√
r2(rcal, rref)
∆d2M
+
δ2(rcal, rref)
∆D2M
(2.19)
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with
r(rcal, rref) = |rcal − rref| (2.20)
and
δ(rcal, rref) = Dcal(rcal) −Dref(rref) (2.21)
The pass-fail criteria are: γ(rref) ≤ 1 the calculation passes, γ(rref) > 1 the calculation
fails. The criterion used was ∆dM=2 mm and ∆DM=2%.
The dose distributions were compared considering DDs and gamma analysis. In terms
of DDs the test absolute mean value (|DD|mean) and pass-percentage (DD2%-pp) , i.e., the
percentage of pixels whose DD was inferior to 2% of the prescribed dose (pD). For the
gamma-index the test pass-percentage, i.e., the percentage of pixels whose gamma-index
was inferior 1, was calculated. 2%pD and 2 mm were defined as tolerance criteria for DDs
and distance in accordance with UCLH’s internal clinical standards for the comparison
of dose distributions.
The tools needed for the geometric and dosimetric evaluations were implemented;
freely available code was used and modified when relevant [95, 96].
2.5.2 Results
The registrations were grouped by varying one of the four parameter settings and/or
approaches: (i) different BE (3% and 5%), (ii) different CPS (5 and 10 voxels), (iii) pre-
processing of the CBCT and, (iv) masking, giving a total of 16 registrations per dataset.
For example, all the registrations were separated in two groups: those with a bending
energy weight of 3% and those of 5%. The four approaches were compared in terms of
their effect on the different quantities averaged over all structures and datasets (Table 2.3),
and for individual structures and datasets:
• Different BE: a lower bending energy gave better results in 66% of the cases. It had
a general good impact in all quantities, particularly for soft tissue structures. Lower
BE implies more freedom to perform extreme contractions/expansions, so it was
easier to capture more extensive tissue deformations.
• Different CPS: smaller CPS gave better contour statistics on 59% of the cases. It
particularly improved statistics for soft tissue surrogates.
• Choice of preprocessing the reference image with non-linear intensity adjustment:
this pre-processing improved contour statistics on 70% of the cases. All statistics but
OI were improved, particularly for bones and body outline. This reduction in OI
might be related with reducing the overestimation of the volume of the structures,
as schematically explained in Figure 2.11.
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Table 2.3: Mean ± standard deviation of dice similarity coefficient (DSC), overlap index (OI), distance transform
(DT) and centroid position error (CoM) grouped by varying parameter.
Parameter Value DSC OI |DT|2mm (%) CoM (mm)
Bending Energy weight 3% 0.843±0.012 0.867±0.015 8±3 1.4±0.2
(BE) 5% 0.837±0.013 0.861±0.016 8±4 1.4±0.3
Control Point Spacing 5 0.851±0.006 0.877±0.014 7±3 1.5±0.3
(CPS) 10 0.828±0.005 0.852±0.011 9±4 1.4±0.2
Masking the reference Yes 0.839±0.014 0.862±0.013 8±3 1.4±0.3
image No 0.841±0.013 0.867±0.015 8±3 1.4±0.2
Pre-processing the Yes 0.842±0.014 0.864±0.012 8±3 1.4±0.2
reference image No 0.837±0.012 0.866±0.016 9±4 1.5±0.3
Figure 2.11: Advantage of using dice similarity coefficient (DSC) over overlap index (OI). Overestimating
the volume of a structure results in higher OI, which may not be indicative of a better matching.
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Figure 2.12: Variation of a) DSC (squares) and OI (circles) and b) |DT|2mm for different combinations of
parameters: BE=3% (#1,3,5,7,9,11,13,15) and BE=5% (#2,4,6,8,10,12,14,16); CPS=5 (#1-8) and CP=10
(#9-16); mask (#3,4,7,8,11,12,15,16) and no mask (#1,2,5,6,9,10,13,14); pre-processing (#5-8,13-16) and
no-preprocessing (#1-4,9-12). Smaller control point spacing translated in larger values of DSC and OI.
Pre-processing the CBCT improved DSC and |DT|2mm values.
Figure 2.13: For the two registration approaches: a) difference in pixel intensity, b) dose-differences and c)
gamma-index. The similarity between the images is high, with most of the differences smaller than 10 HU.
The regions where the differences in dose were higher occurred outside the CBCT field-of-view, in the skin,
immobilisation mask and airways, and these had little effect on the dosimetry of the OARs.
• Choice of masking: masking gives better contour statistics only on 44% of all the
cases. Like visually assessed, masking has an unpredictable effect on the registra-
tions accuracy.
These findings suggested that combining pre-processing, CPS=5 and BE=3% resulted
in better registrations. The benefits of masking were not obvious, since it appeared to
slightly degrade the registrations. The differences in CoM were negligible in all cases, as
the variations were a fraction of the dimensions of the pixel.
This assessment considers that the effect of a parameter on the registration is indepen-
dent of the other parameters, which is not the case. To confirm that the chosen parameters
did stand out compared with the rest, the mean DSC, OI, |DT|2mm and CoM were analysed
for each registration separately. Figure 2.12 shows how the registrations in the light blue
region (CPS=5 and pre-processing) with odd number (BE=3%) gave the best results in
general.
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Dose distributions were calculated by applying the same IMRT plan to the registration
results that used a mask, and those that did not. The goal was to assess if accuracy
for speed trade-off had a big impact in the dose calculated. The two dose distributions
obtained were similar. DD was smaller than 2%pD on 96.2±0.4% of the voxels, with a
mean value of 0.38±0.01%pD. The comparison passes a gamma-test on 99.4±0.1% of the
voxels. Figure 2.13 gives a qualitative overview of the results obtained.
2.5.3 Discussion
Properly choosing the registration parameters is one of the most important steps in
using DIR on clinical data as the parameters determine the actual deformations produced.
The parameters cannot be tuned for each individual case, but should be tuned for different
sites, imaging modalities, image size and quality, etc. Often default parameters which
work well on a wide range of different images will be sub-optimum for a particular
registration task.
Lower BE allowed more flexibility for the algorithm to perform larger contractions and
expansions, however if its weight was too small the registrations were under-constrained
and unrealistic deformations were likely to occur. The JL encouraged the registrations to
be folding-free and ensured one-to-one mapping.
Non-linear intensity adjustment of the CBCT image increased the contrast between
structures, sharpening the anatomy boundaries. This process helped the DIR distinguish-
ing different structures. This was reflected on higher DSC and closer matching of warped
structures’ surfaces (better |DT|2mm values), at the price of lower OI values (Figure 2.12).
Masking had an unpredictable effect on the registrations accuracy, depending on the
particular dataset. The reduction of computation time in one order of magnitude is good
reasoning for always masking the registrations, and the differences in accuracy had a
negligible effect on the dose calculations (Figure 2.13).
2.6 Conclusions
In this chapter, the preliminary investigations into the major points of interest of this
thesis were performed. The concepts of DIR and ART were introduced, together with
the clinical problems. An in-house DIR algorithm (NiftyReg) was tested and investigated
in detail to achieve excellent performance at CT-to-CBCT registrations in the HN site,
for images obtained in our clinic. The optimal parameters found for the deformable
registration were: BE of 3%, JL of 1%, 3 levels of resolution, a maximum number of 1000
iterations, a binning of 32 for the joint histogram calculation, thresholding the intensities
to the range [-1000 2000], CPS of 5 voxels, non-linear intensity adjustment of the CBCT
and masking. The understanding achieved of the DIR software provided the expertise
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necessary to tune NiftyReg registrations for other sites and imaging modalities, as will
be the case in later chapters of this thesis. In such cases, the full detailed optimisation
process was omitted of this thesis since a similar protocol was followed. The work
performed in this section was also fundamental to identify strategies for the geometric
and dosimetric evaluation of DIR. Finally, the tools here described for the evaluations
and data communication with TPS were used multiple times throughout the remaining
of this thesis.
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Chapter 3
Cone-beam CT and deformable
image registration for “dose of the
day” calculations
One never notices what has been
done; one can only see what remains
to be done.
Marie Curie
NiftyReg was optimised for CT-to-CBCT registrations in HN patients in chapter 2.
ART workflows require an assessment of the dose delivered to the “anatomy of the day”,
i.e., the “dose of the day”; in this chapter the use of CT-to-CBCT for this clinical application
is explored.
The work in this chapter resulted in the following outputs:
• C. Veiga, J. McClelland, S. Moinuddin, A. Lourenço, K. Ricketts, J. Annkah, M.
Modat, S. Ourselin, D. D’Souza, and G. Royle, “Toward adaptive radiotherapy
for head and neck patients: feasibility study on using CT-to-CBCT deformable
registration for “dose of the day” calculations,” Med. Phys. 41 031703 (2014).
• C. Veiga, J. McClelland, S. Moinuddin, K. Ricketts, D. D’ Souza, and G. Royle, “Cal-
culation of the dose of the day using an in-house validated deformable registration
algorithm,” Radiother. Oncol. 106(S2), S478 (2013). (Geneva, Switzerland, 2013).
3.1 Rationale
To calculate the “dose of the day” and assess if the current plan is still acceptable,
an image of the patient in treatment position with structures of interest delineated is
CBCT and DIR for “dose of the day” calculations
necessary, and DIR can provide a solution to answer both those needs. CT-to-CBCT
DIR can be used to map the HU information from the planning to the daily geometry,
and therefore assess the actual dose delivered in each treatment fraction. Two other
common approaches suggested in the literature to calculate the “dose of the day” are
based on image guidance with CT imaging [69], and direct dose calculations on the CBCT,
using pixel correction techniques [97, 98] or relative electron density (RED) calibration
[9, 99]. The first increases the dose given to the patient in the image guidance protocols
and requires an in-room CT scanner, which is not available at UCLH. The second is
more limited by the inherent properties of CBCT imaging, such as proneness to motion
artefacts, increased noise, reduced contrast and limited FoV. Treatment planning also
requires delineation of structures of interest, which can be challenging in a CBCT scan.
DIR validation is challenging due to the lack of gold-standards in clinical and non-
clinical settings [100]. While there is a wide variety of studies assessing the quality of
CT-to-CT deformable registration with patient data [51, 54], for CT-to-CBCT the studies
are scarcer and usually focused on the deformation properties rather than dosimetry [10,
88, 101, 102]. In this chapter image inspection, feature-based evaluation and comparison
of dose distributions were used to assess the suitability of DIR for the clinical application
of dose calculations in HN patients.
3.2 Methods and Materials
3.2.1 Patient data acquisition
Retrospective data from five HN patients treated at UCLH and referred for possible
replan was used in this study. The same cohort that was described in Section 2.5.1.1 was
used. Table 3.1 provides additional details of the patients included.
Replanning referral occurred when the CBCT oﬄine review study found the spinal
canal or brainstem outside their respective planning organ at risk volume, the external
contour decreased more than 5 mm and/or if the immobilisation mask was no longer
effective. The treatment isocenter is usually set to bony anatomy on the identifiable
vertebrae, and does not represent any normalisation point or high dose region. The
CBCT is aligned to the pCT following a standardised online image-guidance protocol for
isocenter alignment based on manual rigid registration to the cervical spinal vertebrae.
By rigidly aligning the pCT with the CBCT and defining the new body external contour
on the pCT based on the CBCT external, target coverage and possible overdosage to OARs
were verified and the decision to replan taken. Four of these patients were replanned
midway. A replan/rescan CT (rCT)1 was acquired in the same scanner as the pCT (with
1The terms replan and rescan CT are often used for the same purpose, but have a subtle difference
in definition. Rescan means that the same positioning as planning was reproduced; in a replan CT the
positioning may change. Therefore, in this chapter the most correct term is replan CT.
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Table 3.1: Characteristics of the patients included in the study.
Pt
no
Age
(y)
GenderTumour site TNM
classification
Replan
(Y/N)
∆Wa
(%)
∆Vextb
(%)
LPTVc
(mm)
VPTVd
(%)
1 64 F Oropharynx T3N1M0 N N/A -8.5 +15 6.5
2 61 M Larynx T3N1M0 Y +0.4 -3.5 +8 0.5
3 73 F Base of the tongue T4N2cM0 Y -1.7 -4.7 0 0.0
4 60 M Larynx T3N0M0 Y -4.4 -12.4 +14 3.0
5 64 M Pharyngeal wall T4N2cM0 Y -11.7 -8.6 -26 9.4
a∆W = relative weight variation at plan evaluation
b∆Vext = relative external volume variation at plan evaluation, in the region imaged by the
CBCT;
cLPTV = length of the target volume outside the CBCT in the superior/inferior direction, at
replan referral;
dVPTV = target volume fraction not imaged by the CBCT, at replan referral
contrast) and a new plan built from scratch; a new immobilisation mask was necessary
but the previous positioning was reproduced as close as possible. Typically the last two
weeks of treatment were completed with the new plan.
3.2.2 Image registration settings
The registrations were defined by a set of parameters optimised to suit the datasets
being registered, discussed in chapter 2. The standard, unidirectional and asymmetric
implementation on the GPU of NiftyReg was used. Two regularisation terms were used:
BE, which encourages a smoothly varying deformation field [21] and JL, which penalises
large volume changes [36]. A folding correction scheme is applied every iteration and to
the final deformation field. When folding occurs the correction scheme updates the CP
coefficients in the vicinity of folded voxels to try and produce a folding-free transformation
[103]. The folding correction scheme ensures the invertibility of the DVF. NMI was
preferred as similarity measure over other popular measures, such as the SSD, since it not
only handles the non-linear relationship between CT and CBCT intensities but also the
local variations of intensity characteristic of CBCT imaging.
The patient images and structures were exported from the TPS in DICOM format to a
standalone registration workstation. The registration workstation had an Intel Xeon CPU
E25606 (2.13GHz, 12GB RAM) with a NVIDIA Tesla C2070 GPU card (14 multiprocessors,
6GB dedicated memory). A rigid registration was first applied in order to estimate the
global alignment between the pCT and the CBCT. The obtained transformation was then
used to initialise the deformable registration. The deformable registrations using images
at full resolution ran in approximately 1 minute. The output DVF was used to propagate
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Figure 3.1: Standard B-spline control point grid covering (a) the CBCT volume only and (b) the CBCT
volume extended to cover the CT field of view. The second control point position matches the centre of the
first voxel of the image.
the contours from the pCT to the dCT, and the results saved in DICOM format. Both the
dCT and warped structures were then imported back in the TPS for dose calculations.
A well-known issue with CBCT imaging is that the limited FoV often makes the
images unusable for treatment planning due to missing patient information [9]. Methods
proposed to handle this issue include acquiring two consecutive CBCTs [104], or directly
using pCT slices to extend the CBCT [61]. The deformation outside the CBCT FoV
was estimated by continuity, using the initial rigid alignment and the regularisation of
the deformable registration. The CBCT volume was extended in the superior/inferior
direction, to cover the whole CT FoV. The B-spline control point grid is placed on the
CBCT by aligning the second CP with the centre of the first voxel. By “padding” the
CBCT the B-spline control point placement is modified (Figure 3.1). The deformation
outside the FoV was initialised using the rigid alignment. During the registration the
transformation is optimised over the whole of the extended volume; as there is no image
data to drive the registration outside the FoV it is purely driven by the constraint terms
in these regions. This has the effect of causing a smooth transition between the image
driven deformation inside the field of view and the rigid alignment outside the FoV. A
good rigid alignment between the pCT and CBCT is then required, and it provides a
good approximation mostly in the superior region, as the patient’s head moves in a rigid
fashion. The superior region is usually the most important due to presence of OARs
such as brainstem and parotids. The brainstem only moves rigidly, but the parotids can
shrink and migrate [43], and if not imaged the registration will likely represent the wrong
deformation.
3.2.3 Evaluation of the suitability of deformable image registration for “dose
of the day” calculations
Two independent tests were performed to assess the appropriateness of the proposed
registration methodology for “dose of the day” calculations in a dCT. A geometric eval-
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uation was performed to assess the ability of the proposed DIR method to map identical
structures between the CT and CBCT datasets. Features delineated in the pCT were
deformed using the output DVF and compared with the same features manually drawn
on the CBCT. The results obtained were compared with those of using a rigid-only regis-
tration of the vertebrae. A dosimetric evaluation was performed to evaluate the impact
of the registrations errors in the application proposed, to identify the limitations of the
out-of-field approximation proposed, and assess how the method compares with other
approaches. Dose distributions for the same IMRT plan were calculated on the dCT and
rCT, and compared. For the second test the DIR results were compared not only with
those from a rigid-only registration of the vertebrae, which approximates UCLH’s current
alignment protocol, but also with dose calculations directly on an calibrated and extended
deformed CBCT (dCBCT) [97, 98].
3.2.3.1 Geometric evaluation
The purpose of this test was to assess the DIR ability to align the same anatomical
features in CT and CBCT images. For each patient a set of easily identifiable features
(Figure 2.10) was drawn by the same clinical expert on both the pCT and the CBCT, as
described in Section 2.5.1.3. Typical HN OARs, such as parotids and brainstem, were not
considered in this evaluation because they cannot be unequivocally seen in a CBCT scan.
The CBCT used for each patient was the last acquired before replan referral.
The quantities calculated to assess the quality of the transformation for each structure
were also previously described (section 2.5.1.3): DSC, OI, CoM and DT. For DT several
statistics were used: the fraction of the DT distribution that is larger than 2 mm (|DT|2mm),
the signed and unsigned mean (DTmean and |DT|mean) and standard deviation (DTstd
and |DT|std), and the 95th percentile and maximum values of the unsigned DT (|DT|95%
and |DT|max). While the signed DT provides a measure of bias (i.e., the registration
being more likely to understimate or overestime contours), the unsigned DT provides an
absolute measure of the variations. In addition, two other measures were also included:
• False positives (FP) as the fraction of deformed pixels (B) that are not part of the
manual volume (A).
FP =
|B \ A|
|A| (3.1)
• False negatives (FN) as the fraction of manual pixels (A) that are not part of the
deformed volume (B).
FN =
|A \ B|
|B| (3.2)
Using FP and FN as well as DSC provides additional insight into the cause of geometric
errors, and will indicate if one structure is consistently larger/smaller than the other
(Figure 3.2).
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Figure 3.2: False negatives (FN) and false positives (FP) versus dice similarity coefficient (DSC) and
overlap index (OI).
3.2.3.2 Dose comparison
In this second test the aim was to show that the pCT can be deformed into an image
which is functionally equivalent to a rCT as far as dose calculation is concerned. To test
this hypothesis, five different dose distributions were computed for each patient:
1. recalculated dose in the rCT (DrCT), considered as gold-standard;
2. recalculated dose in the dCT, (DdCT), the method here proposed;
3. recalculated dose in a rigidly aligned pCT (DpCT), the current clinical approach;
4. recalculated dose in a not calibrated CBCT with superior/inferior extension
(DCBCT(nc));
5. recalculated dose in a calibrated CBCT with superior/inferior extension (DCBCT);
In an ideal situation the rCT and CBCT would have been acquired at the same time,
or at least in the same day, so that the two modalities contained the same (or comparable)
geometric information. However using retrospective data such effort is not possible since
there is no clinical reason to acquire a CT and a CBCT on the same day. The CBCT used for
each patient was the one acquired on the first fraction after replanning. Since the rCT and
following CBCT were not acquired simultaneously, but 5-7 days apart, noticeable changes
to the patients’ positioning and anatomy occurred between the scans. To minimise the
errors in dose estimation due to discrepancies between the rCT and the CBCT, the pCT
was actually registered to a dCBCT, obtained by deforming the regular CBCT to match
the rCT. This dCBCT was closer to the ideal dataset discussed above. The rCT could have
been deformed to match the CBCT instead but was not due to three reasons: (i) since the
aim was to reproduce the dose calculated on a rCT it was preferable to not modify the rCT
in any way, (ii) the plan isocenter was intrinsically defined in the rCT (further explanation
on this point below), and (iii) since CBCT inherently has lower imaging quality possible
errors in the dCBCT will be less noticeable than similar errors in deforming the rCT. All
the quantitative results reported in the following sections refer to the use of dCBCT, and
therefore the nomenclature dCBCT or CBCT is interchangeable.
To calculate DCBCT the dCBCT values were replaced, pixel by pixel, with CT values and
the image was extended in the superior and inferior direction using the corresponding
rigidly aligned pCT slices. This approach was chosen in favour of defining REDs since the
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Figure 3.3: Capthan 504 (a) position and composition of the inserts (adapted from [106]) and (b) image
acquired with a CT scanner. Courtesy of James Annkah.
Figure 3.4: (a) Relationship between CBCT and CT hounsfield units (HU) using the Catphan 504. The
conversion curve between CT and CBCT numbers was approximated by a quadratic polynomial. (b) Relative
electron density calibration curve for the CT scanner used in this study (CIRS Phantom).
TPS does not allow to define multiple curves for the same dose calculation (i.e., one curve
for the CBCT region, and other for the rigidly-aligned pCT). The relationship between
CT and CBCT values was obtained using the Catphan-504 (The Phantom Laboratory,
Greenwich, NY, USA) calibration phantom. Imaging and measuring of the phantom were
performed by James Annkah (Department of Medical Physics & Biomedical Engineering,
UCL) [105]. The average HU for each of its constituting materials was calculated for each
of the imaging modalities (Figure 3.3a). The conversion curve between CT and CBCT
numbers was approximated by a quadratic polynomial (Figure 3.4). Figure 3.5 shows the
data used and registrations performed for each patient. DCBCT(nc) was calculated to verify
if the calibration used did improve the dose calculations directly on the CBCT.
Doses were calculated for an IMRT plan using Eclipse (Varian Medical Systems, Palo
Alto, CA, USA) External Beam TPS AAA with the highest available resolution (1 mm).
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Figure 3.5: Diagram of the data and registrations used in the dosimetric evaluation. The structures included
in the dosimetric evaluation were the brainstem, spinal canal and parotid glands.
For each patient the same IMRT plan, including beam arrangement, monitor units and
fluence maps, were employed. The choice of IMRT plan should be clinically relevant, so
a dose distribution the patient was treated with was chosen. The plan chosen to perform
the dose calculations was the replan, which was built and optimised in the rCT. This
minimises the issues with the isocenter definition both in the gold-standard, DIR-based
dose calculation and dCBCT. The uncertainties with isocenter positioning are only an
issue when calculating DpCT. The isocenter uncertainty positioning in this case was dealt
with by using the UCLH’s protocol for isocenter alignment (i.e., matching to the spinal
canal). The RED curve used in the dose calculations was the same used clinically at UCLH,
which is yearly monitored using the CIRS phantom (Computerized Imaging Reference
Systems Inc, Norfolk, VA, USA). The RED curve was fitted using a two-piece linear fit
(Figure 3.4b).
The dose distributions were compared considering DD, gamma analysis, described in
section 2.5.1.3, and similarity of the 95% isodose volume (representing target coverage).
The DD distributions were compared in terms of test pass-percentage (i.e., percentage
of pixels whose DD was inferior to 2%pD (DD2%-pp), average absolute DD mean and root
mean square (RMS) (DDmean and DDRMS), and the 99th percentile of the DD distribution
(DD99%).
3.2.3.3 Propagation of structures and “dose of the day”
The dose analysis was extended to examine the impact within different OARs. In clini-
cal settings, DVHs are routinely used to assess if the plan is appropriate for the patient, by
displaying in a concise and comprehensive way the information of dose delivered both to
targets and OARs. DVHs were computed using both manually drawn and warped struc-
tures of interested. The structures were delineated by the radiographers as part of clinical
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Figure 3.6: Geometric matching of manual and warped features overlaid on the CBCT image. Blue
corresponds to manual-only, red to warped-only voxels, and green to the region of agreement. The features
shown are (from left to right): (a) right sternocleidomastoid muscle (RSCM), C4 and left sternocleidomastoid
muscle (LSCM), (b) vertebrae C1, C4 and C7; and (c) RSCM, C1 and LSCM.
practice. Complementary to DVHs analysis, overlap between OARs manually drawn in
the rCT and warped from the pCT was also assessed and the differences predicting the
mean (∆Dmean) and maximum doses (∆Dmax) to OARs were computed.
3.3 Results
3.3.1 Geometric evaluation
Figure 3.6 shows a representative example of the matching of manual and warped
features. The visual matching of the features is satisfactory after registration, particularly
for complexly shaped features such as the vertebrae.
In Table 3.2 the mean DSC, OI, FN, FP, DT and CoM obtained for different types of
features is presented. Figure 3.7 shows the complete information of the distribution of
DT values, for different feature and registration types. DIR aligns the features well and
considerably better than rigid registration, and the results obtained are more consistent
between different structures types. The results obtained are also poorer in soft tissue re-
gion than in bone anatomy. Inherent lower soft tissue contrast in the CBCT degrades both
the registration accuracy and the quality of manual segmentations. A major improvement
in FN and FP can be found when using DIR, particularly for soft tissues. The tail of the
DT distribution, and consequently maximum DT values, are thought to be more related
with local poor manual segmentation than to registration errors. The positive values of
DTmean are indicative that the registration is slightly biased toward overestimating the
size of the structures. Since in the HN cohort in general the patients lose weight, it means
the registration is more likely to not be able to fully capture the contraction of the tissues.
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Table 3.2: Mean values ± standard deviation of dice similarity coefficient (DSC), overlap index (OI),
false positives (FP), false negatives (FN), distance transform (DT) and centroid position error (CoM)
obtained using deformable (DIR) and rigid-only (RIG) registrations. The results were presented for
all structures/patients, and also grouped by different structure type: external contours, bony anatomy
(vertebrae C1, C4 and C7), and soft tissues (left and right sternocleidomastoid muscles).
Externalcontours Bony anatomy Soft tissues Overall
RIG DIR RIG DIR RIG DIR RIG DIR
DSC 0.945
±0.017
0.986
±0.001
0.72
±0.12
0.85
±0.03
0.64
±0.14
0.79
±0.06
0.73
±0.16
0.85
±0.08
OI 0.983
±0.007
0.988
±0.003
0.74
±0.12
0.89
±0.04
0.68
±0.12
0.80
±0.06
0.76
±0.15
0.88
±0.08
FP 0.10
±0.04
0.016
±0.003
0.31
±0.15
0.21
±0.05
0.5
±0.2
0.23
±0.08
0.3
±0.2
0.19
±0.09
FN 0.015
±0.006
0.012
±0.003
0.25
±0.11
0.11
±0.04
0.28
±0.08
0.19
±0.06
0.22
±0.13
0.12
±0.08
DTmean (mm) 1.5
±0.8
0.13
±0.09
0.7
±0.5
0.43
±0.15
1.2
±0.9
0.52
±0.18
1.0
±0.8
0.4
±0.3
DTstd (mm) 2.8
±1.1
1.3
±0.4
1.2
±0.4
0.9
±0.17
1.8
±0.8
1.1
±0.4
1.7
±0.9
1.0
±0.4
|DT|mean (mm) 1.9
±0.8
0.4
±0.1
1.4
±0.6
0.8
±0.1
1.9
±1.0
1.0
±0.2
1.6
±0.8
0.8
±0.3
|DT|std (mm) 2.8
±1.1
1.3
±0.4
1.2
±0.4
0.9
±0.2
1.6
±0.6
1.1
±0.4
1.6
±0.8
1.0
±0.4
|DT|95% (mm) 8
±3
2.1
±0.3
3.5
±1.4
2.4
±0.6
5
±2
2.9
±1.1
5
±3
2.5
±0.9
|DT|max (mm) 22
±9
19
±8
7
±2
5.5
±1.6
10
±4
9
±4
10
±7
9
±6
|DT|2mm (%) 31
±9
3.6
±1.5
20
±18
5
±4
29
±22
9
±5
25
±19
6
±4
CoM (mm) 4.4
±1.4
0.8
±0.3
2.5
±1.6
0.8
±0.4
4
±3
2.1
±0.6
3.2
±2.2
1.2
±0.8
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Figure 3.7: Distribution of distance transform (DT) values for deformable (DIR, in grey) and rigid only
(RIG, in black) registrations. The results are grouped by different structure type: external contours, soft
tissues (left and right sternocleidomastoid muscles) and bony anatomy (vertebrae C1, C4 and C7).
3.3.2 Dose comparison
Overall DdCT matches DrCT well (Figure 3.8). The dose similarity results were analysed
based on different regions of the patient (Table 3.3), providing evidence of the dose
behaviour outside the CBCT FoV. DdCT results were better than the DpCT and DCBCT
results in all regions, although the major benefits of using DdCT were in the region imaged
in the CBCT where most anatomical changes occur and higher dose is delivered. Doses
similarity statistics on a calibrated CBCT were superior to those on a non-calibrated CBCT,
showing that machine-specific calibration improved the usability of CBCT for direct dose
calculations.
Target coverage similarity was then assessed in terms of the 95%-isodose volumes
obtained for DdCT, DpCT and DCBCT in comparison with DrCT (Table 3.4). There is a good
agreement with the rCT in terms of similarity of the isodose curves obtained when using
the dCT.
The DD inside the OARs are most relevant clinically (Figure 3.9). In the brainstem all
methods behave similarly since all are based, directly or indirectly, in information from the
rigidly aligned pCT. DdCT DD values were in general clinically insignificant inside OARs,
and the results obtained are superior to those from other dose estimation approaches.
The poor image quality of the CBCT in the inferior direction (i.e, larger imaging volumes
such as the shoulders) is responsible for the inferiority of DCBCT in comparison with DpCT.
This affected both the dose estimation in the high dose region (Table 3.3 and Figure 3.8)
and in the spinal canal (Figure 3.9b). The inconsistency in HU is less problematic in the
remaining OARs.
3.3.3 Propagation of structures and “dose of the day”
Figure 3.10 contains DVHs calculated using (i) DrCT and manually drawn structures on
the rCT, (ii) DdCT and the same manual structures, and (iii) DdCT and structures warped
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Figure 3.8: Rigid (left), extended CBCT (middle) and deformable registrations (right) (a) intensity difference
image with the replan CT (b) dose difference with DrCT as percentage of the prescribed dose (%pD) and (c)
gamma analysis. Between 60-90% of the treatment field-of-view was imaged in the CBCT in the available
datasets. Treatment (black line) and CBCT (purple line) fields-of-view are indicated in (a). Deformable
results are clearly better than rigid and extended CBCT. Most striking registration errors, and therefore
dose estimation errors, occurred in the skin and airways. The inconsistency in HU is visible for the CBCT
results, particularly in the shoulder region. This degrades the accuracy of the dose estimation in a fraction
of the high dose region and spinal canal.
Figure 3.9: Dose difference with DrCT: distribution of values (as percentage of the prescribed dose, %pD),
for different regions of interest and dose calculations (DdCT, DpCT and DCBCT).
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Table 3.3: Similarity between dose distributions [deformable (DdCT), rigid-only (DpCT), extended CBCT
[(calibrated (DCBCT and non-calibrated (DCBCT(nc))] and gold-standard (replan CT) within different regions
of interest: mean ± standard deviation for DD pass-percentage with a tolerance of 2%pD (DD2%−pp), mean
(DDmean), root-mean square value (DDRMS) and 99th percentile (DD99%) and gamma test pass-percentage
(2%/2mm criterion).
Dose Difference (DD) test Gamma test
Region of
interest
Method DD2%-pp
(%)
DDmean
(%pD)
DDRMS
(%pD)
DD99%
(%pD)
Pass-percentage
(%)
Treatment
FoV
DdCT
DpCT
DCBCT(nc)
DCBCT
87±6
76±4
75.3±1.7
78.6±1.0
1.6±1.0
3.9±0.8
2.2±0.5
2.0±0.5
5±2
10.9±1.4
5.5±1.9
5±2
25±12
55±7
26±11
24±12
94±5
85±3
88.7±1.9
91±3
CBCT FoV DdCT
DpCT
DCBCT(nc)
DCBCT
90.0±0.9
74±3
75±10
80±8
1.2±0.2
4.4±0.8
1.9±0.6
1.6±0.5
4.5±1.0
12.1±1.6
4.4±0.8
3.7±0.5
22±6
59±8
20±4
17±2
97.1±1.1
84±2
90±5
93±4
Non-imaged
treatment
FoV
DdCT
DpCT
DCBCT(nc)
DCBCT
86±11
84±9
84±9
84±9
1.8±1.5
2.1±1.3
2.0±1.3
2.0±1.3
5±3
6±3
5±3
5±3
26±17
29±17
28±17
28±17
92±8
90±7
90±7
91±7
Treated
Volume
DdCT
DpCT
DCBCT(nc)
DCBCT
93±8
68±7
81±5
84±5
0.7±0.2
2.1±0.6
1.5±0.3
1.2±0.2
1.2±0.5
5±4
2.1±0.3
1.8±0.2
4±2
29±37
6.2±0.6
5.4±0.8
97±4
80±6
88±5
90±4
Table 3.4: Similarity between the isodose volumes [deformable (dCT), rigid-only (pCT) and calibrated
CBCT], and the gold-standard (replan CT): mean ± standard deviation (and range) of dice similarity
coefficient (DSC), overlap index (OI), fraction of the distance transform distribution larger than 2 mm
(DT2mm) and centroid position error (CoM).
Method DSC OI DT2mm (%) CoM (mm)
dCT 0.962±0.015
(0.937-0.978)
0.974±0.007
(0.963-0.982)
5±6
(0.2-14.4)
1.1±1.0
(0.2-2.9)
pCT 0.929±0.016
(0.908-0.950)
0.930±0.028
(0.884-0.958)
20±5
(12.1-26.8)
2.7±0.4
(2.2-3.2)
CBCT 0.957±0.011
(0.940-0.971)
0.979±0.007
(0.968-0.986)
14±4
(10.6-20.7)
1.6±0.2
(1.3-1.9)
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Figure 3.10: Example of a DVH for different OARs using DrCT and manually drawn structure (rCT), DdCT
and structures deformed from the pCT (dCTd), and DdCT and manually drawn structures (dCTm). Right
parotid omitted for figure clarity.
from the pCT. Measures of overlap obtained for OARs show that although the volumes are
similar the differences can be non-negligible in the DVHs. The mean DSC obtained was
0.81±0.04, 0.82±0.06, 0.76±0.05, 0.770±0.010, for the brainstem, spinal canal, left parotid
and right parotid respectively. From Figure 3.10 it can be seen that differences in DVHs
were mainly due to differences in the OARs definition (manual vs warped), and not due
to differences in dose estimation (DrCT vs DdCT). The same trend was found for the errors
in estimating the maximum and mean doses to an OAR (∆Dmax and ∆Dmean). Using
dCT combined with manually drawn structures on the rCT the mean value obtained for
∆Dmean was 0.1±0.1% of the pD (range: 0.0-0.3%pD), while for ∆Dmax was 0.3±0.2%pD
(range: 0.0-0.6%pD). However, using the warped structures these errors increased to
2.4±2.1%pD (range: 0.3-7.8%pD) and 1.5±1.6%pD (range: 0.1-6.2%pD), respectively.
3.4 Discussion
Regarding the geometric evaluation, all metrics showed an improvement when com-
paring deformable to rigid registration, up to a relative improvement of 80%. The values
found for DSC were comparable to the ones obtained by Castadot et al. using CT-to-CT
DIR [87]. DT metrics and CoM values were comparable to image resolution. Combin-
ing the DSC, OI, FN, FP, DT and CoM the ability of the DIR method to map identical
structures between the CT and CBCT datasets could be evaluated. However, each of
these quantities can be misleading on its own. For example, DSC is inherently bigger for
larger structures, such as the external contours, and in this case DT is a better measure of
similarity between features.
One of the main limitations of the geometric evaluation was not including the localisa-
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tion of anatomical landmarks. Anatomical landmarks were not used in this study due to
the difficulty detected by the clinical expert in consistently identifying points in a CBCT
image. The uncertainty in landmark locations could produce misleading accuracy results,
so the option chosen was to only use structures in the geometric evaluation. Furthermore,
for the current goal of calculating the “dose of the day” accurate point-to-point mapping
is not required.
The method presented allowed for accurate dose calculations, comparable to doses
recalculated on a rCT and superior to both the current clinical approach at UCLH and dose
calculations on the CBCT (with extended FoV). CBCT images include larger amounts of
scattering than CT, resulting in larger variation in HU values that limit the HU calibration
and reliability [49]. The CBCT calibrations are usually done using a small phantom
which provides consistent results in such a small FoV. However, for larger volumes the
calibration is no longer consistent which has a considerable impact in dose calculations.
Figure 3.8 showed the effect in dose estimation of such inconsistency in HU in the neck
and shoulders region. Imaging larger volumes result in increased scatter and reduced
transmission. The increase in scatter introduces non-uniformities and additional quantum
noise to the reconstructed image [107]. This indicates the need for more specific and
appropriate calibration phantoms for CBCT, which should cover the size of the treatment
region. The choice of phantom is crucial as others showed different phantoms result
in very different RED calibration curves, and particularly the Catphan may not be the
most appropriate due to issues with its bone-equivalent material [99]. While the results
found are indicative of how reliable CBCT currently is for direct dose calculations, it
was not in the scope of this work to optimise treatment planning on CBCT images.
The imaging protocol was not optimised for that purpose, and so the calculations were
clearly suboptimal. It was verified that calibrating the CBCT improved all the results
when compared with non-calibrated CBCTs. This improvement was considerable but not
enough, informing that artefacts and scatter have a large impact that a single calibration
curve cannot recover. Calculating dose distributions directly on CBCT images is still an
active area of research and the fact that specialised calibrations and optimisations are
required is a current disadvantage of such methods. The deteriorated image quality of
CBCT leads to serious concerns about its reliability for direct dose calculations. CT is still
far superior to CBCT for treatment planning, and DIR is a good interim solution for ART
until CBCT data is directly usable.
The results presented were promising even to obtain dosimetric information outside
the CBCT FoV. The interpolation of the information outside the FoV allowed performing
dose calculations even when the CBCT FoV was smaller than the treatment FoV. The
method proposed to estimate the transformation, and hence the anatomy, outside of
the CBCT FoV will however not always give trustworthy results. If there is significant
deformation outside the FoV then it will not be able to recover this. Such deformations
occurred for one of the patients included in this study where the CBCT FoV did not
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extend far enough in the inferior direction. Further research will be required to study the
validity of this approximation. For future clinical applications, the imaged region must
be selected properly to minimise possible out-of-field errors on critical regions of the
individual patient. For example, if the major concern is the dose given to the brainstem,
then the brainstem should be imaged. If target coverage is more important, the high dose
region should be properly captured. Informing the imaging procedures will be even more
important for bigger patients and/or tumours.
Figure 3.10 shows how structure delineation has an important impact in plan evalua-
tion. Structure contours deviations explain the differences in DVHs and mean/maximum
doses to OARs. The overlap found between OARs is similar to values reported by Tsuji
et al. for CT-to-CT DIR [51]. Visually most discrepancies in spinal canal and brainstem
were actually due to differences in defining the extent of these organs in the superior
direction in the different scans. Generating appropriate structure delineations for ART
is an important and on-going area of research [10, 51, 54], which is beyond the scope
of this work. In future applications of the tool presented and validated here, deformed
structures will be used as a starting point to speed up the evaluation process, but will
likely require manual verification and editing to be used clinically. Extra care must be
taken if modifying targets during ART. Even though authors suggest the use of DIR to
monitor tumour shrinkage [55], in CT-to-CBCT DIR warping target volumes may not
be appropriate as they are usually not visible in CBCT imaging. Also, even if the GTV
shrinkage is visible, there is no evidence that microscopic proliferation has shrunk in the
same proportion. Guidelines for target propagation during ART need to be developed.
Including routine functional imaging, such as MRI, in the ART workflow may provide
not only a solution for target propagation, but also early evidence of the patient response
to the treatment [108, 109]. The topic of multimodal and functional imaging will be the
focus in chapter 7.
Further work on this topic should focus on measuring the accuracy of the deformation
maps and further improvements of the registrations. One of the sources of errors in DIR
is the inherent deformation of bony elements, which physically can only move rigidly.
Rigidity penalty terms, that constrain the registration to be rigid in regions of interest,
are desired in a realistic deformable registration algorithm to increase the accuracy of
the tissue mapping [110]. Other similarity measures can also be investigated to improve
the robustness of the registrations [29, 111]. In chapters 4 and 5 other algorithms and
similarity measures are investigated for dose warping and summation applications, as
well as proton therapy.
The patients included in this study had considerable anatomical changes during the
course of their treatment. Therefore the tests applied to the registration algorithm were
quite severe as those patients were selected from the group of identified sensitive cases
treated at UCLH. The registrations were particularly challenging for the dose compar-
isons since not only anatomical changes but also different positioning systems had to be
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reproduced. For this reason it is expected that routine clinical cases will be less demand-
ing.
The initial clinical application of the method presented in this chapter will be weekly
oﬄine calculations of the “dose of the day” to help inform the decision of whether
the current plan is still acceptable. At this point if a plan is found to be unacceptable
the current replan pathway will be followed (i.e., acquire a rCT and replan). Replanned
patients will be used on further validation to support the effectiveness and efficiency of the
proposed method. With more patients it may be possible to understand the relationship
between DIR and dose errors, which could be used to establish quick and easy methods
for detecting regions where DIR errors are significant from a dose calculation point-of-
view. On a longer term the aim is to use dCT directly in the replan procedure itself and to
remove the need for acquiring a new CT when a new immobilisation is not necessary. The
final aim is to enable the implementation of a controlled “dose-driven” ART approach
that can be built into the patient pathway: to perform routine online modifications to the
treatment plan based on the dose that has already been delivered.
3.5 Conclusions
This work presented a proof-of-principle of the application of an in-house developed
deformable registration for ART purposes. CT-to-CBCT DIR was developed, optimised
and evaluated, and it was demonstrated that using a pCT scan deformed to match a
CBCT scan resulted in similar dose calculations to those performed on a new CT scan.
The DDs were clinically acceptable, and DIR and CBCT-based dose calculations provided
an estimation closer to the gold-standard than calculations in a rigidly aligned pCT
and extended CBCT. The results obtained support the use of non-rigid registration and
provide further evidence in the challenging objective of validating deformable registration
for routine clinical use. The registration methodology and validation protocol were
implemented in a friendly and semi-automated fashion using MATLAB (MathWorks,
Natick, MA, USA), and was made available in a clinical workstation at the Radiotherapy
Department (UCLH) to be used in evaluating the need to replan newer patients and
further clinical validation.
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Chapter 4
Dose warping and summation
applications
Measure what can be measured, and
make measurable what cannot be
measured.
Galileo Galilei
In the previous chapter the use of a dCT as a platform for ART, particularly dose
recalculation, in the context of IMRT treatments was investigated. This chapter focuses
on dose warping and summation applications. The evaluation of more recent and so-
phisticated registration algorithms available in NiftyReg was a major point of the current
chapter.
The work in this chapter resulted in the following outputs:
• C. Veiga, A. Lourenço, S. Moinuddin, M. van Herk, M. Modat, S. Ourselin, D.
D’Souza, G. Royle, and J. R. McClelland, “Toward adaptive radiotherapy for head
and neck patients: uncertainties in dose warping due to the choice of deformable
registration algorithm,” Med. Phys. 42(2) 760-769 (2015).
• A. M. Lourenço, C. Veiga, G. Royle, and J. McClelland, “Dose remapping and
summation for head and neck adaptive radiotherapy applications”, NPL PPRIG
Proton Therapy Physics Workshop (London, United Kingdom, 2014).
4.1 Rationale
The concept of dose warping stands for the clinical application of using DIR to map
the dose delivered by a treatment between different time points. Mapping the dose from
different treatments at different time points allows for dose summation, i.e., knowing the
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total dose deposited over a period of time when the anatomy is varying. Dose warping is
therefore sensitive to the underlying deformation, and algorithms that ensure symmetry,
inverse-consistency and diffeomorphism (concepts introduced in section 2.2.4) may be
preferable over more traditional implementations.
Dose warping and summation is an important topic in ART research, since knowledge
of the total dose delivered at each time point is fundamental in the ART decision-making
and replanning process. Validation of DIR is not only a key aspect, but also one of
the most challenging; therefore some authors have been evaluating the accuracy of DIR
and dose warping using manually annotated points and structures [10, 54, 112, 113],
physical plausibility of the transformations [114, 115] and by developing deformable and
virtual phantoms with known deformations [116–119]. Others focused on estimating
the accuracy requirements for dose warping [120, 121] or estimating its precision [39,
122–124]. Monte Carlo methods have also been proposed to recalculate doses using a
deformed grid (with deformed and irregular voxels), which still uses DIR but minimises
the errors associated with dose interpolation [125–127]. Finally, some groups have been
using dose warping to evaluate the benefits of replanning [55, 56, 128]. Most of the work
done on these topics uses CT-to-CT registration on different anatomical sites, and/or
registration algorithms that do not ensure symmetry and inverse-consistency.
In this chapter an ART framework for HN patients using the CT and CBCT imaging
was investigated. The HU information is mapped to the daily geometry for “dose of
the day” calculations, and the dose is remapped to the planning geometry for dose sum-
mation. Therefore estimates of both forward and inverse transformations are required.
Other groups suggest using CT and CBCT for dose remapping without requiring both
transformations by calculating the “dose of the day” directly in the CBCT [55, 113]. How-
ever, and as seen in chapter 3, CBCT imaging is still unreliable for direct dose calculations
and until the image quality of CBCT is improved a dCT is a good interim solution. Four
approaches to obtain those transformations were tested and evaluated, using three differ-
ent DIR algorithms implemented in NiftyReg, all of which use a B-spline parametrisation
of the transformation with different theoretically desirable properties. The aims of this
work were to compare different DIR algorithms available in NiftyReg in terms of their
geometrical accuracy, physical properties and computation time, and to evaluate the un-
certainties inherent to using different algorithms for dose warping. Since algorithms from
the same software package (i.e., similar implementation) are compared, the differences
found are due to the physical properties of the underlying algorithm and not due to other
differences in implementation.
The preliminary work on this topic must be acknowledged to Ana Mónica Lourenço
(Department of Medical Physics & Biomedical Engineering, UCL), whom as part of her
MSc thesis investigated different methods to numerically calculate the inverse of a DVF,
how to evaluate the inverse-consistency and how to use NiftyReg for dose warping [129].
I was closely involved in the supervision of her work.
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4.2 Methods and Materials
4.2.1 Patient data acquisition
A total of five head and neck patients were used in this study. This was the same
cohort described in sections 2.5.1.1 and 3.2.1.
4.2.2 Image registration settings
The different algorithms available in NiftyReg were used: standard asymmetric,
inverse-consistent symmetric and velocity fields implementations. BE was used as a
regularisation term for all of the registrations [21]. In addition JL [103] was used for
the unidirectional registrations and the IC [36] was used for the inverse-consistent reg-
istrations. The penalty term weights were optimised for each algorithm independently.
The remaining parameters and approaches used (such as out-of-field approximation) to
register the images are in agreement with the methods described in chapters 2 and 3.
The DIR algorithm used in this study was an updated version of the code used in
chapter 2. NiftyReg was constantly updated throughout the duration of this thesis, and
the code suffered alterations that were reflected in quality of the registrations obtained.
The newer code was tested and evaluated with the same criteria described in the previous
chapters. The conclusions derived previously are still true at this point, and the newer
version was found to have improved performance in terms of propagation of structures
and accuracy of the dose calculations.
4.2.3 Dose warping and summation in an adaptive radiotherapy workflow
The method proposed to compute, map and accumulate dose distributions while ac-
counting for anatomic variations requires the pCT and CBCTs images acquired throughout
the treatment. The process consists of each of the following steps (Figure 4.1):
(i) Mapping the HU information from the pCT to the CBCT geometry using DIR. The
process is repeated for each CBCT available for the patient.
(ii) Dose calculations are performed on each dCT (“dose of the day”).
(ii) Mapping the “dose of the day” back to the space of the pCT.
(iv) Dose distributions are accumulated and displayed on the pCT space. When a CBCT is
not available for every fraction of the treatment, the weighting used when summing
the doses will depend on the fractionation scheme and scans available.
The accumulated dose can potentially be used clinically to feed the ART decision-
making process. At each imaging time point the dose delivered is mapped to the same
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Figure 4.1: The use of dose warping and summation in an adaptive radiotherapy workflow. The registration
maps the Hounsfield units from the CT to the daily CBCT scans, and the deformed CT is used for “dose of
the day” calculations. The dose delivered is mapped back to the planning stage, where it is accumulated and
the need to replan assessed.
reference space, chosen to be the pCT, where it is summed to the dose from previous
time points. Choosing the pCT as reference allows to iteratively compare the planned
objectives with the delivered values as the treatment progresses, such that the need to
replan can be regularly assessed [55, 56]. The total dose delivered can also be warped to
the daily geometry to assess the need to replan (using the CBCT as reference) and to feed
the replanning process (using a rCT). In the first case additional registrations would be
required between the fractions since the reference space would change at each fraction.
The latter process should be performed with utmost care as uncertainties in registration
will not only affect the decision to replan but also the newly planned treatment.
Four different approaches to dose warping available with the NiftyReg software were
compared (“forward direction” stands for the CT-to-CBCT transformations and “back-
ward direction” stands for the CBCT-to-CT transformations):
1. Standard asymmetric registration in both forward and backward direction
(DIRsas+sas);
2. Standard asymmetric registration in the forward direction followed by the numeri-
cal estimation of the inverse of this transformation (DIRsas+inv);
3. Inverse-consistent symmetric registration which provides both the forward and
backward transformations (DIRics);
4. Symmetric registration parameterised by a stationary velocity field which inherently
94
Methods and Materials
Table 4.1: DIR mapping approaches used in this study, and theoretical properties of the algorithms in terms
of symmetry, inverse-consistency and diffeomorphisms.
Bidirectional Symmetric Diffeomorphic Inverse-consistent
DIRsas+sas No Yes Yes (by constraint) No
DIRsas+inv No No Yes (by constraint) Yes
DIRics Yes Yes Yes (by constraint) Yes (by constraint)
DIRsvf Yes Yes Yes (by implementation) Yes
provides both the forward and backward transformations (DIRsvf)
All the algorithms use a B-spline parametrisation of the transformation with differ-
ent theoretically desirable properties: while DIRsas+sas is symmetric but not inverse-
consistent, DIRsas+inv is inverse-consistent but not symmetric. DIRics and DIRsvf are both
symmetric, but while the first encourages inverse-consistency using a penalty term, the
second guarantees it by using a velocity field parametrisation [37]. Table 4.1 describes
the theoretical properties of each of the parametrisations, in terms of directionality (i.e.,
if T−1 is generated explicitly), symmetry, inverse-consistency and diffeomorphisms.
4.2.4 Evaluation scheme
The different DIR algorithms were evaluated and compared in terms of geometrical
matching, properties of the underlying deformations and computation time. All the
statistical tests performed on this chapter were done using the MATLAB (MathWorks,
Natick, MA, USA) statistics toolbox and the Wilcoxon signed ranked test (95% confidence).
4.2.4.1 Geometric matching
The purpose of this part of the study was to assess the ability of the different approaches
to align the same anatomical features in CT and CBCT images, using the following
quantitaties: DSC, OI, FN, FP, DT and CoM (section 2.5.1.3 and 3.2.3.1); and the structure
set consisting of the external contours, vertebrae C1, C4 and C7, RSCM and LSCM (section
2.5.1.3). Since the registrations were evaluated in both direction, care was necessary when
calculating the signed DT to interpreter correctly the results. Therefore, in the forward
direction DT is negative if the deformed contour is inside the manual contour, otherwise
it is positive (and vice-versa for in the backward direction).
4.2.4.2 Characteristics and similarity of the deformation fields
By optimising properly the parameters used in the different algorithms, it should be
possible to obtain similar geometric matching. However, different algorithms can result
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in very different DVHs, particularly inside anatomy that lacks internal features or regions
of increased noise and reduced contrast in the CBCT scans. Therefore, characteristics of
the underlying deformations were evaluated in this section.
The smoothness of the transformations was analysed using the harmonic energy (HE)
and the properties of the determinant of the Jacobian of the transformation [det(Jac)].
The HE refers to the mean Frobenius norm of the displacement field, and is inversely
proportional to the smoothness of the deformation [115]. det(Jac) indicates the level of
expansion/contraction at each voxel, and negative values are indicative of noninvertible
and unrealistic deformations. Additionally, the ICE was calculated to investigate if the
transformations were true inverses. Considering that the forward and backward transfor-
mations are inverse-consistent if their composition is equal to the identity transform, the
ICE was calculated as the voxelwise difference between the composed transformations
and the identity transform. The code used to calculate the ICE was implemented Dr. Jamie
McClelland (CMIC, UCL) and benchmarked by Ana Mónica Lourenço (Department of
Medical Physics & Biomedical Engineering, UCL).
Additionaly, the similarity between mappings using different algorithms was assessed
by measuring voxel-by-voxel the Euclidean distance between the DVFs (computed as a
L2-norm). This measure is indicative of the variability in mapping between different DIR
algorithms.
4.2.4.3 Computation times
The time taken to complete the registrations is important for clinical translation, there-
fore the computation times for each approach were measured three times per dataset.
Non-GPU implementations were done on an Intelr CoreTM i7-2600S CPU (2.80GHz, 8GB
RAM), and the GPU registrations used a NVIDIA Tesla C2070 GPU card (14 multiproces-
sors, 6GB dedicated memory).
4.2.4.4 Dose warping comparison
The purpose of this part of the study was to investigate the uncertainties in dose
warping when using different DIR algorithms.
Dose calculations were performed on a dCT, and mapped back to the original pCTs
using the results from the four different methods (in all cases cubic spline interpolation
was used). Varian Eclipse External Beam Planning System AAA was used to calculate
the dose distributions using the highest available resolution (1 mm). For each patient the
same IMRT plan was applied, including beam arrangement, monitor units and fluence
maps. The dose distributions were compared within different volumes of interest using
DD, by calculating the percentage of pixels whose DD was inferior to 2% of the prescribed
dose (pD) (DD2%-pp), mean value (DDmean), RMS value (DDRMS), and the 99th percentile of
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Figure 4.2: Basic flow diagram of the distance to dose-difference (DTD) algorithm, with a distance to
agreement (DTA) tolerance level of δ. Adapted from [120].
the DD distribution (DD99%); the differences predicting the mean (∆Dmean) and maximum
doses (∆Dmax) to OARs and dose volume histograms (DVHs).
The distance to dose-difference (DTD) was also calculated for all the planned dose dis-
tributions (using an accuracy of 2%pD) [120]. DTD is a method to estimate the required
spatial accuracy of a DVF for dose warping based on the distance that one has to travel
within the dose map to find a DD above a tolerance value. A DTD algorithm uses a single
dose distribution, and determines the minimum distance one must traverse in this dose
distribution to observe a DD greater than the tolerance (δ). The DTD algorithm was im-
plemented using the DTA concept introduced in section 2.5.1.4. Figure 4.2 schematically
describes the workflow of the DTD implementation: from the original dose distribution
(A) two are created, B+ and B− (that correspond to A±δ), and the DTA calculated. Then
the DTD is the minimum value of the (DTA+, DTA−). The DTD in different regions of
interest was compared to the variability in mapping between different algorithms, by
measuring voxel-by-voxel the RMS of the DTD (DTDRMS) and the Euclidean distance
between the backward DVFs (also computed as a L2-norm).
4.3 Results
4.3.1 Geometric matching
In Table 4.2 the values of DSC, OI, FN, FP, DT and CoM obtained averaged over both
the directions of the registrations and for all structures/patients are presented. All the
implementations provided similar results in terms of an overall geometric matching. The
differences in DSC per structure were in general statistically insignificant (p∈[0.1, 1]) and
of little clinical relevance. The two exceptions were an underperformance of DIRics in the
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Table 4.2: Mean values ± standard deviation of dice similarity index (DSC), overlap index (OI), false
negative (FN), false positives (FN), distance transform (DT) and centroid position error (CoM). The results
were averaged over all structures, patients and both registration directions.
DIRsas+sas DIRsas+inv DIRics DIRsvf
DSC 0.851±0.080 0.847±0.082 0.848±0.075 0.851±0.073
OI 0.864±0.086 0.848±0.097 0.865±0.079 0.852±0.086
FP 0.17±0.11 0.15±0.11 0.18±0.12 0.15±0.10
FN 0.14±0.09 0.15±0.10 0.14±0.08 0.15±0.09
DTmean (mm) 0.3±0.4 0.4±0.4 0.2±0.4 0.3±0.4
DTstd (mm) 1.3±0.4 1.3±0.3 1.3±0.4 1.3±0.3
|DT|mean (mm) 0.8±0.3 0.8±0.3 0.8±0.3 0.8±0.3
|DT|std (mm) 1.0±0.3 1.1±0.3 1.1±0.3 1.1±0.4
|DT|95% (mm) 2.7±0.9 2.7±0.9 2.8±0.9 2.7±1.0
|DT|max (mm) 9±9 10±10 9±9 9±9
|DT|2mm (%) 9±6 10±6 10±6 9±6
CoM (mm) 1.1±0.9 1.2±1.0 1.3±1.2 1.2±0.9
external contours (p=0.02), and slightly better results for DIRsvf in the muscles (p<0.01).
This was in agreement with the findings when visually inspecting the registrations: DIRics
had difficulty in recovering larger and complex deformations, while DIRsvf performed
particularly well in the alignment of soft tissues. The effect of inverse-consistency became
evident when analysing the FN and FP results: FP≈FN for DIRsas+inv and DIRsvf, as the
FP in one direction coincided with the FN in the other direction, and vice-versa, and so
they averaged to similar values. FP,FN for DIRics because even though this algorithm
encourages inverse-consistency the resulting forward and backward transformations are
only approximate inverses to each other.
4.3.2 Deformation field analysis
Table 4.3 shows the values of HE, det(Jac) and ICE found for each of the approaches.
The voxels outside the patient were ignored when calculating the results. All the DVFs
obtained had no negative det(Jac), thus were effectively invertible. In terms of physical
plausibility of the DVFs, DIRsvf provided deformations with more desirable physical
properties. Lower values of HE indicate smoother transformations, therefore the level of
smoothness of the DVFs was higher in symmetric approaches (DIRics and DIRsvf), which
resulted in tighter intervals of the det(Jac) values. Transformations constrained with an
inverse-consistent penalty (DIRics) considerably improved the ICE in comparison with
DIRsas+sas, but the two resulting DVFs were clearly not real inverses as with DIRsas+inv
and DIRsvf, for which the mean and standard deviation of the ICE were sub-mm. Figure
4.4 shows quantitatively the ICE for different registrations and its effect when composing
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Table 4.3: Mean values ± standard deviation for properties of the deformation vector fields: harmonic
energy (HE), 1% and 99% percentiles of det(Jac), and mean, standard deviation and 99% percentile of the
ICE. The results are averaged over all patients and both registration directions.
DIRsas+sas DIRsas+inv DIRics DIRsvf
HE 0.14±0.05 0.16±0.05 0.11±0.05 0.11±0.04
det(Jac)1% 0.53±0.12 0.57±0.12 0.69±0.11 0.67±0.08
det(Jac)99% 1.49±0.16 1.57±0.18 1.33±0.13 1.40±0.13
ICEmean (mm) 1.6±0.7 0.012±0.005 0.5±0.2 0.008±0.003
ICEstd (mm) 2.4±1.1 0.04±0.03 0.8±0.4 0.02±0.02
ICE99% (mm) 13±6 0.12±0.07 4±2 0.06±0.03
Figure 4.3: L2-norm between the deformation vector fields obtained with the stationary velocity field
implementation and other algorithms.
the forward and backward transformations on a slice of one of the patient’s anatomy.
DIRsas+sas and DIRics largest ICE values were found close to airways and in the shoulders
region, where the CBCTs showed reduced contrast and higher noise. DIRsas+inv and DIRsvf
maximum values of ICE resulted from numerical errors when composing the DVFs in
regions of high contrast boundaries.
L2-norm was calculated between DIRsvf and other approaches DVFs. Figure 4.3 plots
the distribution of L2-norm. The RMS value of the L2-norm was 5±2 mm for DIRsas+sas,
4.5±0.6 mm for DIRsas+inv and 2.6±1.3 mm for DIRics. DIRics produces DVFs more similar
to DIRsvf, particularly when looking at the maximum L2-norm values. However, 15% of
voxels were mapped more than 2 mm apart by all methods, a distance clinically relevant.
4.3.3 Computation times
Table 4.4 shows the registration computation times measured for the different algo-
rithms. When comparing the computation time taken to complete the registration in both
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Figure 4.4: Hounsfield unit variation after applying the composition of the forward and backward transfor-
mations to the pCT (top row), and inverse-consistency error (ICE) maps (bottom row) for a patient included
in this study: (a) DIRsas+sas, (b) DIRsas+inv (c) DIRics, and (d) DIRsvf.
Table 4.4: Mean values ± standard deviation registration of the computation times (in minutes) per DIR
algorithm.
Forward Backward Total
DIRsas+sas 15±3 8±5 23±6
DIRsas+inv 15±3 5±1 20±3
DIRics 37±12 37±12
DIRsvf 61±15 61±15
directions and in the same processor, DIRsas+sas and DIRsas+inv resulted in similar times,
while DIRics and DIRsvf took on average 2-3 times longer. In comparison, the standard
forward asymmetric registrations ran in 0.9±0.2 min (range: 0.7-1.2 min) in the GPU.
There are plans to implement all of the DIR algorithms available in NiftyReg so they can
run on a GPU, but until then the use of DIRics and DIRsvf is limited to oﬄine studies as
current non-GPU computation times are too slow for online applications.
4.3.4 Dose warping comparison
Differences between the DVFs generated by different DIRs algorithms will affect the
final warped dose distribution. Each of the two DVFs generated per patient (forward
and backward) contributed to the differences in the final warped dose. First, differences
in forward DVFs resulted in different dCTs and therefore different “doses of the day".
Second, the backward DVFs remapped differently the “doses of the day” to the pCT
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Table 4.5: Mean values ± standard deviation for the dose difference test pass-percentage (DD2%-pp), mean
value (DDmean), root mean square value (DDRMS), and 99th percentile of the DD distribution (DD99%)
between different approaches and DIRsvf within different regions of interest (as a percentage of the prescribed
dose (pD). The CBCT region stands for the imaging volume (dose voxels outside the patient were ignored).
The treated volume (TV) corresponds to the volume encompassed by the planning 95% isodose surface,
while the irradiated volume (IV) to the corresponds to the volume encompassed by the planning 50% isodose
surface. Therefore IV-TV is the volume where 50 to 95% of the dose was planned to be delivered. PIV was
defined as the body slices close to the shoulders (a larger imaging volume) intersected with IV, where the
CBCT HU were not reliable.
Method CBCT FoV TV IV-TV PIV
DD2%-pp (%) DIRsas+sas
DIRsas+inv
DIRics
81±5
80±8
84±6
91±3
92±4
91±5
79±5
79±6
80±7
72±7
70±11
73±10
DDmean (%pD) DIRsas+sas
DIRsas+inv
DIRics
1.6±0.4
1.6±0.6
1.3±0.5
0.8±0.2
0.8±0.3
0.9±0.4
1.7±0.3
1.6±0.4
1.5±0.4
2.1±0.4
2.3±0.8
2.0±0.9
DDRMS (%pD) DIRsas+sas
DIRsas+inv
DIRics
3.7±1.4
3.2±1.3
2.9±0.9
1.7±0.5
1.6±0.7
1.9±0.8
3.9±1.1
3.1±0.8
3.3±0.9
4.2±1.3
4.2±1.6
3.9±1.6
DD99% (%pD) DIRsas+sas
DIRsas+inv
DIRics
16±7
15±6
11±4
7±3
7±3
9±5
14±4
14±4
13±4
16±4
19±7
15±8
space. The contribution of the first factor was small as the “doses of the day” differed by
less than 2% of the prescribed dose on over 95% of the body voxels.
Dosimetric differences between the warped doses obtained with DIRsvf and every other
approach were assessed. DIRsvf was arbitrarily chosen as the basis of this comparison
since it generated the DVFs with more desirable physical properties.
Table 4.5 presents the DD found between different methods and DIRsvf in different
regions of interest. There was no statistical evidence of any method being more similar to
DIRsvf (p∈[0.6-1.0]). The differences were smaller in the treated volume (TV) and larger in
the 50-95% of the prescribed dose volume (i.e., the irradiated volume (IV) that is not within
the treatment volume, IV-TV), where higher gradients are more likely to occur. Regions of
poorer CBCT quality (low contrast and high noise within larger imaging volumes [9], i.e.,
near the shoulders) within IV (PIV) showed higher variability between warped doses. The
differences between DD2%-pp between all the different identified regions were statistically
significant (p<0.01). Therefore regions of higher dose gradient and poorer CBCT image
quality were more prone to having larger variability in warped doses, but for different
reasons. DTDRMS was 1.6±0.4 and 2.7±0.8 mm within IV-TV and TV, respectively. The
RMS value of the L2-norm within IV-TV, TV and PIV was 2.7±1.1, 3.4±1.5 and 4.2±2.1 mm.
L2-norm values found for PIV were statistically different from other regions (p<0.01),
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Figure 4.5: Relationship between dose gradient and dose differences. (a) Distribution of dose gradient
values within TV and IV-TV; (b) average dose difference as function of the dose gradient, and fraction of
dose difference values per bin of dose gradient (c) 3D rendering and (d) top view.
while between TV and IV-TV were not (p=0.1). Voxels within IV-TV had larger DD than
voxels within TV due to the local characteristics of the dose distribution (shown by DTD),
while inside PIV the larger spatial mapping variability between DIR algorithms explained
the larger DD (shown by L2-norm).
The effect of the DVF in the dose mapping is complex, and was theoretically expected to
depend on the location of the dose gradients [120, 124]. The dose gradient of the planned
dose distribution was correlated with the values of DD within IV-TV. The correlation
between gradient and DD was weak (Pearson correlation coefficient, ρ=0.281), but it was
clear that as the dose gradient increased the distribution of DD values became more
spread and the average DD increased (Figure 4.5).
The DD, ∆Dmean and ∆Dmax to the spinal canal, brainstem, and parotids were computed
(Table 4.6). The wide distribution of values found for ∆Dmean and ∆Dmax was indicative
that larger dose differences occur depending on the particular dose distribution and
relative positioning of the OARs. When analysing the DVHs curves obtained for each
patient it was found that in general all algorithms led to similar clinical outcomes, i.e.,
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Table 4.6: Mean values ± standard deviation (range) for the dose difference test pass-percentage (DD2%-pp),
mean and root mean square of the DD (DDmean and DDRMS), and differences predicting the mean (∆Dmean)
and maximum doses (∆Dmax) to the OARs: spinal canal (SC), brainstem (BS), and parotids (PAR).
Method DD2%-pp (%) DDmean DDRMS (%pD) ∆Dmean (%pD) ∆Dmax (%pD)
SC
DIRsas+sas
DIRsas+inv
DIRics
90±12 (69-100)
94±5 (86-100)
90±8 (77-96)
0.8±0.5 (0.2-1.5)
0.8±0.6 (0.2-1.9)
0.9±0.5 (0.5-1.7)
1.1±0.6 (0.3-1.9)
1.7±1.9 (0.3-5.0)
1.7±1.4 (0.8-4.2)
0.4±0.6 (0.1-1.5)
0.4±0.6 (0.0-1.4)
0.5±0.4 (0.2-1.1)
1.0±0.9 (0.4-2.6)
0.7±0.8 (0.0-2.0)
0.3±0.2 (0.0-0.5)
BS
DIRsas+sas
DIRsas+inv
DIRics
92±14 (67-100)
92±11 (72-100)
91±10 (79-100)
0.8±1.0 (0.1-2.7)
0.8±0.9 (0.1-2.3)
0.6±0.5 (0.1-1.2)
1.4±1.9 (0.1-4.7)
1.3±1.6 (0.1-4.2)
1.0±0.8 (0.2-2.0)
0.6±0.8 (0.0-2.0)
0.6±0.8 (0.0-2.0)
0.5±0.4 (0.1-1.1)
0.6±0.4 (0.2-1.1)
0.7±1.0 (0.0-2.5)
1.1±1.1 (0.2-2.8)
PA
R
DIRsas+sas
DIRsas+inv
DIRics
86±4 (79-93)
86±7 (74-95)
83±9 (70-98)
1.0±0.2 (0.6-1.3)
1.0±0.3 (0.7-1.4)
1.1±0.5 (0.4-1.7)
1.5±0.3 (1.1-2.0)
1.5±0.4 (1.0-2.0)
1.9±0.8 (0.7-3.0)
0.6±0.3 (0.2-1.0)
0.3±0.4 (0.0-1.4)
0.9±0.5 (0.1-1.6)
0.2±0.2 (0.0-0.5)
0.3±0.3 (0.0-1.1)
0.2±0.2 (0.0-0.7)
that a replan was needed since OARs were receiving more dose than tolerated and targets
less dose than planned. However, for one of the patients included in this study while
DIRsas+sas and DIRics estimated a dose above the spinal canal tolerance, DIRsas+inv and
DIRsvf did not (Figure 4.6). This is an example where the decision to replan could be
affected by the choice of algorithm.
4.4 Discussion
Regarding the geometric evaluation, all the methods resulted in good alignment be-
tween anatomical contours. In some cases DIRics had worse results than the other ap-
proaches, indicating a reduced ability to capture more complex deformations due to the
introduction of additional constraint terms. The differences in geometrical alignment
from DIRsas+sas and DIRsvf were statistically and clinically insignificant, but the underly-
ing properties of the deformations were different. DIRsvf resulted in deformations with
more desirable physical properties, where both symmetry and inverse-consistency were
satisfied.
Different DIR algorithms generated different DVFs which resulted in differences when
warping the dose to the planning geometry. DIRics DVFs were found to be an overall better
match to DIRsvf, but this did not result in higher similarity in warped doses. This could be
explained by the fact that all algorithms had similar variability in mapping for differences
larger than a clinical tolerance for distances (i.e., 2 mm). Also properties of the dose map
will also have an effect in the dose uncertainties, not only the variability in mapping. The
mean and maximum values found for DD between different DIR implementations were
comparable to the values found by Salguero et al. when estimating the dose uncertainties
of a DIR algorithm due to lack of inverse-consistency [123]. In this small feasibility study
situations where the choice of algorithm led to higher uncertainties in dose warping were
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Figure 4.6: Dose volume histogram obtained for a patient included in this study, using doses warped by
different DIR algorithms: (a) all organs-at-risk and target volumes and (b) zoom of the maximum dose to
the spinal canal. DIRsas+sas and DIRics estimated a dose above the tolerance, while DIRsas+inv and DIRsvf
did not.
identified. The first important point was the effect of the dose gradient. Where there
was a high dose gradient there was more likely a larger variability in dose between the
different DIR algorithms. OARs within the high gradient region can be of concern, as
different methods could predict maximum doses to the spinal canal and brainstem with
a difference of up to 2.8%pD. The correlation between gradient and DD was weak and
similar to the values reported in the same study by Salguero et al.. The weak correlation
can be explained due to the fact that if a registration error occurs in uniform dose region
the resulting dose error will be small, but when a registration error occurs in high dose
gradient the resulting dose difference may be large but does not mean it will be, since
there are other factors to consider besides the gradient (i.e, how large the uncertainty in
spatial mapping is, whether the registration error is in the same direction as the gradient).
The results obtained are also in agreement with the findings of Saleh-Sayah et al., as
the required spacial accuracy depended on the local dose distribution [120]. A second
important point is the effect of the lower quality of the CBCT in the registration uncertainty.
Regions of reduced contrast and increased noise (particularly evident in larger imaging
volumes like the shoulders) were more susceptible to variability in mapping between
registration algorithms, and therefore in larger differences between warped doses. The
impact of the choice of DVF will depend on the dose distribution and relative positioning
of OAR, and generic validation frameworks (based exclusively on geometric analysis of
the deformations as explored in chapter 3) are not sufficient for dose warping applications.
The patients included in this study were a challenging cohort to test DIR, and it is likely
that the issues reported may have less impact for less demanding patients (but then these
patients will benefit less from ART). A larger study could potentially identify patterns
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of when different algorithms provide significant differences between doses, and flag the
regions where the dose warping algorithm may be unreliable.
For an application that is sensitive to the underlying deformations such as dose warp-
ing we believe a more complex algorithm like DIRsvf is preferable over other approaches.
This opinion is based on the similar ability to recover deformations while generating de-
formations with more desirable physical properties. Other studies support the theoretical
advantages of ensuring symmetry and inverse-consistency to improve the precision of
dose warping using DIR. Bender et al. studied the effect of inverse-consistency and tran-
sitivity in DIR for a single HN patient [39]. Lack of Transitivity means that different dose
distributions will be obtained depending on the order in which the registrations are used,
and the time point chosen for summation. They found dose differences at OAR when
different image time points were used as a reference for summation; however, when
increasing the inverse-consistency and transitivity those differences were considerably
reduced. Inverse-consistent algorithms do not enforce transitivity making this an inter-
esting area of research for registration developers. Yan et al. showed that dose mapping
ICE observed when mapping doses back-and-forth was reduced 1.5-3 times when the
spatial inverse-consistency was improved [38].
The reliability of using dose warping in clinical settings is a current and open debate
[130]. This work contributes to this discussion by evaluating theoretically better DIR algo-
rithms and investigating the uncertainties in dose warping due to the choice of algorithm
in ART frameworks that use CT-to-CBCT registration. One of the main difficulties with
validating dose warping is that the true point to point mapping is difficult or impossible to
establish, especially in regions of homogeneous image intensities as is often found inside
individual structures [100, 131]. When new plans are based on accumulated dose, regis-
tration inaccuracies will also affect the newly planned treatment. The difficulties inherent
to validate DIR for dose warping do not necessarily discourage its use for clinical research,
but users should carefully consider their choice of DIR algorithm and the conclusions that
should be drawn from the results. Extensive and detailed studies on the behaviour of
DIR algorithms can be particularly problematic when using commercial products that,
unlike NiftyReg, do not allow flexibility in selecting appropriate parameters [130, 132].
It should be noted that the real changes occurring in the tissue are complex and variate:
sometimes tissue appears or disappears (e.g. weight loss and tumour shrinkage) and
sometimes it expands/contracts or deforms in other ways. The vast majority of current
DIR algorithms use a transformation model that represents expansion/contraction, but
map constant image intensities, which in CT represents a constant density and so is more
representative of appearing/disappearing tissue. To accurately model and recover the
real physical changes that occur during a course of radiotherapy is extremely challenging
but it is what an ideal DIR algorithm should be able to do and what should be an
aim of the next generation of DIR algorithms. Several groups are actively working on
making DIR algorithms more realistic. Examples include incorporating missing tissue in
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image registration by modifying existent DIR algorithms [133] and further regularising
the transformation to avoid deformation of bony anatomy [110]. However, there is still
a very long way to go to achieve truly realistic DIR, and indeed this will not just involve
developing new algorithms and computational techniques, but will also require a better
understanding of the actual physical and biological processes that occur during a course
of radiotherapy.
4.5 Conclusions
This chapters presents the evaluation of several DIR algorithms for CT-to-CBCT reg-
istrations and investigated the uncertainties inherent to using different DIR algorithms
to warp doses to a reference geometry. Standard asymmetric and stationary vector field
implementations resulted in similar geometric matching, but the properties of the DVFs
were very different, with the second providing deformations with more desirable physical
properties. The choice of DIR implementation had a larger impact on the dose warped in
regions where the dose gradient was higher and/or the CBCT image quality was poorer.
The reliability of using dose warping and summation in clinical settings is indeed a topic
of interest; however, the lack of gold-standards for validation of DIR is still an unsolved
issue. Further understanding of the limitations of current DIR algorithms is necessary
before clinical translation.
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Head and neck proton adaptive
therapy
If I have seen further it is by standing
on the shoulders of giants.
Isaac Newton
This chapter consists of an extension of the work reported in chapter 3 to proton
therapy. The appropriateness of the translation of the CBCT and DIR method to this
treatment modality was investigated and compared to the results previously obtained
for photon treatment. The most recent registration algorithms (used in chapter 4) and
similarity measures available in NiftyReg were utilised for this clinical application.
The work in this chapter resulted in the following outputs:
• C. Veiga, J. Alshaikhi, R. Amos, A. M. Lourenço, M. Modat, S. Ourselin, G. Royle,
and J. R. McClelland, “CBCT and deformable registration based “dose of the day”
calculations for adaptive proton therapy,” Int. J. Particle Ther. 2(2) 404-414 (2015).
• C. Veiga, J. Alshaikhi, M. Modat, S. Ourselin, G. Royle, R. Amos, and J. R. Mc-
Clelland, “CBCT and deformable registration based dose calculations for adaptive
proton radiotherapy,” 4D Treatment Planning Workshop (London, United King-
dom, 2014).
5.1 An introduction to proton therapy
Proton therapy optimises radiation treatment by delivering radiation doses with great
precision due to the finite range of protons within matter [4]. The different shape of the
dose-depth curves obtained using different types of particles (Figure 5.1), and therefore
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Figure 5.1: Schematic dose-depth curves of different particles: photons, electrons and protons.
precision of cancer treatment with such particles, is related with the physical processes
that occur when interacting with matter [134]:
1. Photons are electrically neutral and interact stochastically with matter. Photons do
not steadily lose energy as they penetrate matter, but instead travel until absorbed
or scattered (i.e., changing direction of travel, with or without loss of energy). The
probability of interaction depends on its energy and medium traversed, and is
known as the linear attenuation coefficient. Therefore, photons do not have a finite
penetration depth, and several physical processes can remove photons from the
primary beam: photoelectric effect, Compton effect, pair production, photo-nuclear
reactions and Rayleigh scattering.
2. A proton traversing matter loses energy primarily by ionising and exciting the atoms
of the medium. A heavy charged particle is only able to transfer a small percentage
of its energy in a single collision with an atomic electron, and its deflection is
negligible. Therefore, a proton travels an almost straight path through matter (they
are slightly deviated from their path due to multiple Coulomb scattering), losing
energy almost continuously in small amounts. Charged particles have a finite
penetration depth unlike photons, and exhibit a low ionisation density at surface,
that slowly increases till almost the end of their range, at which point there is a
narrow peak of high ionisation density (known as Bragg Peak), with negligible dose
deposition after this point. The dose falls off sharply both laterally and distally
[135]. Due to the statistical nature of the interactions, all particles with the same
initial energy do not travel exactly the same distance. This phenomenon is called
range straggling. The average linear rate of energy loss of a heavy charged particle
in a medium, –dE/dx, is called the stopping power.
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3. Electrons are also charged particles and thus lose energy almost continuously as
they slow down in matter. In contrast to protons, electrons do not generally travel
in straight lines; because of their smaller mass they can lose a large fraction of their
energy in a single electronic collision, and are frequently scattered large angles by
nuclei. In addition, they can also radiate energy by bremsstrahlung. Electron beams
are therefore characterised by a maximum range in tissue beyond which one can
see a low intensity tail due to the bremsstrahlung photons.
A pristine Bragg peak cannot be used in cancer treatment as it is too narrow when
compared with the normal size of a tumour. The solution is to irradiate the tumour
volume uniformly by combining proton beams of different energies into a spread-out
Bragg peak (SOBP) [136]. To produce a SOBP of desired width and shape the beam to
the tumour, two delivery techniques are available in proton therapy gantries: scattering
and scanning systems (Figure 5.2). In a passive scattering proton therapy (PSPT) the
primary proton beam transverses a scattering system to broaden the beam to treatment
dimensions, and the energy is degraded using range modulator wheels. Patient specific
hardware, like blocks and compensators, are used to shape the beam according to the
target volume. An alternative to scattering systems is to scan a monoenergetic pencil
beam magnetically across the target volume. Different depths are scanned using different
energies and no beam shaping devices are needed. Scanning systems are commonly used
in clinical settings to create single-field uniform dose (SFUD) plans, where each beam spot
positions and weights are optimised independently, such that each beam covers uniformly
the target. However, scanning system also allow true intensity modulated proton therapy
(IMPT), where the beam spots from multiple beams are optimised simultaneously (this is
also often called multiple-field optimisation (MFO)).
5.2 Rationale
The introduction of IMRT as state of the art treatment considerably improved the sur-
vival and quality of life of HN patients [137]. However, achieving optimal conformality to
target volumes with IMRT can lead to substantial irradiation of the brainstem, oral cavity,
salivary glangs, cochlea, larynx and optic apparatus, which can cause both acute and
chronic morbidity. The reduction in integral dose made possible with the development
of proton therapy may result in improved care of HN patients [138].
Numerous reports have been published documenting the theoretical advantages [138–
141] and clinical evidence [142–146] of the benefits of proton over photon therapy for HN
malignancies. The general outcomes of these studies show that disease free survival
and overall survival were comparable between photon and proton therapy, while local
control was statistically significantly increased. It is possible with proton therapy to
achieve decreased doses to the optical nerves, to the parotid glands and to the oral cavity,
leading to reduction in feeding tubes used. This is accomplished without compromising
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Figure 5.2: Schematic of (a) passive scattering and (b) scanning proton delivery systems.
the conformity index, dose homogeneity and coverage to the target volume [57].
It has been subject of debate whether the high initial and treatment costs of particle
therapy are justified given the currently available evidence of its effectiveness. Based on
the available evidence, particle therapy seems at least as effective as photon therapy in
tumour control, and may have advantage in sparing OARs. The superiority in terms
of tumour control and survival remains uncertain. However, the number of published
studies is limited and the data gathered in less than optimal physics-based settings,
making difficult to establish the real effectiveness of proton therapy in HN care [57].
The majority of clinical experience in HN is with a combination of traditional photon
therapy and PSPT [144]. Currently, insufficient data is available to recommend proton
therapy for routine HN cancer treatment outside of clinical trials [147]. University of
Texas MD Anderson Cancer Center (Houston, TX, USA) and University of Pennsylvania
Roberts Proton Therapy Center (Philadelphia, PA, USA) have recently started reporting
the treatment of HN with spot scanning; nevertheless, it is within the plans of the UK
proton center project to prioritise the treatment of HN malignancies.
Although there are a plethora of image-guidance techniques available in the photon
world, the same technology is still underdeveloped when it comes to proton therapy.
The fundamental physical differences between photon and proton interactions with the
matter make photon imaging techniques sub-optimal for proton therapy. The most imme-
diate example is CT. Stopping power of different tissues cannot be obtained directly from
the electron density extrapolated from CT data for treatment planning. As consequence,
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the current practice is to convert CT values to material composition and density using
stoichiometric approaches [148]. Taking advantage of the properties of protons has been
a major motivation to develop proton specific imaging modalities, such as proton radio-
graphy/CT [149] for treatment planning, and positron emission tomography (PET) [150]
or prompt gamma emissions [151] for in vivo range verification. However, such imaging
modalities are still in research or development stage and not available clinically, which has
somehow stalled the translation of photon imaging modalities to the proton clinic over
the last decade. Most operational centres worldwide only perform image-guidance with
planar kV imaging, and only recently bidimensional (2D) real-time imaging and gating
systems have been reported [152]. Translating existing 3D photon imaging technology,
particularly CBCT, into the proton clinic has recently gained interest. The development
of CBCT in proton therapy systems required solving engineering problems related with
the geometry of a proton-gantry. Seabra et al. described the major challenges for CBCT
integration in proton therapy gantry compared to a LINAC [153]:
• Source to isocenter distance is 3 times longer than in a LINAC, so a larger x-ray power
is necessary. This requires a higher thermal capacity of the tube for a complete arc.
• Nozzle to isocenter distance is approximately half than in a LINAC. The smaller
clearance imposes additional safety measures to avoid collision between parts.
• The flat panel detectors are fixed in tractable arms extending from the back of the
gantry. The long cantilevered distance leads to deviation of the panel trajectory.
At the time of the conclusion of the work included in this chapter (November 2014),
several groups were conducting the commissioning of CBCT systems for clinical use in
proton therapy [153–155], in collaboration with manufacturers that already advertised the
selling of such products with their proton therapy solutions. The world’s first prototype
of a clinical CBCT system on a proton-gantry was installed at Roberts Proton Therapy
Center (Philadelphia, PA, USA) during the summer of 2014; however, patient data only
started being acquired regularly from December 2014. In chapter 6 the first patient data
acquired on a proton-gantry mounted CBCT will be used in the context of adaptive lung
proton therapy. Currently, this technology is still not widely available, and in-room CT
is the only reliable alternative for volumetric image-guidance. The clinical availability of
in-room CT is however also still very limited [156].
Although theoretically protons have dosimetric advantages versus photons, to fully
take advantage of the potential of proton therapy and achieve clinical benefit, the vari-
ations in anatomy (such as weight loss and tumour shrinkage) have to be monitored
and accounted for, as it is becoming popular in photon therapy [73]. In chapter 3 the
feasibility of using DIR to map the HU from the CT to the geometry of the CBCT was
investigated. This method provided a good estimation of the “dose of the day” for IMRT
treatments which can be used to feed an ART workflow. However, the challenges found
in conventional photon therapy are even more concerning for proton therapy, and this
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approximation may no longer be valid for proton therapy mainly for two reasons. First,
since the dose gradient in proton dose distributions is steeper, accurate positioning is
even more crucial to minimise the risk of overdosing OARs and/or underdosing target
volumes. Additionally, fraction to fraction changes in size and position of tissue het-
erogeneities will adversely affect the dose distribution properties of protons to a greater
extent than photons since proton dose-depth curves are more dependent on the physical
properties of the tissue than photons. In the HN region the changes can be complex as
protons travel through a complex anatomy composed of air, bone, and soft tissues [138].
Proton dose calculations are therefore expected to be more sensitive to registration errors
than analogous IMRT cases. The aim of this work is to evaluate the feasibility of a CBCT
and DIR based “dose of the day” calculation for adaptive proton therapy, which was
previously evaluated for IMRT treatments.
5.3 Methods
5.3.1 Patient data acquisition
A total of three HN patients were used in this study. This selection corresponded to
PT# 3, 4 and 5 described in Table 3.1 from the cohort described in sections 2.5.1.1 and
3.2.1.
5.3.2 Treatment planning
The choice of beams was to optimise target coverage while minimising dose to the
brainstem, spinal canal, oral cavity, salivary glands and larynx. The same prescribed
doses and volumes were used in all treatment approaches. 65 Gy(RBE) to the primary
disease and 54 Gy(RBE) to the secondary disease were planned to be delivered in 30
fractions. The planning target volumes (PTVs) were defined as a 3 mm expansion of
the clinical tumour volumes (CTVs). The primary objective of the plans was to achieve
95% of the prescribed dose to the PTV while maximising conformity. The plans were
then optimised to minimise the dose to the OARs without compromising target coverage.
Tolerance doses followed the UCLH guidelines for IMRT treatments: maximum doses of
46 Gy(RBE) and 55 Gy(RBE) to the spinal canal and brainstem, and mean unilateral dose
of 20 Gy(RBE) and bilateral dose of 25 Gy(RBE) to the parotid glands.
Treatment planning was performed on the pCT scan using Eclipse External Beam
planning system (version 10.8, Varian Medical Systems, Palo Alto, CA, USA). For IMRT
cases the patients had been planned as part of UCLH’s clinical workflow using a 7-field
protocol, and were treated with the plans used in this study. Thus, the IMRT plans used
were the same as chapter 4), but do not match those of chapter 3 (i.e., the initial plan was
used here instead of the replan). Proton treatment planning was done retrospectively by
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Figure 5.3: Dose volume histogram comparing proton and photon plans. Right parotid omitted for figure
clarity.
Jailan Alshaikhi and Dr Richard Amos (Radiotherapy Physics, UCLH), with the plans
generated per patient consisting of two types of optimisation: IMPT and SFUD, and
two different beam arrangements: 3 beams with gantry rotations of 60◦, 180◦ and 300◦
and 5 beams with gantry rotations of 45◦, 135◦, 180◦, 225◦, and 315◦. A total of three
plans were generated, IMPT with 3 and 5 beams (IMPT3B and IMPT5B), and SFUD with 3
beams (SFUD3B). IMPT3B represents a standard curative approach, which maximises the
potential benefits of proton therapy (i.e., reduced integral dose, minimised dose to OARs
and higher homogeneity inside the PTV) [141, 146]. However, such plans can be sensitive
to positioning errors and anatomical changes. In contrast, IMPT5B and SFUD3B are more
robust planning strategies at the cost of smaller dosimetric benefits. Particularly, SFUD3B
reduced the ability to minimise the maximum dose to the spinal canal as all the fields
have similar weight, while IMPT5B increased the integral dose. Table 5.1 presents the
dose statistics and properties of the plans, such as mean and maximum doses to OARs,
conformity index [157], homogeneity index [158] and non-target integral dose [159]. The
focus of this study was not treatment planning, and therefore the proton plans were
designed to be clinically acceptable and to demonstrate the benefits of proton therapy,
and not necessarily to be optimal (Figure 5.3).
5.3.3 Image registration settings
The implementation based on the stationary velocity field transformation model avail-
able in NiftyReg [37] was used. The DIR algorithm does not match that of chapter 3, and a
different measure of similarity was used here in comparison to chapter 4. Instead of NMI,
LNCC was used as similarity measure as it is well suited to account for the differences
in image intensities between CT and CBCT. As LNCC calculates the similarity over local
windows rather than the whole volume, it can better account for the spatially varying
intensity values in the CBCT image than global similarity measures such as NCC or SSD.
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Table 5.1: Mean ± standard deviation of the dose statistics and properties of the plans used in this study.
IMRT IMPT3B SFUD3B IMPT5B
Spinal Dmean [Gy(RBE)] 28±4 13±2 20.5±1.4 11±3
canal Dmax [Gy(RBE)] 41±2 33±4 42±2 28±3
Brainstem Dmean [Gy(RBE)] 14±6 87±4 7±4 5.6±1.0
Dmax [Gy(RBE)] 38±9 29±9 24±11 25±4
Left Dmean [Gy(RBE)] 40±7 29±5 34±5 29±4
parotid Dmax [Gy(RBE)] 63±5 63±4 64±4 64±5
Right Dmean [Gy(RBE)] 43±6 33±2 37.8±0.7 33.3±1.6
parotid Dmax [Gy(RBE)] 67.1±1.6 66.8±0.4 67.1±0.1 66.9±0.4
Conformity Indexa 0.87±0.02 0.81±0.06 0.88±0.03 0.80±0.05
Homogeneity Indexb 1.08±0.02 1.08±0.02 1.10±0.02 1.10±0.07
Integral Dosec [Gy(RBE)×L] 160±40 120±20 120±20 130±20
aCI=VPTV∩V95%/V95%, where VPTV is the volume of the PTV and V95% the volume
of the 95% isodose level.
aHI=D5%/D95%, where D5% and D95% are doses received by 5% and 95% of the PTV
aID=VNTV×Dmean, where VNTV is the non-target volume and Dmean its mean dose.
The out-of-field approximation was reliable for IMRT treatments, but mostly in the supe-
rior direction, where the anatomy moved rigidly. The limited FoV is expected to be more
problematic in proton therapy so the suitability of this approximation is evaluated in this
work.
5.3.3.1 Geometric matching and properties of the deformation fields
The registrations using the LNCC and NMI were compared in terms of the following
using the following quantitaties: DSC, OI, FN, FP, DT and CoM (section 2.5.1.3 and
3.2.3.1); HE, properties of the determinant of the Jacobian [det(Jac)], and ICE. The structure
set consisting of the external contours, vertebrae C1,C4 and C7, RSCM and LSCM (section
2.5.1.3). The full cohort of five HN patients (versus three in the rest of this chapter) was
used in this part of the study.
5.3.4 Dose comparison
DIR was used to map the HUs from the pCT to a CBCT that closely resembled the
rCT (the calibrated dCBCT described in section 3.2.3.2). A dosimetric evaluation was
performed to evaluate the impact of the registrations errors in calculating the “dose of
the day”. The data and registrations used match those of Figure 3.5. Dose distributions
recalculated on rCT were considered gold-standard, and compared to doses on dCT (our
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method) and directly on a calibrated dCBCT and rigidly-aligned pCT (alternative meth-
ods). Therefore, dose distributions for the same IMRT and proton plans were calculated
on the pCT, rCT, dCT and calibrated dCBCT (DpCT, DrCT, DdCT and DCBCT respectively).
The isocenter was placed in the same point in both cases based on rigid alignment of the
vertebrae. All doses were calculated with a resolution of 2 mm.
The uncertainty of the dose calculations was evaluated by computing the voxelwise
difference between dose distributions, known as the DD test, and using dose-volume
histograms DVHs, similarly to the methodology used in section 3.2.3.2.
5.4 Results
5.4.1 Geometric validation
Table 5.2 presents the results of the performance of LNCC in the geometrical and
deformation field analysis, in comparison with the results from using NMI in chapter
4. The geometrical accuracy is considerably improved when using LNCC, while the
underlying global properties of the deformation are relatively unchanged. Particularly,
there is an increase in the values of DSC and OI, and the mean value of the signed DT
becomes closer to zero.
5.4.2 Dose comparison
Tables 5.3 and 5.4 provides the results obtained for DD2%−pp and DDRMS between the
different methods and the rCT within different regions of interest. Due to the anatomical
changes, the pCT does not give a good estimate of the “dose of the day”, particularly for
proton plans. Dose calculations on the calibrated dCBCT also result in a poor estimation
of the “dose of the day” in spite of the images closely representing the anatomy of the
day. Visual inspection of the DD maps revealed that the major source of dose mismatch
was within regions where the CBCT imaging quality was degraded (such as nearby the
shoulders where the imaging volume is larger). In such larger volumes a single calibration
curve failed to recover the correct HU, resulting in inaccurate dose calculations. Proton
plans were therefore more sensitive both to anatomical changes and to the inconsistency
in HU characteristic of CBCT imaging than photon plans. The errors in the “dose of the
day” calculations on the dCT were also larger for the proton plans than for the IMRT plans,
but in all cases were considerably lower than for the calibrated CBCT and rigidly-aligned
pCT.
Different regions of the dose map were more sensitive to registration errors. The
DD2%−pp differences between the volume encompassed by the planning 95% isodose
surface (TV), and the volume receiving 50-95% of the prescribed dose (the IV minus
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Table 5.2: Mean values ± standard deviation of dice similarity index (DSC), overlap index (OI), false negative (FN),
false positives (FN), distance transform (DT),centroid position error (CoM), harmonic energy (HE), properties of the
determinant of the Jacobian [det(Jac)], and inverse consistency error (ICE) for NMI and LNCC registrations. The
results are averaged for all patients, structures or DVFs, and registration directions.
DIRNMI DIRLNCC
Geometric matching
DSC 0.851±0.073 0.863±0.067
OI 0.852±0.086 0.863±0.076
FP 0.15±0.10 0.14±0.08
FN 0.15±0.09 0.14±0.08
DTmean (mm) 0.3±0.4 0.1±0.4
DTstd (mm) 1.3±0.3 1.2±0.3
|DT|mean (mm) 0.8±0.3 0.7±0.2
|DT|std (mm) 1.1±0.4 1.0±0.3
|DT|95% (mm) 2.7±1.0 2.5±0.8
|DT|max (mm) 9±9 9±10
|DT|2mm (%) 9±6 8±5
CoM (mm) 1.2±0.9 1.1±0.9
Characteristics of the deformation fields
HE 0.11±0.04 0.13±0.02
det(Jac)1% 0.67±0.08 0.66±0.07
det(Jac)99% 1.40±0.13 1.43±0.12
ICEmean (mm) 0.008±0.003 0.009±0.003
ICEstd (mm) 0.02±0.02 0.018±0.011
ICE99% (mm) 0.06±0.03 0.07±0.03
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Table 5.3: Mean ± standard deviation of the dose difference test pass-percentage (DD2%−pp) between doses calculated
using a rigidly-aligned planning CT, calibrated CBCT and deformed CT in comparison with a replan CT within
different regions of interest. The CBCT and non-imaged field-of-view (FoV) stand for the regions where more than 10%
of the prescribed dose was deposited that were imaged or not, respectively. The treated volume (TV) corresponds to the
volume encompassed by the planning 95% isodose surface, while the irradiated volume (IV) corresponds to the volume
encompassed by the planning 50% isodose surface. Therefore IV-TV is the volume where 50 to 95% of the dose was
planned to be delivered.
Non-imaged FoV CBCT FoV TV IV-TV
IMRT DpCT 92.3±1.2% 72±6% 64±16% 73±5%
DCBCT 89±4% 74±3% 84±9% 62±5%
DdCT 96.0±0.6% 93.2±0.7% 99.1±0.4% 94.3±0.2%
IMPT3B DpCT 59±12% 51±4% 49±9% 32±8%
DCBCT 65±7% 62±3% 72±5% 44±2%
DdCT 76±6% 85±2% 88.8±0.3% 71.1±1.1%
SFUD3B DpCT 67±8% 62±2% 81±8% 43±11%
DCBCT 69±7% 69.7±0.8% 91±4% 54±5%
DdCT 80±3% 87±2% 97.7±0.8% 76±5%
IMPT5B DpCT 65±9% 57±8% 52±11% 36±7%
DCBCT 68±4% 66±3% 76±8% 44.7±0.8%
DdCT 79.3±0.4% 88±3% 91±4% 75±3%
the TV, IV-TV), where higher gradients are more likely to occur, indicate that the local
properties of the dose map affect the accuracy of the “dose of the day” calculations.
Proton plans were also more sensitive than photon plans to higher dose gradients. For
example, for IMPT3B the DDRMS was 2.6±0.6%pD within TV, and this value increased to
8.2±0.4%pD within IV-TV. Similar behaviour was found for all the plans, but in IMRT
the DDRMS was considerably lower (0.57±0.11%pD and 3.1±0.3%pD for TV and IV-TV,
respectively). Figure 5.4 provides a qualitative view of this effect. While in IMRT most
errors occurred near skin and airways, in proton plans the differences are larger within the
high dose and dose gradient regions. Additionally, in proton plans the DD2%−pp outside
the imaging FoV was consistently smaller than within the CBCT FoV, unlike the IMRT
case. This is indicative that while using the pCT outside the imaging FoV was a valid
approximation for proton treatments (particularly in the superior direction) special care
is needed if high dose gradients occur outside the imaging FoV.
Different optimisation and delivery techniques for the proton plans resulted in different
DD2%−pp and DDRMS. IMPT3B is the approach more sensitive to DIR errors, particularly
within IV-TV. SFUD3B performed particularly well within TV, since all fields deliver a
uniform dose to the high dose region, making it less sensitive to DIR errors. In general
IMPT5B also performed better than IMPT3B as less dose is delivered outside the target per
beam. The DIR method appears to perform better in photon cases, while for proton cases
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Table 5.4: Mean ± standard deviation of the root mean square of the dose difference distribution (DDRMS) between
doses calculated using a rigidly-aligned planning CT, calibrated CBCT and deformed CT in comparison with a replan CT
within different regions of interest. The CBCT and non-imaged field-of-view (FoV) stand for the regions where more than
10% of the prescribed dose was deposited that were imaged or not, respectively. The treated volume (TV) corresponds
to the volume encompassed by the planning 95% isodose surface, while the irradiated volume (IV) corresponds to the
volume encompassed by the planning 50% isodose surface. Therefore IV-TV is the volume where 50 to 95% of the dose
was planned to be delivered.
Non-imaged FoV CBCT FoV TV IV-TV
IMRT DpCT 2.5±0.2%pD 8.6±1.1%pD 4.6±1.6%pD 8±3%pD
DCBCT 2.1±0.2%pD 3.5±0.3%pD 1.8±1.6%pD 4.0±0.7%pD
DdCT 1.5±0.4%pD 2.5±0.2%pD 0.57±0.09%pD 3.1±0.3%pD
IMPT3B DpCT 5.9±1.1%pD 10±3%pD 6.0±1.7%pD 14±4%pD
DCBCT 5.2±1.5%pD 6.7±0.9%pD 3.3±0.5%pD 9.9±1.5%pD
DdCT 3.3±0.8%pD 4.0±0.1%pD 2.6±0.6%pD 8.2±0.4%pD
SFUD3B DpCT 4.9±1.1%pD 9±2%pD 2.7±0.8%pD 12±3%pD
DCBCT 4.3±1.1%pD 6.1±0.5%pD 1.4±0.5%pD 8.3±0.9%pD
DdCT 2.8±0.6%pD 3.4±0.2%pD 1.0±0.3%pD 7.1±0.5%pD
IMPT5B DpCT 5.0±1.2%pD 9±3%pD 7±3%pD 11±4%pD
DCBCT 4.4±0.5%pD 5.8±0.8%pD 3.2±1.1%pD 8.6±1.0%pD
DdCT 2.9±0.3%pD 3.5±0.2%pD 2.5±0.5%pD 7.0±0.1%pD
Figure 5.4: Dose colourwash overlayed on the replan CT (top row) and difference in dose between replan
CT and deformed CT (bottom row) for (a) IMRT plan, (b) IMPT3B, (c) SFUD3B and (d) IMPT5B, for one of
the patients included in this study. The horizontal purple lines indicate the length of the CBCT field-of-view
(FoV).
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Table 5.5: Mean ± standard deviation of the dose difference test pass-percentage (DD2%−pp), mean and root mean
square of the dose differences (DDmean and DDRMS) and differences in calculating the mean and maximum doses (∆Dmean
and ∆Dmax) to OARs (spinal canal, brainstem and parotids)
Plan DD2%−pp (%) DDmean (%pD) DDRMS (%pD) ∆Dmean (%pD) ∆Dmax (%pD)
IMRT 99.9±0.1 0.2±0.1 0.3±0.1 0.1±0.1 0.2±0.1
IMPT3B 81±17 1.3±1.0 2.3±1.6 0.8±0.9 1.8±1.7
SFUD3B 85±12 0.9±0.6 1.6±0.8 0.5±0.5 1.3±2.5
IMPT5B 80±21 1.7±2.1 3±3 1.4±2.0 1.8±1.6
SFUD optimisation and/or additional IMPT beams also lead to better performance.
Table 5.5 presents the results found for DdCT within OARs. The same trend of better
results being obtained for photon plans is observed here. The larger standard deviation
found for DD2%−pp in proton plans is due to the relative positioning of the different OAR
in the dose map for each patient. For IMPT3B the DD2%−pp was 94±6% for the brainstem
and spinal canal and 68±14% for the parotids. In general, the parotids have the worst
results due to being partially within the TV, and therefore being more susceptible to high
doses and high dose gradients. One of advantages of using DIR to generate a dCT is to
also generate deformed contours automatically, removing the need to delineate all the
regions of interest from scratch. The differences when plotting the DVHs were small when
the manual structure set was considered. If the pCT structures were used to generate
deformed contours in the dCT, the differences between curves became more evident
(Figure 5.5). The same trend was also found for IMRT plans. The variability in OAR
contouring plays a significant role when evaluating the need to replan independently
of the treatment modality, and therefore consistent delineations between time-points are
important.
5.5 Discussion
CBCT imaging is a very common imaging modality in photon therapy, but it is still
in its infancy in proton therapy. With CBCT becoming clinically available, it becomes
important to understand how to use it for treatment adaptation and what the inherent
uncertainties associated are. Very recent studies by Landry et al. also evaluated DIR
and CBCT based proton dose calculations on a deformable phantom and patient data,
but unlike this work these studies were less focused on the dosimetric implications and
the impact of different treatment strategies [11, 12]. Calculating the “dose of the day”
directly on the CBCT was extensively studied for photon therapy [9, 55]. Both approaches
can benefit from further refining due to the greater accuracy required for proton therapy
applications. Using a dCT was more accurate than a calibrated CBCT approach. Visual
inspection of the doses obtained showed that larger imaging volumes have higher noise
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Figure 5.5: Dose volume histogram comparing dose in replan CT (rCT) and deformed CT (dCT) for (a)
IMRT and (b) IMPT3B, using manual (dCTm) and deformed (dCTd) structures. Right parotid omitted for
figure clarity.
and lower contrast, and are the main source of errors in recalculating proton dose directly
on a CBCT. The CBCT imaging and calibration protocol was equal to that of chapter 3
(i.e., indicative but clearly suboptimal).
The results reported here for photon plans were comparable but not equal to those
reported in chapter 3 (i.e., Table 3.3). The improvement results from the higher similarity
between dCT and rCT in this study, as using LNCC over NMI as similarity measure proved
to result in better alignment after registration; however, there are two other sources that
cause differences between the results. The cohort used here was smaller than the one of
chapter 3 and the IMRT plans used were different.
The results found for the dose similarity between dCT and rCT are promising for
proton therapy applications, even though significantly inferior to the IMRT cases. The
estimation of the IMPT3B dose was less accurate in the region of high dose gradient but
still showed good accuracy in the regions of highest clinical importance, (i.e., TV and
OARs). The lack of a perfect gold-standard is the major limitation of studies evaluating
the “dose of the day”, as is the focus here and was in chapter 3. However, as there
would still be setup errors between the CBCT and rCT scan even if they were acquired
on the same day (as the scanners are in different rooms), the extra and unnecessary (from
a clinical perspective) imaging dose to the patient needed to acquire an extra CBCT on
the same day as the rCT was not justifiable, particularly for patients that were treated
with IMRT originally. The effect of using an imperfect gold-standard is more likely to
have a negative than a positive impact on our results, i.e., any mismatching between the
rCT and dCBCT should not help the proposed method to appear better than it really
is. It is true that this could happen by chance, if the errors in registering the pCT to the
dCBCT are the exact opposite of the errors when generating the dCBCT, but this is very
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unlikely. Furthermore, the impact of using an imperfect gold-standard was estimated
by also performing the same dose analysis on a dCT resulting from warping the pCT
to match the rCT (dCTrCT). In such case, the geometric information is correct thus the
additional uncertainty caused by the incorrect gold-standard should lay between the
values reported in this study and the results found on the dCTrCT. For proton plans
this additional uncertainty within the CBCT FoV was estimated to be approximately 5%
and 1.5%pD for DD2%−pp and DDRMS, respectively. An additional limitation is the small
patient sample used. While it is appropriate for a proof-of-concept study such as this,
follow-up studies with larger samples are required to fully characterise the uncertainty
of CBCT and DIR based “dose of the day” calculations.
The method proposed is of potential interest for adaptive proton therapy, but further
work is necessary to address its poorer reliability in regions where the dose varies rapidly.
Three major points that are crucial for CBCT and DIR-based adaptive proton therapy
workflow, and that can be further improved were identified: (1) registration algorithm,
(2) CBCT acquisition for ART applications and (3) treatment plan robustness. (1) Proton
plans are more sensitive to inaccuracies in the registrations. Even though the state-of-art
registration algorithm available in NiftyReg was used, this is a general purpose algorithm
designed to be applicable to a wide range of medical images from different modalities
and of different parts of the anatomy. General purpose algorithms can be made more
realistic by incorporating additional constraints (e.g., to avoid bone deformation [110]).
Alternatively, algorithms specifically designed for the treatment site could be used, such
as biomechanical-based algorithms that model the physical properties of the tissues being
registered [160, 161]. Further work is also necessary to ensure the registration of (and
attenuation by) the immobilisation devices. For simplicity reasons the immobilisation
mask and treatment couch were removed from the dose calculations, but the mask can
contribute significantly to the attenuation of proton beams. Furthermore, Landry et al.
point also discussed the importance of properly dealing with errors in the registration
of the trachea and airways, which are very common in the HN site due to swallowing
motion, and were shown to locally impact the dose recalculation [12]. (2) The information
acquired by the CBCT has to be adequate as missing important geometrical information
due to limited FoV is concerning particularly for adaptive proton therapy. Since the length
of the CBCT scan is limited by the geometry of the system, acquiring two consecutive
images may be the most appropriate solution for larger treatment volumes. Further
improvement of the image quality will also facilitate the registrations. (3) SFUD3B and
IMPT5B dose distributions were less sensitive to registration errors than IMPT3B, which
can be related with the robustness of the plan. Robust treatment plan optimisation can
result in plans that maintain target coverage and normal tissue sparing in the presence of
setup errors and range uncertainties [162]. Robust planning will play an important role in
minimising and accounting for the issues generated by the anatomical changes, and could
be used to make plans that are less sensitive to registration errors. The level of accuracy
necessary for the dose calculations will depend on the final application. For example,
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if the aim is to use the “dose of the day” to identify which patients may benefit from
replanning the accuracy requirements are not necessarily high as the decision to replan
is being made clinically on a patient-by-patient basis. It is crucial for clinical translation
to fully characterise the errors and uncertainties inherent to the dose calculations, and to
develop planning methods that account for and are robust to them.
This study assumes that CBCT imaging quality is the same as if the system was
mounted on a LINAC head, which may not be the case. The larger source to detector
distance and the flex of the support system induced by gravity increase the magnitude of
the geometric deformation in comparison with photon systems, and degrade the recon-
struction process of the CBCT image [163]. The effect of such degradation will have to be
verified once patient CBCT data during proton therapy becomes available. It is expected
that the lower image quality will have more of an effect on dose calculations directly on
CBCT than on a dCT.
Even though the method proposed is still not optimal and can certainly be improved, it
is clear the importance of treatment adaptation in HN proton therapy, as dose differences
between pCT and rCT show. It becomes evident that the range of proton beams within the
patient needs to be predicted as accurately as possible not only during treatment planning
but also throughout the treatment course. Knowledge of where the proton dose is being
delivered throughout the treatment and online treatment adaptation is made possible by
the introduction of CBCT imaging, which has the potential to bring additional confidence
to reduce the larger safety margins characteristic of proton therapy, and therefore fully
utilise the potential advantages of this treatment modality [164]. The framework here
presented is not exclusive to HN and could be further extended to other anatomical
sites of interest. However, site-specific validation work will be necessary as it is crucial
for the DIR algorithm to be tailored for the specificities of the region being registered
and the quality of the images acquired in such volumes. Chapter 6 will investigate the
use of CBCT and DIR for adaptive lung proton therapy using CBCT data acquired in a
proton-gantry.
5.6 Conclusions
In this chapter a feasibility study was conducted to investigate the use of CBCT and
DIR for adaptive HN proton therapy dose recalculation. This was an extension to proton
therapy of the work presented in chapter 3 using a more sophisticated DIR algorithm.
Promising results were found even though the proposed method performed worse for
proton than for photon treatments. This work allowed to identify the major areas where
further work is necessary to facilitate CBCT and DIR driven ART, which include improve-
ments to registration, image acquisition and robust planning strategies.
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Lung adaptive proton therapy
You may delay, but time will not.
Benjamin Franklin
The use of CBCT and DIR was investigated for dose calculations for HN in the context
of IMRT and proton therapy (chapters 3 and 5). Following the installation of the world’s
first CBCT system at Roberts Proton Therapy Center (Philadelphia, USA), real CBCT for
proton patients became available. Therefore, the natural following step of this thesis was
to investigate and further develop the dCT method for adaptive lung proton therapy.
The work in this chapter resulted in the following outputs:
• (In preparation) C. Veiga, G. Janssens, T. Baudier, L. Hotoiu, S. Brousmiche, J. R.
McClelland, C.-L. Teng, L. Yin, G. Royle, and B.-K. K. Teo, “The accuracy of CBCT
and deformable registration for adaptive lung proton therapy” (2016).
• C. Veiga, G. Janssens, C.-L. Teng, T. Baudier, L. Hotoiu, Lingshu Yin, J. R. McClelland,
G. Royle, C.B. Simone II, and B.-K. K. Teo, “Quantitative assessment of proton range
deviations using lung CBCT,” Proceedings of the 55th Annual Conference Particle
Therapy Co-Operative Group (Prague, Czech Republic) (2016).
• C. Veiga, G. Janssens, C.-L. Teng, T. Baudier, L. Hotoiu, J. R. McClelland, G. Royle,
L. Lin, L. Yin, J. Metz, T. D. Solberg, Z. Tochner, C. B. Simone II, J. McDonough, and
B.-K. K. Teo, “First clinical investigation of CBCT and deformable registration for
adaptive proton therapy of lung cancer,” Int. J. Radiat. Oncol. Biol. Phys. 95(1)
549-559 (2016).
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6.1 Rationale
In the context of lung malignancies, proton therapy offers better dose localisation than
that achieved by conventional photon therapy [73, 165–168]. The dosimetric advantage of
protons over photons has been used to improve the poor outcome of lung cancer patients
[169], allowing the reduction of dose to critical structures such as the lung, heart and spinal
cord [170]. PSPT has predominantly been used in the clinic as a robust strategy to deal
with the intra-fractional motion aspect of lung tumours; however, other inter-fractional
changes during the course of radiotherapy may also affect the dose delivered to target
and healthy tissues [85, 171]. These factors include changes in tumour size and position,
alterations in tissue anatomy, variations in respiratory patterns, and fluctuations in patient
weight [86]. In conventional photon radiotherapy tumour regression was found to occur
in 40% of patients undergoing definitive treatment [172], with reductions of up 70% of
their volume reported in the literature [173]. Lung changes during the course of treatment,
such as increase or decrease of atelectasis (i.e., lung collapse) and pleural effusion (i.e.,
liquid accumulated between lungs and the ribs or diaphragm), are less frequent but can
dramatically modify the range of the proton beam. Additionally, movement of the tumour
can evolve throughout the treatment fractions; therefore, re-evaluation of the targets may
be required [174]. At HUP replanning is triggered in about 10-20% of the lung cancer
patients treated with PSPT.
Proton dose distributions are highly sensitive to changes in patient geometry and
tumour volume, especially in the lungs [175]. To fully utilise the advantage of proton
therapy, positioning uncertainties and anatomical changes have to be monitored and
accounted for. The position of the SOBP is sensitive to changes in tissue density along the
beam path, which may result in potential shifts of the SOBP. For example, interfractional
tumour enlargement or development of atelectasis increase density along the beam path
and shorten beam penetration. The under-ranging can potentially reduce target coverage.
Conversely, tumour regression reduces density along the beam path and increases beam
penetration. The over-ranging may result in unplanned dose to otherwise spared organs
distal to the tumour volume. Inter-fractional adaptive replanning is therefore beneficial
to select patients [176]. Therefore, accurate patient positioning and regular evaluation
CTs scans are critical components of proton therapy [170]. Replanning will be required if
the new dose distribution based on evaluation CTs compromises target coverage and/or
exceeds tissue tolerance. Volumetric imaging afforded by CBCT is an alternative to routine
CT imaging and, as previously seen for HN patients, may play an important role in lung
adaptive proton therapy.
Gantry mounted CBCT systems are now available for image-guidance in proton ther-
apy. The world’s first CBCT mounted in a proton-gantry was installed in HUP, and the
first patient scanned in August 2014. dCT was shown in chapter 5 and other literatures
studies [11, 12] to be a potential surrogate for repeat CTs for proton treatment verification
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in the context of HN malignancies; however, these retrospective studies used data from
LINAC CBCT systems.
This chapter is focused on two complementary studies. First, a comprehensive evalu-
ation of the uncertainties associated with an adaptive proton therapy workflow based on
CBCT, DIR and a fast range-corrected estimate of the “dose of the day” was performed.
The accuracy of the dCT was assessed in terms of water equivalent thickness (WET) and
“dose of the day” estimation. Secondly, a clinical ART workflow using on-board CBCT
where a replan is triggered after three decision points was proposed. This workflow was
evaluated in terms of clinical indicators of replanning for a diverse cohort of lung cancer
patients summarising common radiation-induced changes in the lung. A rCT was used
as the gold-standard to gauge the accuracy of the dCT for both studies. This was both the
first study focused on quantifying the accuracy of DIR and CBCT for ART, and evaluating
the proposed clinical workflow in lung proton therapy.
6.2 Methods and Materials
6.2.1 Patient selection and data acquisition
Data from twenty consecutive patients treated for lung malignancies were included
in this retrospective study. All patients underwent PSPT using two treatment fields with
a median dose of 66.3 Gy(RBE) (range: 40-66.6 Gy(RBE)) in a median of 1.8 Gy(RBE) per
fraction (range: 1.5-4 Gy(RBE) per fraction). The patient cohort included a variety of
tumour sizes, locations and anatomical changes that occurred throughout the treatment
course (Table 6.1). Those changes included dramatic changes in the lung (10%), such
as atelectasis and lung reinflation, small changes in tumour and setup variations (35%),
moderate (<25% of the GTV volume) tumour shrinkage/enlargement and drift in tumour
location (35%) and large (>25% of the GTV volume) tumour shrinkage (20%).
The imaging protocol consisted of a 4D PET/CT (Gemini TF Big Bore PET/CT, Philips
Healthcare, Andover, MA, USA) for treatment planning, proton-gantry mounted CBCT
(Ion Beam Applications SA, Ottignies-Louvain-la-Neuve, BE) and rescan 4D CT (Sensa-
tion Open, Siemens Healthcare, Malvern, PA, USA) acquired in treatment position for
plan verification during the course of treatment. The average of the 4D CT was used for
treatment planning and to generate the CTs. One pair of CBCT and rCT at mid-treatment
were selected for evaluation for each patient. The chosen rCT and CBCT scans were
acquired with up to 2 days difference (85% same day, 5% 1 day difference, 10% 2 days
difference) 1. The CBCTs were acquired using a half scan mode at 110 kVp and 1142 mAs.
The CBCT system has a source-to-axis distance of 288.4 cm, detector-to-axis distance of
1Unlike with the datasets of the HN region used in this thesis, at HUP it was approved to acquire CT and
CBCT scans at the same day. This additional imaging was allowed as part of the commissioning of the first
proton-gantry mounted CBCT system.
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Table 6.1: Characteristics of the patients included in this study: age, TNM staging, treatment fields, target volumes, fraction at which the CBCT was acquired, and anatomical changes detected
at the verification scan.
PT Age G TNM Fields ViCTVa FrCT/Ftb Characteristics at verification scan Tumour motion: SI/LR/APc (mm)
# (Y) (gantry angle/name) pCT rCT
1 85 M T3N2M0 175(LPO1) & 135(LPO2) 130 9/37 Atelectasis 6/6/4 6/7/5
2 71 F T3N2M0 210(RPO1) & 220(RPO2) 410 20/37 Large tumour shrinkaged 8/5/5 10/4/4
3 68 F T4N2M0 220(RPO) & 180(PA) 280 4/30 Lung reinflation 10/4/10 12/3/2
4 69 M T4N2M0 180(PA) & 220(RPO) 280 21/37 Small tumour shrinkage/setup error 5/1/3 5/1/3
5 72 M T3N3M0 180(PA) & 10(RAO) 260 8/27 Tumour position drift 9/2/4 8/3/2
6 81 M T4N0M0 180(PA) & 155(LPO) 320 9/37 Small tumour shrinkage/setup error 3/1/2 2/1/1
7 77 M T2aN2M0 180(PA) & 200(RPO) 180 10/37 Small tumour shrinkage/setup error 7/3/2 5/2/2
8 62 F T4N2M0 270(ASO) & 180(PA) 340 4/34 Large regression of infiltrating tumour 2/3/6 4/2/5
9 64 M T2aN0M0 180(PA) & 155(LPO) 130 22/37 Small tumour shrinkage/setup error 4/2/2 4/1/3
10 65 M T4N1M0 180(PA) & 150(LPO) 180 10/25 Small tumour shrinkage/setup error 5/3/4 8/3/4
11 31 M T2aN2M0 0(AP) & 205(RPO) 200 20/37 Moderate tumour shrinkagee 7/2/5 7/4/4
12 76 F T2bN0M0 180(PA) & 210(RPO) 150 20/37 Moderate tumour shrinkage 2/0/0 2/0/1
13 71 M T3N2M0 180(PA) & 145(LPO) 190 21/25 Moderate tumour shrinkage 6/3/3 6/3/6
14 65 F T4N0M0 180(PA) & 150(LPO) 500 20/37 Large regression of infiltrating tumour 2/2/2 1/0/0
15 57 F T3N2M0 180(PA) & 225(RPO) 340 10/30 Moderate tumour shrinkage 3/2/0 1/0/0
16 58 F T4N0M0 205(RPO) & 20(LAO) 580 15/33 Moderate tumour enlargement 6/6/4 2/1/1
17 62 F T1aN2M1b 175(LPO1) & 150(LPO2) 100 5/37 Moderate tumour shrinkage 2/0/2 3/1/4
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18 67 M T3N1M0 0(AP) & 335(RAO) 330 20/30 Small tumour shrinkage/setup error 3/3/3 5/3/3
19 69 M T3N0M1b 180(PA) & 205(RPO) 310 7/16 Small tumour shrinkage/setup error 2/2/2 1/1/1
20 78 M T2aN0M1b 195(RPO1) & 210(RPO2) 140 9/15 Large tumour shrinkage; density changes 5/2/2 5/4/3
aViCTV=volume of the iCTV
bFrCT/Ft=treatment fraction at which rCT was acquired/total number of fractions
cSI=superior-inferior; LR=left-right; AP=anterior-posterior
dLarge tumour regression = visually apparent change in tumour volume greater than 25% of its original GTV
eModerate tumour regression = visually apparent change in tumour volume less than 25% of its original GTV
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Figure 6.1: Relative stopping power calibration curve imported in the clinical treatment planning system.
58.6 cm and a maximum FoV of 34 cm in diameter and length. The image resolutions were
1.17×1.17×3.0 mm3, 1.33×1.33×2.5 mm3 and 0.98×0.98×3 mm3 for the pCT, CBCT and
rCT, respectively. The open-source Reconstruction Toolbox (RTK) was used for CBCT re-
construction [177]. The two CT scanners had the same stopping power calibration curves
for proton dose calculations (Figure 6.1).
6.2.2 Overview of an adaptive lung proton therapy workflow
A clinical ART workflow using on-board CBCT is proposed, where the replan process
is triggered after three decision points (Figure 6.2). The first is a fast online process, where
a range-corrected dose distribution based on WET is rapidly calculated on a dCT derived
from the CBCT. When significant dosimetric changes are observed, an oﬄine review
process is triggered for a full dose recalculation on the dCT. If the dosimetric impact is
still evaluated as significant, a rCT is scheduled. If dosimetric changes are confirmed on
the rCT, a replan is triggered. The online decision point is based the following steps:
1. The pCT is deformed onto the CBCT acquired for treatment verification, creating a
dCT. This dCT contained the HU information of the pCT and the geometry of the
daily anatomy.
2. DIR alone cannot account for all the complex changes that occur in the region of
the thorax, which include changes to both lung and tumour. When appropriate, the
dCT was corrected for gross registration failures based on the difference between
dCT and CBCT.
3. The WET was calculated in the anatomy along the beam path for each field and
used to rapidly estimate the range and dose distribution of the treatment fields.
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Figure 6.2: Workflow for ART. A corrected dCT was created using pCT-to-CBCT DIR, and the variation
in WET between dCT and pCT was used to range-correct the planned dose. This process can be performed
online to trigger an in-depth oﬄine review of the dCT (and rCT) if deemed necessary.
Variation in WET on the distal surface of the target is also a good surrogate for
potential under/over-ranges.
4. Clinical indicators based on under/over-ranges, underdosage of target volumes
and/or overdose of OARs are then calculated to trigger the oﬄine workflows (i.e.,
investigate the need for a rCT and subsequent replanning).
6.2.2.1 Deformable registration
The first step of the workflow is to register the pCT to the CBCT. A rigid registration
was first applied in order to estimate the global alignment between the pCT and the
CBCT. The rigid registration was a manual alignment in the treatment planning system
of the images based on the same criteria used during treatment for correction of the
patient positioning, i.e., matching bony anatomy at the target volume level. The obtained
transformation was then used to initialise the DIR. The couch was delineated and removed
from the images prior to DIR in order to avoid any influence on the registrations. The DIR
was implemented using the Morphons algorithm available in REGGUI [178]. Because this
algorithm is based on the matching of local phases, it was robust to changes in intensity
when applied to CT images of the thorax with and without contrast enhancement [41]. In
the present study, the Morphons algorithm used eight resolution scales with ten iterations
for the six coarsest scales, five and two for the second finest and finest scales, respectively.
A Gaussian regularisation of 1.25 mm standard deviation was used.
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Figure 6.3: General pipeline for the detection of regions of interest for dCT correction. The pipeline is initialised
by correcting the intensities of the CBCT via a global linear regression. The low density regions are then segmented
on both images using a watershed-cuts algorithm. An exclusive OR logical operator then compares the segments to
identify areas where tissue density has changed. A Perceptron based classifier compares the detected areas and classifies
regions of interest (ROIs). Detected areas within the PTV are automatically classified as ROI.
6.2.2.2 Deformed CT correction
Some anatomical changes in the thorax cannot be modelled by deformation alone.
DIR algorithms use a transformation model that represents expansion and contraction of
tissues, and therefore are not adequate in situations where tissue appears or disappears.
The clinical situations are diverse and include changes within the lung (such as atelectasis
and pleural effusion) and complex tumour change in response to treatment (such as
regression of infiltrating tumours and erosion [179]). A pipeline that identifies problematic
regions needing further corrections for gross registration failures was developed (Figure
6.3). This method detects low density differences between the dCT and CBCT as they are
the type of issues attempted to be corrected. The pipeline is initialised by correcting the
intensities of the CBCT via a global linear regression between CBCT and dCT intensities.
The low density regions are then segmented on both dCT and CBCT using a watershed-
cuts algorithm [180, 181]. An exclusive OR logical operator then compares the segments to
identify areas where tissue density has changed between dCT and CBCT (e.g. atelectasis).
A Perceptron based classifier [182, 183] compares the detected areas and classifies region
of interests (ROIs) with significant mismatch between dCT and CBCT. The classifier uses
the decimal logarithm of the ROI size and the mean absolute difference between CBCT
and dCT within the ROI to define the acceptability limit. Detected areas within the
PTV are automatically classified as ROI because they have an important impact on the
dose calculations. In this current prototype version of the workflow, the ROI step was
implemented in a semi-automatic fashion, i.e., the regions of mismatch are automatically
identified but the user has the opportunity to discard any ROIs that were incorrectly
detected. In general, gross errors are easy and quick to spot, as most of the false detections
occur outside the lung due to scatter artefacts. The user can also dynamically relax the
acceptability criteria thus allowing more regions to be detected. Furthermore, the lung
contours and target volumes can be used to automatically discard ROIs outside the lung.
Within the ROI, the dCT pixel values were replaced by the bulk value of lung or tissue
based on thresholding of the intensity-corrected CBCT, i.e. if the CBCT intensity is lower
than -400, the dCT was replaced with value of lung (-650 HU); otherwise, it was replaced
with value of water (0 HU). These values were empirically chosen based on the average
intensity of lung and tissue on the CBCTs and CTs.
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6.2.2.3 Water equivalent thickness
WET represents the equivalent thickness of water that would cause a proton beam to
lose the same amount of energy in a given thickness of a different medium. The WET was
calculated per beam angle on both the real and deformed CT scans using the following
steps. The CT HUs were first converted to relative stopping power using the tissue-
substitute calibration method [184]. The WET map was then obtained by accumulating
the relative stopping power on a voxel-by-voxel basis of all tissues crossed by an infinitely
thin beam reaching the point from a virtual proton source. In the current implementation,
the WET was calculated for every voxel in the body (i.e. 3D WET map), as well as projected
into surfaces with respect to the beam’s eye-view (i.e. 2D WET maps).
6.2.2.4 Range-corrected dose
For a fast online workflow to estimate the “dose of the day”, a range-corrected dose
approximation method similar to the one described by Park et al. was implemented
[185]. The method relies on the assumption that anatomical changes impact only the
in-depth distribution of the dose and not its lateral distribution. The “dose of the day” is
approximated by warping the planned dose based on the in-depth mapping between the
anatomy at planning and the anatomy of the day. The mapping is derived from the WET
maps computed from the pCT and the dCT. As a result of the warping, the dCT dose
in one voxel of given WET in the dCT-based WET map is equal to the pCT dose at the
position along the beam path of equal WET in the pCT-based WET map. An additional
correction is applied based on the source-to-axis distance to account for the loss in protons
in a divergent beam. This method estimates the impact of the anatomical change in
the planning dose distribution without requiring a traditional dose recalculation on the
treatment planning system. This algorithm was benchmarked against a dose recalculation
using the clinically commissioned proton therapy treatment planning system at HUP
(Eclipse, version 11.0, Varian Medical Systems, Palo Alto, CA, USA). A sample of 40 dose
distributions pairs (range-corrected and recalculated) were used in this benchmarking.
6.2.2.5 Clinical indicators
The WET and dose 3D information can be used to automatically generate a set of clinical
indicators to estimate the impact of anatomical changes on the treatment objectives, and
thus aid the decision-making process.
Variation in WET on the distal surface of the target is a good surrogate for poten-
tial under/over-ranges. Changes in range were estimated by computing the difference
between the WET from the pCT and dCT (i.e. WETpCT > WETdCT corresponds to over-
ranging and WETpCT < WETdCT to under-ranging). However, in the case of PSPT,
compensator smearing is used to ensure target coverage in presence of errors in patient
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positioning and motion [186]. Therefore, potential under-ranges are partially taken into
account by the compensator (which increases the beam range); thus, for under-ranges
a morphological dilation using the same radius as the compensator is applied on the
pCT-based WET map before computing the difference with the dCT-based WET map to
identify under-ranges not accounted for in smearing. Quantitative measurements of the
2D WET difference maps at the PTV distal surface (per beam) for the pCT and dCT were
calculated as clinical indicators, which include the percentage of pixels with under/over-
ranges larger than 3 mm (WETunder>3mm/WETover>3mm) and the 95% percentile of the
under/over-range distribution (WETunder-95%/WETover-95%).
DVHs and dosimetric statistics representative of target coverage and OAR tolerances
congruent with HUP guidelines to trigger replanning after oﬄine review of lung patients
were automatically generated by the workflow. These were for PTV and iCTV the V95%
and V99%, respectively, with a threshold of 3% change in the rCT. Similarly, for OARs
the dose tolerances used were: for heart, Dmax=72 Gy, V45Gy <35% and V30Gy <50%; for
oesophagus, Dmax=70 Gy and V55Gy <30%; for cord (and cord+5mm), Dmax=50 Gy(65 Gy);
and for brachialplexus, Dmax=66 Gy. The iCTV/PTV contours were rigidly propagated,
even when the tumour regresses. The OAR contours were propagated automatically to
the verification scans using DIR.
6.2.3 Implementation details
The REGGUI package was used to evaluate the proposed adaptive radiotherapy work-
flow. REGGUI is a MATLAB (MathWorks, Natick, MA, USA) based image processing
software featuring various registration methods, filtering methods, segmentation tools
and other radiotherapy dedicated functions such as CBCT simulation, DVH computation
and gamma index computation. The software was designed in a way that facilitates the
construction of clinical data workflows for research purposes. Several of the different al-
gorithms described previously were implemented in REGGUI particularly for this project.
The WET calculation and range-corrected dose calculation were implemented by Dr Guil-
laume Janssens (IBA); the dCT correction step was implemented by Thomas Baudier and
Dr Lucian Hoitou (iMagX Project, Université Catholique de Louvain); and the CBCT sim-
ulation process was implemented by Dr Guillaume Janssens and Dr Sebastien Brousmiche
(IBA). I contributed closely in the design, optimisation and validation of those tools, and
was mainly responsible for the implementation of the pipelines in REGGUI; furthermore,
I also developed a number of auxiliary functions necessary for complete integration of
the workflows. The pipeline of processes implemented in the adaptive proton therapy
workflow are schematically presented in Figure 6.4.
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Figure 6.4: Diagram of data and processes implemented in REGGUI for the online decision-point of an adaptive lung
proton therapy workflow. The uncertainty in WET and range-corrected dose calculations (boxes highlighted in grey)
were assessed by comparison with those computed on the rCT.
6.2.4 Evaluation of the adaptive proton therapy workflow
In the context of adaptive lung proton therapy, two complementary studies were
performed to assess the workflow proposed:
1. Accuracy of CBCT and DIR for adaptive lung therapy: this consisted of comprehen-
sive evaluation of the uncertainties in WET and estimation of the “dose of the day”
associated with the online decision-point of the adaptive proton therapy workflow
proposed (i.e., uncertainties associated with the use of a corrected dCT).
2. Clinical investigation of replanning indicators: the workflow was evaluated in
terms of the clinical indicators of replanning extracted from the corrected dCT for
a diverse cohort of lung cancer patients summarising common radiation-induced
changes.
The details of each study are described in the following sections.
6.2.5 Accuracy of cone-beam CT and deformable image registration for adap-
tive lung therapy
6.2.5.1 Deformable registration
The ART workflow implemented for clinical use at HUP utilised the DIR algorithm im-
plemented in REGGUI. However, to evaluate the reproducibility of the method proposed
a total of three DIR softwares were used in this study: the open-source softwares REGGUI
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and NiftyReg, and the commercial hybrid deformable registration tool in RayStation (ver-
sion 4.5, RaySearch Laboratories, Stockholm, SE). The settings used for each algorithm
were optimised empirically for the thoracic region.
The parameters used for REGGUI were previously described in section 6.2.2.1. The
asymmetric DIR algorithm available in NiftyReg was used with NMI as similarity mea-
sure, three resolution levels, a CP grid size of 15×15×9 mm3, and two regularisation
terms (the BE and the JL, to facilitate smooth deformation fields and penalise large vol-
ume changes, respectively). Unlike chapter 5, NMI was preferred over LNCC due to
the larger variability in HU for the CBCT available from the proton system. The choice
of algorithm and similarity measure allowed the use of the GPU implementation, as the
workflow was aimed to be used rapidly online. Both REGGUI and NiftyReg were pre-
viously evaluated in the context of HN adaptive proton therapy (chapter 5 and other
publications [11, 12]). The hybrid free-form registration algorithm in RayStation 4.5 used
an intensity based similarity measure, two resolution levels of 5 and 3 mm voxel size.
The maximum number of iterations was set to 1000 per resolution scale.
6.2.5.2 Cone-beam CT dataset definition
In order to demonstrate that the dCT can provide similar clinical information as
the rCT, it is necessary to quantify the uncertainties associated with DIR and WET-
based range-corrected dose. Ideally, the rCT would be the gold-standard to assess the
accuracy of the dCT generated from the CBCT. However, the CBCT and rCT were not
acquired simultaneously and would display differences due to setup as well as respiratory
variations. For the purpose of decoupling these effects, two synthetic CBCT datasets were
generated in addition to the regular CBCT (rCBCT): a simulated CBCT (sCBCT) and a
dCBCT.
Regular CBCT rCBCTs were acquired within two days the rCT. The rCBCTs have the
characteristic image quality and real limitations of the cone beam geometry, namely
variability in HU and reconstruction artefacts (e.g., scatter, streaks and distortions caused
by the couch). The main disadvantage was setup variations between rCT and rCBCT. The
anatomical mismatch for some patients was considerable which limited the quantitative
assessment of DIR accuracy.
Simulated CBCT In order to create an anatomically matched CBCT and rCT pair with
no setup variations, a sCBCT was generated from each rCT. The RTK simulated raw 2D
projection data using the geometry and acquisition parameters of the rCBCT for lung pa-
tients, and image reconstruction [177]. To further mimic the rCBCT image characteristics,
scatter and Poisson noise were added to the raw 2D projections. A scatter kernel su-
perposition method was used [187–189] which parameters have been estimated through
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Figure 6.5: Photos of the RANDO phantom setup for CBCT imaging.
Figure 6.6: RANDO phantom (a) rCBCT (top) and sCBCT (bottom); and (b) corresponding profiles over the horizontal
direction.
Monte Carlo simulations (GATE) [190]. The weight of these parameters was empirically
fine-tuned and tested on the RANDO phantom (The Phantom Laboratory, Greenwich,
NY, USA) (Figure 6.5). The RANDO phantom imaging was acquired with the collabo-
ration of Dr Lingshu Yin (Radiation Oncology, HUP). The sCBCTs do not reproduce all
the features in the rCBCT exactly. For example, scatter artefacts appeared more severe
when farther away from the central region of the volume, cupping artefacts were slightly
different, and streak artefacts and distortions caused by the couch were not reproduced
(Figure 6.6). To investigate its impact, streaks were artificially added to the sCBCT.
Deformed CBCT Another way to create an anatomically matched CBCT and rCT pair
was to use the Morphons DIR algorithm to deform the rCBCT to match the rCT. The
resulting dCBCT contained the HU information of the rCBCT and the geometry of the
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Figure 6.7: Example of (a) rCBCT, (b) sCBCT, (c) dCBCT and (d) rCT for one of the patients included in this study.
Figure 6.8: Diagram of the different data and registrations used in this study. Three CBCT datasets were used to
generate the dCTs: rCBCT, sCBCT and dCBCT. Additionally, an additional dCT was generated by deforming the pCT
directly to the rCT to separate the limitations of the registration process from the limitations of CBCT imaging.
rCT. This process introduces small geometric errors but recreates most of the artefacts
present in real CBCT imaging.
The three CBCT datasets (rCBCT, sCBCT and dCBCT) were employed to generate
three dCTs (dCTrCBCT, dCTsCBCT and dCTdCBCT, respectively), which were used to report
the errors associated with DIR and CBCT imaging in WET and dose estimation. Figure
6.7 provides an example of the different CBCT datasets, and illustrates the associated
limitations. To distinguish between intrinsic limitations of the registration process from
the inferior image quality of CBCT an additional dCT, hereby denominated as dCTrCT,
was generated by deforming the pCT directly to the rCT. The dCTrCT was cropped to
have the same FoV as the other dCTs was generated, so that only the image quality plays
an impact in the validation process. Figure 6.8 summarises how the different four dCTs
were produced.
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6.2.5.3 Validation workflow of the deformed CT method
The accuracy of WET calculation and WET-based dose estimation in the dCT were
compared for every patient, treatment field, registration algorithm and CBCT datasets.
Variation in WET on the distal surface of the target is considered a good surrogate
for potential under-ranges or over-ranges. The under-ranging can potentially reduce
target coverage and/or increase dose to normal tissue proximal to tumour volume. The
over-ranging may result in unplanned dose to otherwise spared organs distal to the
tumour volume. Therefore, the WET calculation error was calculated in both 3D (PTV)
and 2D (distal and proximal surfaces), and was defined as the voxelwise difference in
WET between dCT and rCT. The mean, RMS and percentile 95% of the WET differences
(WETmean, WETRMS, and WET95%) were compared.
The error in range-corrected dose was defined as the difference between the obtained
dose and the full dose recalculation using the TPS in the rCT; this was assessed in terms
of the similarity between isodose curves, voxel-wise dose differences and a gamma-test
(3%/3mm criterion). This includes the DSC for the 50% and 90% isodose volumes, and
the DT between the respective surfaces (mean, RMS and 95% percentile, i.e., DTmean,
DTRMS and DT95%). The mean, RMS and percentile 95% of the difference between dose
distributions (DDmean, DDRMS and DD95%, respectively) were computed; for the gamma-
test the test pass-percentage was calculated. Only voxels with dose larger than 20% of
the maximum dose were considered. The DD results were normalised to the maximum
dose (%mD). The doses were calculated and compared per field.
The treatment couch was considered a constant element (i.e., it exists in all time points
in the same position), and therefore was ignored when calculating the uncertainties of the
workflow.
6.2.5.4 Comparison of the deformed CT method to simpler methods
The uncertainties in WET associated with the dCT method were compared to those
achieved with three simpler methods: (ii) pCT rigidly-aligned to the CBCT; (iii) bulk-
density intensity assignment on the CBCT; and (iv) intensity-corrected CBCT (Figure 6.9).
The main objective of this part of the study was to estimate the benefits in using the
computationally expensive dCT method described previously, in comparison to other
simpler methods.
Automatic tresholding directly on CBCT results in large errors due to scatter artefacts;
therefore, and in place of laborious manual delineation on the CBCTs, the bulk-density
intensity assignment on the CBCT was estimated using automatic thresholding of the
rCT. The intensity-corrected CBCT was based on the Catphan (The Phantom Laboratory,
Greenwich, NY, USA) data. The conversion between CT and CBCT was approximated by
a quadratic polynomial relationship. To minimise the differences in geometric information
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Figure 6.9: Illustrative example of (a) rigidly-aligned planning CT, (b) virtual CT, (c) intensity-corrected vCBCT,
(d) bulk-density assignment and (d) rescan CT.
when comparing the different methods, only the dCBCT was used to generate the dCT
and the intensity-corrected CBCT.
6.2.6 Clinical indicators of replanning
The workflow was evaluated in terms of clinical indicators of replanning. WET and
dose estimation (section 6.2.2.5) were generated for the dCT and rCT, and then assessed
to investigate the impact of the changes on the plan objectives. The aim was to evaluate
if the dCT can be used to detect changes similarly to what would be achievable with the
rCT, and thus the clinical indicators were compared to those generated from the rCT. In
this study, only the dCTs generated using the rCBCT and the Morphons DIR algorithm
were investigated. Hereby, when investigating the clinical indicators the general use of
dCT refers specifically to dCTrCBCT.
WET and dose estimation on the daily anatomy can be used to generate clinical indica-
tors (section 6.2.2.5). Two dose distributions were assessed on the dCTs: range-corrected
dose estimation, and full recalculation on the TPS. The range-corrected dose allows the
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online portion of the workflow to be performed prior to treatment; the recalculated dose
allows to carefully verify the real impact of the changes detected online. Doses were
recalculated using Eclipse (version 11.0, Varian Medical Systems, Palo Alto, CA, USA).
The following abbreviations are used to identify the different doses: pCT dose (DpCT),
dCT range-corrected dose (DdCT-WET), dCT recalculated dose (DdCT) and rCT recalculated
dose (DrCT). These final doses consisted of the sum of the contribution of two proton
fields per plan.
The CBCT couch was, in this study, added back to the dCT after registration. The
CBCT couch influences the dose distribution, and therefore is fundamental to evaluate
clinical indicators of replanning (unlike to evaluate the uncertainties).
6.3 Results
6.3.1 Accuracy of cone-beam CT and deformable image registration for adap-
tive lung therapy
Figure 6.10 presents the DIR results for three patients in the rCT frame of reference
using a color overlay with the different CBCT types. These patients represent different
clinical scenarios found in the patient cohort: small tumour change and setup error (PT#6),
moderate tumour shrinkage (PT#13), and non-deformable lung change (lung reinflation,
PT#3).
The range-corrected dose method was benchmarked against a full dose recalculation.
The average passing rate of a 3D gamma analysis (3%/3mm criteria) was 92±2%, with an
uncertainty in the location of the 50% and 90% isodose surfaces of 0.7±0.5 and 0.5±0.3
mm, respectively. A qualitative comparison between planned, range-corrected and recal-
culated dose is shown in Figure 6.11, including over-ranges caused by tumour regression,
under-ranges caused by atelectasis and little change in range. The range-corrected dose
may not perfectly match the recalculated dose, but provides similar information of over
and under-ranges.
6.3.1.1 Overall uncertainty of the deformed CT on water equivalent thickness and
dose estimation
The overall uncertainties in WET and dose associated with the dCT were computed
with the three CBCT datasets and three DIR algorithms (i.e., nine dCTs per patient). Table
6.2 presents the difference in WET calculation between the dCT and the rCT on the distal
and proximal surfaces, and within the PTV. The results were averaged over all patients,
fields, registration algorithms and CBCT datasets.
Table 6.3 shows the pCT dose and the range-corrected dose on the daily anatomy
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Figure 6.10: Color overlay between rCT (red) and (a) pCT, (b) dCTrCBCT, (c) dCTsCBCT, (d) dCTdCBCT and (e) dCTrCT
(cyan) for three different patients included in this study. PT#6 is a case of small shrinkage/setup errors, PT#13 of
moderate tumour shrinkage and PT#3 of lung reinflation. For PT#3 the dCT correction step was necessary. For this
large patient, the limited FoV cropped the external contour on the right side, which introduced registration errors of the
soft tissues near the external boundaries. The dCTs were generated using REGGUI registration algorithm.
Table 6.2: Overall uncertainty in WET (dCT vs rCT) within the planning target volume (PTV), and on the distal and
proximal surfaces (mean value ± standard deviation). The results were averaged over all patients, fields, registration
algorithms and CBCT datasets.
Region of interest WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
Distal surface 0.5±2.4 3.9±2.1 8±4
Proximal surface 0.2±2.0 2.5±1.5 5±3
PTV 0.4±2.4 3.5±2.0 7±4
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Figure 6.11: Dose colorwash overlay on rCT using (a) pCT dose distribution from TPS, (b) range-corrected dose based
on dCTdCBCT WET changes, and (c) rCT dose recalculation using TPS. Examples of over-ranges (top row), under-ranges
(middle row) and no change (bottom row). The dCTs were generated using REGGUI as registration algorithm.
(dCT), in comparison with the recalculated TPS dose using the rCT. The comparison
with the planned dose provides a baseline of the DDs that occur during treatment. On
average, only a small difference was observed between pCT or dCT versus rCT dose.
The standard deviation over the patient population is considerably higher for the pCT
dose (Figure 6.12), indicating that some patients had larger differences between the pCT
and rCT. In general, dosimetric parameters are less sensitive to anatomical change when
multiple fields were used. Summing the contribution of each field averaged out the
differences. The DDRMS decreased to 4.6±1.9 and 7±4 %mD for dCT and pCT from single
to two proton fields.
6.3.1.2 Effect of different cone-beam CT datasets
The unique features of the dCT generated by each CBCT dataset were used to decouple
the different sources of variation in the WET and range-corrected dose uncertainty (Table
6.4). The dCTrCBCT exhibited the largest differences caused by the anatomical mismatch
between the rCBCT and rCT. For dCTs generated from the sCBCT and dCBCT only
(i.e., ignoring the dCTs from rCBCT), the overall WETRMS measured in the distal surface
decreased from 3.9±2.1 (Table 6.2) to 3.5±1.8 mm.
One limitation of sCBCT is that it does not reproduce the streaking artefacts due to
motion in CBCT imaging. When streaks were artificially added, the effect on the dCT
accuracy was small: a difference of up to 0.3 mm in WETRMS measured in the distal and
proximal surfaces, and on the PTV; the DDRMS value increased by 0.3 %mD.
141
Lung adaptive proton therapy
Table 6.3: Overall uncertainty in dose estimation. Comparison between rCT dose (recalculated on TPS) and pCT
dose and range-corrected dose (based on the dCT): similarity between the 50% and 90% isodose lines and 3D dose
distributions (mean value ± standard deviation). The results were averaged over all patients, fields, registration
algorithms and CBCT datasets.
Method DTmean
(mm)
DTRMS
(mm)
DT95%
(mm)
DSC
50% isodose dCT 0.3±0.2 0.8±0.5 1.4±0.9 0.98±0.01
pCT 0.5±0.3 1.1±0.8 2.2±2.0 0.97±0.01
90% isodose dCT 0.3±0.1 0.7±0.2 1.4±0.4 0.96±0.05
pCT 0.4±0.6 0.9±0.6 1.9±1.7 0.95±0.05
DDmean
(%mD)
DDRMS
(%mD)
DD95%
(%mD)
Gamma-pass
(3%/3mm)
3D dose dCT -0.2±0.9 6±2 12±6 86±5
pCT -0.1±2.6 10±5 21±16 85±5
Figure 6.12: Boxplot of the DTRMS values found for the 90% isodose curve over the whole patient cohort using pCT
and dCT (in comparison with rCT).
Table 6.4: Uncertainty in WET (dCT vs rCT) within the distal surface for the dCTs generated by each CBCT dataset,
and corresponding comparison between rCT dose and range-corrected dose within the 3D dose distributions (mean
value ± standard deviation). The results were averaged over all patients, fields and registration algorithms.
WET (distal surface) Dose (3D dose)
CBCT
dataset
WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
DDmean
(%mD)
DDRMS
(%mD)
DD95%
(%mD)
rCBCT 0.0±3.0 4.8±2.3 10±4 -0.2±1.0 7±3 15±8
dCBCT 0.0±1.9 3.3±2.0 7±4 -0.4±1.0 6±2 11±6
sCBCT 1.6±1.7 3.7±1.7 7±4 -0.2±1.0 6±2 10±6
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Table 6.5: Uncertainty in WET (dCT vs rCT) within the distal surface for the dCTs generated by each DIR algorithm,
and corresponding comparison between rCT dose and range-corrected dose within the 3D dose distributions (mean
value ± standard deviation). The results were averaged over all patients, fields and CBCT datasets.
WET (distal surface) Dose (3D dose)
Registration
algorithm
WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
DDmean
(%mD)
DDRMS
(%mD)
DD95%
(%mD)
REGGUI 0.9±2.0 3.6±1.8 7±4 -0.5±0.9 6±2 11±6
NiftyReg 0.7±2.5 4.1±2.1 8±4 -0.1±0.9 6±3 12±7
RayStation -0.1±2.9 4.1±2.4 8±5 -0.2±1.0 7±3 13±7
6.3.1.3 Effect of different registration algorithms
The performance of the different DIR algorithms used to generate the dCTs is presented
in Table 6.5. REGGUI performed slightly above the average; however the differences were
generally small.
6.3.1.4 Effect of deformed CT correction
The dCT correction step was necessary for six out of the twenty cases (30%). These
patients had the following anatomical changes that could not be recovered by DIR alone:
atelectasis, lung reinflation, and complex tumour shrinkage (such as erosion from within
the gross tumour and regression of infiltrating tumours). Figure 6.13 shows an example of
an infiltrating tumour regression (top) and lung reinflation (bottom), where the correction
step was necessary.
The impact of the correction step on WET and range-corrected dose uncertainty are
presented in Table 6.6. Globally, the dCT correction step resulted in a reduction of the
WETRMS (distal edge) from 4.7±2.5 to 3.9±2.1 mm (Table 6.2). It also caused a reduction
of DDRMS of the 3D dose distribution from 7±3 to 6±3 %mD (Table 6.3). The correction
algorithm improved the accuracy of the dCT for the six patients with substantial anatom-
ical change; nevertheless, the overall uncertainties were still greater for these patients
compared to the others.
6.3.1.5 Uncertainty due to the use of cone-beam CT for registration
Comparison between dCTrCT and rCT provides an indication of the level of accuracy
achievable with current registration algorithms. It further provides a quantitative assess-
ment of the impact of DIR-based WET and dose calculations using CBCT. An additional
uncertainty in WET of approximately 1 mm can be attributed to the poorer quality of the
CBCT compared to CT (Table 6.7). However, image quality is not the only factor to explain
143
Lung adaptive proton therapy
Figure 6.13: Examples of the dCT correction: (a) rCBCT, (b) uncorrected dCT and (c) corrected dCT for a patient with
tumour (top row, PT#8) and lung changes (bottom row, PT#1). The region defined by the red contour was identified by
the correction algorithm as a region of mismatch between the dCT and CBCT and the HUs were replaced by bulk values
of tissue/lung during the correction step. The dCTs were generated using REGGUI as registration algorithm.
Table 6.6: Uncertainty in WET (dCT vs rCT) within the distal surface for cases with and without the dCT correction
step, and corresponding comparison between rCT dose and range-corrected dose within the 3D dose distributions (mean
value ± standard deviation). The results were averaged over all patients, fields and CBCT datasets.
WET (distal surface) Dose (3D dose)
Patient
Cohort
Correction
applied
WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
DDmean
(%mD)
DDRMS
(%mD)
DD95%
(%mD)
Aa N 1±2 3.1±1.4 6±3 -0.4±0.9 6±2 11±6
Bb N 1±5 8±4 19±9 0.2±2.3 10±4 19±14
Y 0±3 6±2 13±4 0.1±1.1 8±2 14±7
Cohort Aa: No dCT correction necessary (70%)
Cohort Bb: dCT correction needed (30%)
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Table 6.7: Uncertainty in WET (dCT vs rCT) within the distal surface for CT-to-CBCT and pCT-to-rCT registrations,
and corresponding comparison between rescan and range-corrected dose within the 3D dose distributions (mean value
± standard deviation). The results were averaged over all patients, fields, and DIR algorithms (for pCT-to-rCT) and
CBCT datasets (for pCT-to-CBCT).
WET (distal surface) Dose (3D dose)
Registration WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
DDmean
(%mD)
DDRMS
(%mD)
DD95%
(%mD)
pCT-to-CBCT 0.5±2.4 3.9±2.1 8±4 -0.2±0.9 6±2 12±6
pCT-to-rCT 0.6±1.7 2.8±1.8 6±4 -0.3±0.7 5±2 8±4
the differences found between pCT-to-rCT and pCT-to-CBCT registrations; the variability
in setup for the different CBCT datasets also contributes to the overall uncertainty.
6.3.1.6 Comparison of the deformed CT method to simpler methods
Table 6.8 shows the uncertainties in WET for the different methods. The dCT method
resulted in the smallest uncertainties. The statistic WETmean illustrates well the limitations
of the rigidly-aligned pCT and intensity-corrected CBCT methods. The rigidly-aligned
pCT method considers that the patient anatomy does not change, and therefore does
not take in consideration tumour shrinkage; therefore, the method is biased toward
overestimating the WET. The error measured is also indicative of the importance of
monitoring the patients with regular imaging throughout the course of lung proton
therapy. The intensity-corrected CBCT does not correct for scatter artefacts, that visually
results in regions of lower intensity in the images; thus, the method is biased toward
underestimating the WET. The bulk-density intensity assignment is less biased, and the
associated uncertainties are closer to those of the dCT method. In spite of being in
theory a simpler method, automatic segmentation methods have to be complex due to
the low CBCT imaging quality; a viable but laborious alternative is manual delineation.
Therefore bulk-density intensity assignment is a good alternative to dCT for cases where
the correction setup is not enough to corrected for registration errors. The good results
obtained for bulk-density intensity assignment versus intensity-corrected CBCT were the
motivation behind using bulk-assignment in the dCT correction.
6.3.2 Clinical indicators of replanning
In appendix A a complete description of the results obtained for the variation in clinical
indicators (Table A.1 for WET, and Table A.2 for dose), as well as a breakdown of all the
correct predictions and false negatives/positives extracted from the clinical indicators per
patient is provided (Table A.3). Within the next sections, the clinical indicators extracted
for select case studies (i.e., individual patients) will be discussed, grouped per type of
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Table 6.8: Overall uncertainty in WET (vs rCT) within the planning target volume (PTV), and on the distal and
proximal surfaces (mean value ± standard deviation), for the deformed CT (dCT), rigidly-aligned planning CT (pCT),
bulk-density intensity assignment (BD) and intensity-corrected CBCT (CBCTc). The results were averaged over all
patients, fields, registration algorithms, and considering only the dCBCT dataset.
Region of interest Method WETmean
(mm)
WETRMS
(mm)
WET95%
(mm)
Distal surface dCT 0.0±1.9 3.3±2.0 7±4
pCT 1±5 8±5 16±10
BD -1.8±2.2 4.4±1.5 8±3
CBCTc -13±11 16±9 24±10
Proximal surface dCT -0.1±1.1 1.7±1.0 3.4±2.0
pCT 0.0±2.1 3.2±1.5 6±3
BD 0.0±1.4 2.2±1.2 4.3±2.1
CBCTc -8±8 10±7 16±9
PTV dCT 0.0±1.7 2.9±1.7 6±4
pCT 1±4 6±3 13±8
BD -1.0±2.1 3.4±1.4 7±3
CBCTc -11±9 13±8 20±9
anatomical changes; general discussion will follow this analysis.
6.3.2.1 Lung changes
Atelectasis is the collapse of lung that is sometimes reversible. PT#1 developed
partial atelectasis at the upper left lobe during week two (Figure 6.14) resulting in in-
creased WET along the beam paths and subsequent under-ranging for the two fields
(WETunder-95%=10.4/12.3 mm for LPO1/LPO2 field, Figure 6.15). Tumour coverage was
compromised and a higher dose was delivered to the oesophagus (Dmax from 50 Gy to
71/71/68 Gy for DdCT-WET/DdCT/DrCT) which triggered immediate replanning. The dCT
predicted similar dosimetric indicators as the rCT.
When tumours regress, the previously blocked airway can reopen and reinflate the
collapsed lung (PT#3, Figure 6.16). Lung reinflation reduced the WET along the beam
path, and caused beam over-ranging (WETover-95%=41.4/4.1 mm for RPO/PA field). The
change in dose distribution compromised tumour coverage (iCTV ∆V99%=-27/-27/-13%
for DdCT-WET/DdCT/DrCT), which triggered replanning. The predicted loss of coverage was
higher in the dCT than in the rCT, which can be attributed to the partial truncation of the
CBCT at the beam entrance (see section 6.3.2.2).
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Figure 6.14: Images used and generated by the workflow for PT#1 (atelectasis), PT#2 (large tumour
shrinkage) and PT#4 (small tumour shrinkage). For PT#1 and PT#2, the dCT needed the correction step
(region defined by the red contour). For PT#4, DIR alone recovered the changes well; however, the truncated
CBCT data affected the similarity between dCT and rCT.
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Figure 6.15: (A) Color overlay of the CTs and corresponding dose distributions and (B) DVHs for PT#1,
PT#2 and PT#5. For PT#1 the appearance of atelectasis increased the WET, resulting in under-ranging
and loss of iCTV coverage. For PT#2 the shrinkage of the GTV resulted in decreased WET, and thus in
over-ranging and increase in dose delivered to the heart and cord. For PT#5 there were only small changes
in WET, and therefore all the dose distributions and DVH curves were similar.
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Figure 6.16: Images used and generated by the workflow for PT#3 (lung reinflation), PT#14 (regression
of infiltrating tumour) and PT#13 (shrinkage and changes in breathing pattern). For PT#3 and PT#14,
correction of the dCT was necessary (region defined by the red contour). For PT#13, DIR was able to recover
the tumour shrinkage; however, visible differences in setup occur between dCT and rCT, particularly in the
relative position of the main airways (yellow arrow).
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6.3.2.2 Tumour changes
Different tumour response scenarios were identified and detailed below.
Infiltrating tumours For PT#14, the GTV decreased from 4.1 cm to 2.7 cm in diameter
after four weeks of treatment (Figure 6.16). The uncorrected dCT resulted in DIR errors
of the lung tissue between the tumour and chest wall. After applying the correction
algorithm, the clinical indicators were nearly identical between dCT and rCT (iCTV
∆V99%=-5/-7/-6% for DdCT-WET/DdCT/DrCT).
Tumour regression When tumours regress, the topological changes may not be handled
by DIR alone. In PT#2 a 22.3 mm cavity appeared within the original tumour volume
(Figure 6.14). Its size and location were accurately identified and accounted for by the
dCT correction step. The reduction in WET along the beam path resulted in beam over-
ranging to the heart (WETover-95%=24.6/25.2 mm for RPO1/RPO2 field, Figures 6.15 and
6.17). Dosimetric indicators between dCT and rCT were similar, i.e., decreased iCTV
coverage (iCTV ∆V99%=-7/-6/-8% at DdCT-WET/DdCT/DrCT), and increased dose to the cord
(Dmax from 45 to 52/52/49 Gy for DdCT-WET/DdCT/DrCT) and to the heart (V45Gy from 25%
to 31/31/35% for DdCT-WET/DdCT/DrCT, Figure 6.15).
Changes in tumour density PT#20 had both regression and changes in tumour density;
the average intensity of the GTV decreased from 30 to -110 HU between the pCT/dCT
and rCT, corresponding to a local WET variation of approximately 7 mm (Figure 6.18).
The dCT retained the HUs from the pCT and underestimated the change in proton range,
i.e., WETover>3mm=27.0/40.7% for dCT/rCT (RPO1 field). Regardless of the differences in
WET between the dCT and rCT, identical reduction in dose coverage was detected in the
DVHs.
Moderate shrinkage/enlargement Moderate tumour regression was here defined as a
visually apparent change in tumour volume less than 25% of its original GTV. An example
is PT#11, who has focal shrinkage (Figure 6.18) resulting in modest beam over-ranging
(WETover-95%=8.5/7.5 mm for AP/RPO field), and an increase in dose to the cord (Dmax
from 30 to 36/37/37 Gy for DdCT-WET/DdCT/DrCT). PT#16 was the only case of tumour
enlargement during radiation treatment; the diameter increased 5 mm along the beam
path (Figure 6.18). Because of the complex organ geometry at the mediastinum, both beam
under and over-ranging were observed (i.e., WETunder-95%=1.1 mm and WETover-95%=3.6
mm for the RPO field), resulting in increased dose to the cord (Dmax from 35 to 46/47/40
Gy for DdCT-WET/DdCT/DrCT), and a right shift of iCTV/PTV DVH curves. In these two
cases the dCT and rCT offered similar clinical indicators with DIR alone (without the dCT
correction step).
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Figure 6.17: WET maps for planning and deformed/rescan CT; and corresponding difference maps for PT#2
(RPO1 field), PT#8 (PA field) and PT#19 (RPO field).
151
Lung adaptive proton therapy
Figure 6.18: Images used and generated by the workflow for PT#11 (focal shrinkage), PT#16 (moderate
tumour enlargement) and PT#20 (tumour density changes). Only PT#20 required the dCT correction step,
but not in the slice shown in this figure; the overall intensity in the gross tumour area (identified in yellow)
changed from 30 HU to -110 HU.
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Other factors affecting WET and dosimetric indicators In addition to DIR errors, setup
variations and differences in the respiratory pattern between CBCT and rCT scans can
result in differences between DdCT-WET/DdCT and DrCT. This implies that different clinical
indicators are being extracted, and can, therefore, create false positive/negative triggers for
oﬄine review. The online workflow was less robust for patients in whom the magnitude
of dose differences arising from setup variations was comparable to those arising from
internal anatomical changes. For PT#13, tumour shrinkage was well recovered by DIR;
however the position of the main bronchi was shifted superiorly in rCT in comparison to
the rCBCT (Figure 6.16). The movement of the main airway cause different predictions
of target coverage in different images (iCTV ∆V99%=+3/+1/-4% for DdCT-WET/DdCT/DrCT).
WET difference maps were also affected: the magnitude of WETover-95% was small but the
2D WET maps gave different indicators (WETover>3mm was 18.8/46.6% for dCT/rCT for
PT#19 RPO field, see Figure 6.17). Clinically, none of these patients required replanning
as the dosimetric changes were generally small and the effects averaged out during the
course of treatment.
Setup errors should not be confused with systematic drift of tumour position through
the treatment course. For PT#5, the primary tumour shifted in the inferior direction, and
this was consistent between the CBCT and rCT. DIR accurately described the change in
tumour position, but the modest change in WET had minimal effect on target coverage
or dose to OAR (Figure 6.15).
Due to FoV limitations, a minority of CBCTs did not encompass the entire exterior of
the patient body at the beam entrance (Figures 6.14, 6.16 and 6.18). If CBCT truncation is
uncorrected, it may lead to inaccurate clinical indicators (PT#3: iCTV ∆V99%=-27/-27/-13%
for DdCT-WET/DdCT/DrCT and, PT#17: iCTV ∆V99% =0/0/-5%).
6.3.2.3 General considerations
Eighteen of the twenty patients exhibited over-ranging of the proton beams. Two pa-
tients (PT#1 and PT#16) showed potential under-ranging. These were cases of atelectasis
and tumour enlargement. For all patients, the average absolute difference in WETover-95%
and WETover>3mm between dCT and rCT were 3.4±2.7 mm and 12±12%, respectively.
Figure 6.17 shows examples of WET and WET difference maps. WET difference maps
identified the same regions of under/over-ranging for all patients with large anatomical
changes. This was true even for PT#8 and PT#20, in spite of the full magnitude of the
over-ranging not being fully recovered due to limitations of the corrected dCT to repro-
duce complex shrinkage and/or density changes. In cases of smaller changes or setup
variations, the WET difference maps were less uniform. In general, values of WETover-95%
needed to exceed 15 mm before significant dosimetric changes could be detected. The
most common issues that could lead to a replan were loss of tumour volume coverage,
increase in maximum dose to the cord, and over-ranging of dose into the heart.
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A 3D gamma-index method (3%/3mm) was used to compare the dose distributions
using a 20% of the pD cut-off. Using DrCT as gold-standard, the percentage of passing
points for all patients were 88.5±6.1%, 89.4±4.7% and 90.1±4.4% for DpCT, DdCT-WET
and DdCT respectively; when considering only patients with changes in lung (PT#1 and
PT#3) and large changes in tumour volume (PT#2, PT#8, PT#14, PT#20) the values were
81.8±5.2%, 86.0±5.9% and 87.3±5.0%.
Considering the dosimetric statistics related with target coverage and OAR tolerances,
the most common issues were loss of coverage and increase in dose to the heart and cord.
For the remaining OAR investigated, in general, either the dose was quite low at planning
stage and small variations were negligible, or the tolerances were never met due to PTV
overlapping.
6.3.3 Discussion
CBCT plays an important role in IGRT. In proton therapy, quantitative applications
require accurate HUs in order to make clinical decisions for ART. dCTs generated from
CBCTs is one step in that direction and may play a complementary role to rCT. The careful
application of CBCT to correct its deficiencies may permit it to replace the majority
of verification scans for lung proton therapy. Quantifying its accuracy is therefore an
important subject prior to clinical implementation.
The accuracy of dCT for WET estimation and consequently the “dose of the day”,
for lung cancer patients was investigated using multiple CBCT datasets and registration
algorithms. Each type of CBCT has its own advantages as well as limitations, but taken
together it offers enough evidence for quantifying the uncertainties associated with DIR
and CBCT imaging for the proposed application. An overall uncertainty of 3.9±2.1 mm
(RMS) in the WET was found at the PTV distal surface. The rCBCT resulted in the
highest uncertainties due to discrepancies in positioning between rCBCT and rCT. The
lower results obtained for the sCBCT were investigated. One specific region with larger
DIR errors was in the posterior interface between lung, tissue and rib, where scatter
artefacts degraded the contrast between the heterogenous tissues. In the sCBCT, scatter
was overestimated in these regions, and was most likely the main source of discrepancy
in WET calculation between the dCBCT and sCBCT datasets. The comparison between
multiple registration algorithms provided a measure of the reproducibility of the method.
Differences between algorithms were small and not significant when dose distributions
were evaluated. This shows the versatility of the workflow proposed, which can easily
be modified to be used with in-house or commercial DIR solutions available at other
institutions. The ART workflow was implemented as a prototype in a research platform,
and therefore not optimised for fast online use. However, the most computationally
demanding processes (DIR, dCT correction and range-corrected dose) can be performed
in several minutes using GPU.
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DIR has inherent uncertainties and associated errors, especially at heterogeneous tissue
interfaces, that lead to inaccuracies in WET and dose computation. The cohort of lung
patients included in this study included a broad range of clinical situations that can
compromise the accuracy of the DIR. The main limitation is related with the mathematical
basis of the most common and popular DIR algorithms, whose deformations include only
translation, expansion and contraction. Changes in topology, such as the appearance or
disappearance of tissue, cannot be reproduced without introducing singularities in the
deformation fields. Since the intensities are mapped from the CT to the CBCT space,
variations in the density of the tissue between images cannot be reproduced [191]. In
fact, subtle changes in density of lung tissues between planning and verification (PT#20)
were undetectable on rCBCT but apparent on rCT. Additionally, the volume of rigid
bodies is not necessarily preserved and the displacement between ribs and lung may not
be accurately modelled without specialised algorithms [110, 192]. An important novel
aspect of this work was the implementation of a correction step of the dCT. This correction
step was a solution found to account for large changes in the lung, such as atelectasis
(PT#1), lung reinflation (PT#3) and pleural effusion; and within the tumour, such as cases
of tumour erosion (PT#2) or the regression of infiltrating tumours (PT#8, #14 and #20).
This method improved the accuracy of the WET calculation and range-corrected dose
estimation. For complex anatomical change such as pleural effusion, the appearance
or disappearance of a small layer of fluid may be too thin to be identified by the dCT
correction step. Further work is necessary to develop DIR algorithms (or additional
corrections) that account for the remaining issues described above. Scatter artefacts in
CBCT decreases image contrast and results in registration errors at the interface of lung-
tissue-bone at the posterior rib wall. The low dose thorax setting with a half-scan was
used for the CBCT acquisitions for all patients, and not adjusted for patient size; thus,
larger patients had poorer images available. Improvement to image reconstruction is
currently being worked by the vendor (IBA). Another common registration error was the
positioning of the scapula, which can move in and out of the path of lateral oblique fields,
and therefore cause variations in WET calculation. The CBCTs used in the study had a
limited FoV which may result in a cropped external contour and introduce errors in the
range-corrected dose for lateral oblique fields where the range was locally overestimated
(4 out of 40 fields) due to missing tissue. On the current system design, the CBCT was
retrofitted using the imaging panel for kV imaging. The panel was not designed to be
offset laterally and this causes the current FoV limitation. This is not a limitation of the
proposed workflow when CBCT systems with larger FoVs become available in the proton
clinic; additionally this limitation can be mitigated by positioning the patient to capture
the beam entrance during CBCT acquisition.
From a clinical perspective, two scenarios are possible with DIR errors. The first is a
false positive trigger, i.e., the dose calculated on the dCT indicated a change in dosimetry
when there is none. The outcome is an unnecessary CT scan to confirm the findings. The
other is a false negative trigger, i.e., the dose calculated on the dCT failed to detect the
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change in dosimetry. While this scenario poses a bigger risk it is unlikely to occur. Higher
DIR errors are associated with larger anatomical changes, and in such cases variations in
dosimetry are usually still predicted even if with a different magnitude.
Proton plans that are more robust to registration errors may be used to minimise
the issues generated by the anatomical changes. Thus, along with the impact of CBCT
datasets and DIR algorithms in the overall uncertainties reported, the impact of field
direction was also investigated. Each patient was treated with two treatment fields, with
the posterior-anterior (PA) direction being the most common treatment approach (85%
of the fields). Within those, lateral oblique beam were used in 38% of the cases. Due
to the distortions caused by the couch and cropped FoV, it was empirically expected to
have larger errors in WET for lateral oblique fields. In fact, a larger uncertainty in WET
was found for lateral oblique field than for posterior fields (WETRMS of 3.4±1.6 vs 4.5±2.4
mm); however we could not definitely link the source of those differences to the beam
direction. In fact, 42% of the lateral oblique fields corresponded to patients that required
dCT correction against only 23% for posterior fields. Since a greater uncertainty occurs
when dCT correction is required, this could be the reason of the differences found. A
larger patient cohort is necessary to further investigate the impact of beam direction.
Using dCT directly for dose recalculation is a viable alternative to remove errors
associated with DIR. Despite the vast work on directly using CBCT in conventional
photon treatments [9, 97, 99], its usability is still limited in proton therapy, as was shown
in chapter 5 and in other studies [193], and the dCT is a viable interim solution. Other
groups are working on more elegant approaches to improve the HU accuracy [194, 195].
The direct use of CBCT leaves other problems unanswered, such as limitations of the FoV
and contour propagation. Other approaches to estimate the “dose of the day” should
also be investigated; while range-corrected dose can be computed rapidly it is still only
an approximation. The uncertainty of the “dose of the day” computed online may be
reduced for instance by incorporating in the workflow a fast GPU-Monte Carlo calculation
[196].
One of the unexplored topics at the current stage of this work was the evaluation of the
workflow for automatic segmentation. The similarity between manually delineated and
automatically propagated (using the deformation fields) structures is a popular method
to validate DIR for clinical applications [10]. The open-source algorithms, NiftyReg
(chapter 3) and REGGUI [11, 12], had been previously validated in the context of HN
malignancies, and therefore their appropriateness for a similar clinical application had
been already investigated. Additionally, fast segmentation is a prerequisite the clinical
translation of a fast online ART workflow. Uncertainty in segmentation propagates to
dose-based clinical indicators of the need of replanning (for example, maximum dose to
the spinal chord), and this is a topic to be investigated in the future. Additionally, the
impact of the dCT correction step has to be accounted for when propagating affected
structures.
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Regarding the investigation of clinical indicators extracted from the dCT, although
the dCT may not reproduce identical WET maps, it identifies the same trends as the rCT
regarding the effect of the WET changes. 90% of the fields with WETunder-95%/WETover-95%
larger than 10 mm were properly identified as such from the dCT. The dose mapping
method reproduced similar clinical indicators for patients with considerable changes that
may trigger a replan. The most common issue was loss of target coverage of the iCTV.
For PT#1, PT#2 and PT#14, the impact to OARs was detected (oesophagus, heart/cord
and cord respectively). For PT#8, the changes in OAR dose were not properly detected,
while for PT#20 an increase in cord dose was incorrectly detected. When smaller changes
occurred, differences in OAR dose were also detected (PT#11, PT#12 and PT#16), but
some false positives/negatives occurred for loss of target coverage (PT#13, PT#15 and
PT#17). Variations in setup can result in overestimation (PT#9) and underestimation
(PT#19) of over-ranging, but with minimal dosimetric impact. In general, OAR doses
were maintained within tolerance; however, special care should be given to fields that
point towards an OAR, such as lateral oblique fields that may range out at the heart (PT#2,
PT#7 and PT#12).
An important conclusion taken from this retrospective investigation was the necessity
to evaluate multiple parameters during the decision-making process: changes in WET,
quantitative review of images and dose distributions, DVHs and corresponding dose
statistics. Flags raised by a single indicator should be backed up by additional evidence.
For example, the iCTV V99% statistic was quite sensitive even when the DVHs did not
reflect major changes. Similarly, large discrepancy in WETover>3mm/WETunder>3mm could
be found while the 2D WET maps were consistent in terms of identified areas of consid-
erable over/under-ranging. In cases where the anatomical changes are small the decision
to replan should not be based on individual scans, but rather on continued monitoring.
Smaller changes can in fact be comparable to setup errors, and may average out.
The rCBCT and rCT were acquired close in time but were not identical due to setup
errors. This is not ideal to validate the clinical workflow and indicators, but is represen-
tative of what would happen on prospective patients (i.e., a rCT would be ordered based
on the CBCT and setup variation cannot be avoided). Daily positioning variations, such
relative position of the trachea (PT#13), pacemaker wires (PT#7) and shape of external
contours can influence the range of the proton beams. This also highlights one of the
limitations of this study, which was to look at a single time point per patient. At the
moment not enough data was available to evaluate multiple images per patient. The
promising results of this first study will be motivation to continue acquiring CBCT and
rCT data simultaneously.
The range-corrected dose distributions lead to very similar clinical indicators as the
recalculated doses on the TPS, and in general similar dosimetric indicators were extracted.
This intermediate step in a clinical ART workflow is of utmost importance to carefully
review all the clinical indicators and avoid requesting unnecessary verification scans due
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to gross operator errors. It is also the most opportune moment to manually edit the dCT in
case gross registration errors were not properly accounting for by the correction step. The
translation of the workflow to prospective clinical routine will allow to build confidence,
and possibly future simplification of the workflow.
CBCT has just recently become available at one of the PSPT treatment rooms at HUP,
hence the reason for this first clinical application to be performed in lung patients. The
method can be directly applicable to spot scanning treatments, as the “dose of the day”
is estimated based on previously calculated dose distributions and WET maps only, and
not on plan-specific parameters. However, compensator smearing is not used in spot
scanning; thus, the plan robustness has to be assessed differently. It can also be fine-
tuned for other treatment sites. Currently, the plan is to extend the CBCT system to
two additional gantries at HUP in 2016; therefore within the next months this study will
be extended to HN malignancies. CBCT imaging has an important role in image-guided
proton therapy, particularly as a substitute for verification scans. In addition to contribute
to patient outcome by allowing to identify those that benefit from replanning and reducing
the dose delivered in imaging, there are other important benefits from an operational
perspective. Depending on the frequency of scans and volume of patients, verification
CT scans take up significant resources and time on the CT scanners. Substitution of the
majority of verification scans with CBCT will have positive operational impact for the
clinic.
Currently the decision support for replanning is based on dosimetric analysis of the
rCT, using dose clinical indicators used in this study. The set of clinical indicators inves-
tigated here were thus chosen as an empirical and sensible starting point for replanning
threshold levels, but were not fully optimised by any means. Based on the data gathered,
large values of under/over-ranges (WETunder-95% >10 mm and WETover-95% >15 mm), dose
to the heart/cord (∆V45Gy >15% and ∆Dmax >5 Gy), shifts of the DVH curves to lower
doses for targets (PTV/iCTV) are good indicators and thresholds to trigger oﬄine review.
To develop an optimised decision support for replanning was out of the scope of this
project, but is a natural evolution of the work here presented. It is crucial for clinical
translation to identify the most adequate clinical indicators, and define clear thresholds
that trigger the following action-level up until the replanning decision. On the techni-
cal side, improvement of the workflow to minimise its current limitations is a priority,
which includes investigating lung-specialised DIR algorithms, automatic segmentation
validation, improvement of CBCT image quality and integration with TPS or using more
accurate dose calculations.
6.3.4 Conclusions
A CBCT and DIR based adaptive proton therapy workflow for lung cancer patients
was proposed and evaluated. In the workflow a fast calculation of the “dose of the
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day” was implemented by computing the WET along the beam paths in the corrected
dCTs. The accuracy of the method was benchmarked to the forward dose calculations
using the rCTs. In addition, multiple surrogates of an ideal CBCT were created to assess
the accuracy of the calculations; different DIR algorithms were applied to estimate the
reproducibility of the results. The dCT provided similar WET and dosimetric information
as a rCT in a multitude of clinical scenarios. However, one important finding was that
DIR alone could not fully reproduce all of the complex changes in the thorax and a novel
correction step was proposed to deal with gross registration failures.
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Chapter 7
Multimodal and multitemporal
imaging in radiotherapy
If a man never contradicts himself, the
reason must be that he virtually never
says anything at all.
Erwin Schrödinger
With the advent of functional imaging to clinical settings it becomes important to
incorporate the information from various imaging modalities (particularly MRI) into the
radiotherapy pathway. The main objective of this chapter was to investigate the feasibility
of automatic DIR in registering multimodal and multitemporal CT and MR images. This
study was, as in chapters 2 to 5, focused on HN malignancies.
The work in this chapter resulted in the following output:
• C. Veiga, R. Mendes, D. Kittapa, S.-L. Wong, R. Bodey, M. Modat, S. Ourselin, G.
Royle, and J. McClelland, “Optimization of Multimodal and Multitemporal De-
formable Image Registration for Head and Neck Cancer”, Imaging and Computer
Assistance in Radiation Therapy Workshop of the 18th International Conference
on Medical Image Computing and Computer Assisted Intervention (Munich, Ger-
many, 2015).
7.1 The role of multimodal and multiparametric imaging in ra-
diotherapy
The most widespread concept of treatment adaptation in radiotherapy is to modify,
in an online and automated fashion, the treatment being delivered such that the physical
dose delivered matches the dose originally planned, considering the possible temporal
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anatomical changes of the patient throughout the treatment course. These changes may
be tumour shrinkage and weight loss during the course of the treatment, such as the
clinical problems studied in the previous chapters. However this kind of approach only
considers physical dose maps and ignores radiobiological aspects; in fact, the relationship
between biological effect and physical dose is not linear. When assessing and verifying the
success of a treatment, biological effects and final outcome (e.g: cure or toxicity) are more
relevant than the actual physical dose map. However the aim is, and has always been,
to obtain a dose distribution that based on clinical experience and biological knowledge
available, will result in the best clinical outcome. Therefore, treatment adaptation should
also be guided by biological parameters [197].
Biological parameters can potentially be measured using sequential multimodal and
functional imaging techniques. Functional imaging stands for imaging modalities that
measure quantitatively biological parameters in healthy tissues and tumours. The pixel
intensity of the images produced can be directly related with a particular physical, chem-
ical or biological property of the tissue. MRI, magnetic resonance spectroscopy (MRS),
single-photon emission computed tomography (SPECT), PET and ultrasound offer addi-
tional and complementary information of the tumour at the physiological, cellular and
molecular levels. Such imaging techniques can provide non-invasive, quantitative and
3D characterisation of diverse physiological mechanisms, such as blood flow, vessel per-
meability, cellularity, cell membrane turnover, cell surface receptor expression, apoptosis,
metabolism, cell proliferation and hypoxia [198]. Potentially, this means being able to
quantitatively measure the tumour growth, tumour status and predict treatment response
and outcome early on. This early assessment would allow for optimisation of individu-
alised treatment for patients with the final objective of maximising treatment outcome,
reducing toxicity and morbidity [199]. This additional information can be incorporated in
an ART workflow to assess early the outcome of a treatment, and intervene if the patient
response suggests that adaptation is necessary. Introducing additional multimodal and
functional imaging into the patient pathway has promising applications in radiotherapy.
The different areas of interest are summarised below:
Pre-treatment imaging
• Pre-treatment prediction of tumour response and personalised medicine: Ra-
diomics, data mining of large patients databases and machine learning can be
used to generate models to predict treatment outcome [200]. Additional imaging
can generate more accurate models and is key for the widespread of personalised
medicine. For example, when the cancer is particularly radio-resistant, more ag-
gressive therapies may be considered.
• Treatment planning strategies: Additional imaging has been used in several appli-
cations to treatment planning such as (i) target delineation [59], (ii) dose boost to
radio-resistant regions of the tumour (also known as dose painting [201]), and (iii) to
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decide on the choice of beam arrangements to avoid regions of high radio-sensitivity
or functionality.
Imaging throughout the course of treatment, including image-guidance
• Predicting response early after initiating therapy: The use of some functional imag-
ing has been shown to predict the success of therapy before conventional mea-
surements of size are measurable [202]. Anatomical and morphological changes
often occur temporally downstream from the underlying physiological, cellular
and molecular changes, so appropriate imaging metrics may be able to provide
insight into early disease response and progression [198]. The early recognition of
failure to respond to a specific treatment may allow alternative treatments to be
explored, and therefore avoiding unnecessary radiation exposure and associated
side effects [203].
• Treatment adaptation: Imaging information can be used to feed an ART workflow,
by providing complementary information on anatomical and functional modifica-
tions of the targets (such as tumour shrinkage or modification in its subregions of
elevated radio-resistance). This is of particular interest for MR-LINAC systems,
where MR is used for IGRT, and therefore available at the moment of treatment
[204, 205].
• Improved understanding of the biologic effects of therapy: Measuring the temporal
biological changes can infer how physical dose correlates with biological effect, and
track the mechanisms and events that lead to the success/failure of the therapy.
Pos-treatment imaging
• Assessment of treatment response: For many years the standard way to assess the
patient’s response to treatment has been to measure tumour size on longitudinal
CT or MR scans, using 1D and/or 2D criteria, such as World Health Organiza-
tion (WHO) guidelines [206] and the response evaluation criteria for solid tumour
(RECIST) [207], respectively. Such anatomy-based response-assessment techniques
have inherent limitations because 1D and/or 2D measurements are used to quantify
changes in 3D. Arbitrary cut-off values categorise response and progression, do
not take in consideration changes in tumour density, and cannot distinguish viable
from dead tumour regions [208]. The increasingly recognition of the importance
of “beyond anatomy” imaging is proved in the 2000 amendment of RECIST [209],
which includes FDG-PET in assessing progressive disease [198]. Additional imag-
ing allows for a more complete assessment of treatment response [210], and opens
up the possibility of correlating physical dose and biological properties with the
outcome.
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7.2 Rationale
The idea of incorporating biological information in the radiotherapy pathway is not
per se novel. As a matter of fact, several strategies are part of routine clinical work,
such as dose boost, dose escalation and lower-dose irradiation of structures suspected of
infiltration but without clear signs of disease. The big challenge is how to incorporate
increasingly amounts of biological information relevant to radiotherapy response into
planning, adaptation and follow-up of individual patients. The ability to make firm
conclusion related with the usefulness of defining sub-regions of interest in the patient
anatomy with anatomical and functional imaging method relies on the accuracy to co-
register multiple sources of information [211]. Therefore, accurate image registration is
a key part in the different applications of multimodal and multiparametric imaging. In
the HN region, MR images are harder to register than other modalities (such as CT and
CBCT) for several reasons: (i) the image resolution is poorer, particularly in the shoulders
and thoracic area (ii) lack of proper immobilisation (i.e., treatment positioning may not be
possible in the MRI scanner due to the coils and patient comfort) [212], (iii) image-specific
artefacts, such as those caused by the inhomogeneities of the magnetic field (bias), and
(iv) limited FoV of the current clinical acquisition protocols.
Due to the difficulties in registering these datasets most of the work done in MR
registration uses rigid alignment or semi-automatic DIR guided by manually annotated
landmarks. Not many studies have been done on validating automatic DIR for multi-
modal and multitemporal data in the HN region in the context of radiotherapy. Leibfarth
et al. use DIR between planning PET/MR and CT images for HN patients, comparing
three different optimisation metrics of a B-Spline DIR for dose painting applications [213].
Slagmolen et al. present a small feasibility study on CT-to-MR and MR-to-MR DIR for
radiotherapy treatment planning [214]. On a more technical side, some groups have been
developing specialised DIR algorithms for multimodal imaging [215, 216]. Other authors
looked a various applications in different anatomical sites [217–219].
In this work the use of DIR for multimodal and multitemporal registrations was in-
vestigated and optimised. The stationary velocity fields implementation available in
NiftyReg is used to co-register images from different modalities at similar timepoints (CT
and MR) and from the same modality at different timepoints (MR) to the same refer-
ence space, and the quality of the registrations was assessed using manually annotated
structures and properties of the DVFs.
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7.3 Methods and materials
7.3.1 Patient data acquisition
The data used in this study was selected from a readily available database of HN pa-
tients acquired in a pre-existing and on-going clinical trial at UCLH. The aim of the trial
was to ascertain the sensitivity and specificity of multiparametric MR for the detection
of active disease in post chemoradiation residual tissue masses, and to investigate the
prognostic value of conventional anatomical and functional MRI in determining early
and final treatment outcome in HN patients. Therefore, each patient included in the
trial would receive a routine radiotherapy pCT, a pre-treatment MR in treatment position
booked as close as possible in time to the pCT (MR1), and a follow-up MR six months after
treatment (MR2). The MR sequences acquired consisted of T1- and T2-weighted, T1-fat sat-
urated, diffusion-weighted (DW), blood oxygen level dependent (BOLD), and dynamic
contrast enhancement (DCE). Different patients had different combinations of multipara-
metric imaging acquired, and the acquisition mode common between all datasets was
T2-weighted. A total of approximately 40 patients had completed the trial at the time of
this study.
The clinical data available had a considerable amount of anatomical and functional
information available, which in theory allowed for potential future studies built on the
work here described. However, the aims of the clinical trial were not defined with the
application of DIR here proposed in mind, and therefore the imaging acquisition protocols
were clearly sub-optimal for our study. Clipping of the FoV of MRI images was a common
acquisition problem that affects the registrations. A complete body contour is crucial for
global alignment and to avoid registration errors near the edge of the FoV. Additionally,
some patients did not acquire the first MR as they could not endure being inside the MRI
scanner. For other patients the images were acquired but not in treatment position. In
these cases (and similarly to pos-treatment images) the pCT and MR1 had very different
positioning, particularly in the flexion of the neck and lack of neck support system. This
variability in the data required selection of adequate datasets and grouping based on
differences in pre-treatment setup.
Thus, a total of 8 datasets were used to qualitatively investigate the most appropriate
strategies for DIR; however, only 3 out the 8 datasets were used for in-depth quantitative
analysis. The remaining patients were not included at this stage due to incomplete
expert delineations. The inclusion criteria of this study was solely based on minimising
acquisition issues characteristic of routine MR (such as clipping of the FoV), and not to
select patients with smaller anatomical changes (Figures 7.1 and 7.2). These 8 datasets
were all cases of MR1 acquired in treatment position.
The pCT imaging protocol was as described in section 2.5.1.1. The MR images were
acquired using the MAGNETOM Avanto (Siemens Healthcare, Erlangen, Germany) MRI
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Figure 7.1: Example of a patient included in this study: axial (left) and sagittal (right) view of (a) planning
CT, (b) pre-treatment and (c) pos-treatment MRs. The pos-treatment MR was not acquired in treatment
position.
scanner (1.5T). In T2-weighted images, TE varied between 90 and 110 ms, TR between
2400 and 8100 ms, slice thickness between 3 or 5 mm with a gap of 0.5 mm, and number
of slices between 29 and 61. In addition, image resolution was 0.703×0.703 mm2 or
0.859×0.859 mm2.
7.3.2 Multimodal and multiparametric imaging in a radiotherapy workflow
For integration of MR data into the radiotherapy pathway, image registration is nec-
essary between CT at the planning stage and repeat MR at different time points. To
co-register multitemporal MRs with CT, two registration pathways can be followed (Fig-
ure 7.3):
1. the pos-treatment MR is registered with the pre-treatment MR, which is indepen-
dently registered to the CT;
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Figure 7.2: Example of limitations of the MR data available: sagittal view of (a) reduced field-of-view
issues and (b) poor image quality and (c) large anatomical differences between pre-treatment (left) and
pos-treatment (right) MRs, such as patient weight and tumour volume (for this particular patient the
pre-treatment MR was not acquired in treatment position).
Figure 7.3: Schematic diagram of registration pathways. To register CT with a pos-treatment MR two
pathways can be followed: (A) the pos-treatment MR is registered with the pre-MR, which is registered to
the CT or (B) the pos-treatment MR is registered directly with the CT.
2. the pos-treatment MR is registered directly with the CT.
In this work only the results from the first pathway were assessed quantitatively. Due
to the 6 months gap between pCT and MR2 it was very challenging to tune the DIR
parameters to be universally good, and in general the results were poor and physically
implausible. Therefore, it was a preferable approach to independently register similar
anatomical information from different modalities at similar time points (pCT-MR1) and
anatomical deformations from the same modalities at different time points (MR1-MR2).
This allows to decouple the difference in image intensity between modalities from the
anatomical deformations that occur over time. Therefore, two registration methods were
investigated:
• CT-MR1: if the two images were acquired close in time and with same immobilisa-
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tion, a rigid registration is the easier and natural approach. However, DIR can be
used to compensate for residual setup errors. This may introduce additional issues,
which will be investigated here.
• MR1-MR2: monomodal DIR was investigated to track over time changes in anatomy.
The ability to map anatomy between time points also allows to propagate co-
registered functional information (using the same DVFs as in the anatomical se-
quences).
7.3.3 Image registration settings
NiftyReg stationary velocity fields implementation was the algorithm chosen for the
registrations. As seen in chapter 4 it generates registrations with a geometric matching
comparable to the standard unidirectional and asymmetric algorithms, while ensuring
more desirable physical properties such as symmetry and inverse-consistency. DVFs are
generated in both registration direction, facilitating both contour propagation between
modalities and time points. Additionally, to propagate functional information acquired
simultaneously with the anatomical sequences theoretically more plausible registrations
are preferable since it involves tracking voxel-by-voxel changes over time of quantitative
biological markers, such as the apparent diffusion coefficient (ADC) maps from DW-MRI.
Preliminary evaluation of the DIR quality was performed to find suitable parameters
for the registrations, similarly to the work described in section 2.4 for CT-to-CBCT reg-
istrations. Several combinations of weight of the penalty terms, CPS and registration
strategies were investigated. A total of six registrations parameters were selected and
now more extensively tested per application. NMI was chosen as similarity measure for
multimodal registrations, and LNCC for monomodal registrations. LNCC was preferred
over other monomodal similarity measures since it handles better the non-uniform biases
that cause artefacts in MR images [111]. Unlike the CT-to-CBCT registrations, here the
CPS was defined in mm due to the varying resolution between datasets. Additionally,
since the tumour is visible in some images (pCT and MR1) and not in others (MR2) the tu-
mour was masked out to avoid optimisation of the registration in regions were there is no
anatomical matching. CT-MR1 registrations with immobilisation require larger constrains
to reduce the risk of the registration causing additional uncertainties in comparison with
rigid-only alignment (such as deformation of bones, etc). When the immobilisation is not
present, those constrains are relaxed to give the algorithm enough freedom to recover
larger deformations.
A total of six registration parameters with variable weight of the BE and CPS were
investigated per registration type. The values of BE varied between 0.01% and 1%, while
the CPS values tested ranged from 8 to 12 mm. NMI was chosen as similarity measure for
multimodal registrations, and LNCC for monomodal registrations. LNCC was preferred
over other monomodal similarity measures since it handles better the non-uniform biases
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Figure 7.4: Structure set manually delineated on the CT and MRs of each patient. This set consisted
of vertebrae C3 and C5, mandible, thyroid cartilage (bony anatomy), spinal canal, brainstem, parotids
(OARs), submandibular gland and sternocleidomastoid muscles (soft tissues).
that cause artefacts in MR images [111]. To minimise the impact of artefacts due to field
inhomogeneities, the MR images were corrected for bias using the N4ITK algorithm [220],
which is available incorporated in NifTK. To avoid the optimisation of the transformation
in regions where there is no anatomical matching, the tumour was masked out in MR1-
MR2 registrations for patients where the gross tumour disappeared between MR1 and
MR2 (as a result of the treatment). This avoids unrealistic deformations in these regions
of no real one-to-one matching. The resulting deformation is a smooth interpolation
between the mapping outside the mask, guided by the regularisation of the registration.
7.3.4 Quantitative analysis
The registrations were compared qualitatively, by visual inspection, and quantitatively
by similarity of structures with the manually delineated gold-standard. The registration
quality was assessed in both directions.
The structures were manually delineated on the pCT, MR1 and MR2 per patient by
the same expert radiation oncologist, Dr Dhanasekaran Kittappa, Dr Swee-Ling Wong,
and Dr Ruheena Mendes. A total of 12 structures were delineated on the CT, MR1 and
MR2. This structure set provided an indication of how well the registration accounted for
anatomical differences and positioning errors (Figure 7.4). This set consisted of vertebrae
C3 and C5, mandible, thyroid cartilage (bony anatomy), spinal canal, brainstem, parotids
(OARs), submandibular gland and sternocleidomastoid muscles (soft tissues).
The registrations were assessed in terms of the following using the following quanti-
taties: DSC, OI, FN, FP, DT and CoM (section 2.5.1.3 and 3.2.3.1); HE, properties of the
determinant of the Jacobian [det(Jac)], and ICE.
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Figure 7.5: Example of registrations: (a) MR2, (b) MR1, (c) MR2 deformed to MR1, and (d) overlay between
MR1 (magenta) and deformed MR2 (green).
7.4 Results
Analysing the quantitative results obtained for all the registrations performed, the
combination of parameters that worked the best in the available datasets were BE=1%
and CPS=12 mm for CT-MR1, and BE=0.1% and CPS=12 mm for MR1-MR2. In CT-MR1
registrations, it was preferable to use a higher weight of the BE than for MR1-MR2. This
reduced the risk of the registration causing additional uncertainties in comparison with
rigid-only alignment (such as deformation of bones). However, if the immobilisation is
not present, those constrains should be relaxed to give the algorithm enough freedom
to recover larger deformations. Since multimodal registrations had to capture larger
anatomical changes the constrains had to be relaxed (Figure 7.5), and the properties
of the DVFs reflect also this. A higher CPS in general resulted in DVFs with more
desirable properties, which did not compromise the similarity between structures. For
this combination of registration parameters, the results obtained for the quantitative
evaluation of the DIR can be found in Table 7.1.
Additionally to the global results provided in Table 7.1, the results were also grouped
and analysed by structure type. In MR1-MR2 registrations, the DSC values were 0.62±0.12,
0.77±0.08 and 0.84±0.07 for bony anatomy, soft tissues and OAR in DIR cases, and 0.4±0.3,
0.63±0.18 and 0.65±0.19 when using a rigid-only registration. The use of a rigid-only
transform in MR1-MR2 registrations was not adequate, as for some anatomical structures
the overlap could be close to zero due to the large anatomical changes and differences
in positioning between pre and pos-treatment scans. For CT-MR1 registrations the DSC
values were 0.57±0.18, 0.79±0.06 and 0.81±0.04 for bony anatomy, soft tissues and OAR
when using DIR, and 0.57±0.18, 0.74±0.09 and 0.79±0.04 when using rigid-only registra-
tions. The results obtained with DIR and rigid-only registrations were very similar, with
DIR performing marginally better in the soft tissue regions.
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Table 7.1: Mean values ± standard deviation of dice similarity index (DSC), overlap index (OI), false negative (FN),
false positives (FN), distance transform (DT), centroid position error (CoM), harmonic energy (HE), properties of the
determinant of the Jacobian [det(Jac)], and inverse consistency error (ICE) for CT-MR1 and MR1-MR2 registrations.
The results are averaged for all patients, structures or DVFs, and registration directions.
CT-MR1 MR1-MR2
Geometric matching
DSC 0.72±0.16 0.74±0.13
OI 0.73±0.19 0.75±1.5
FP 0.3±0.3 0.3±0.2
FN 0.27±0.19 0.24±0.15
DTmean (mm) -0.1±1.8 0.1±1.7
DTstd (mm) 2.2±1.2 2.3±1.6
|DT|mean (mm) 1.8±1.0 1.6±1.1
|DT|std (mm) 1.9±1.3 2.1±1.7
|DT|95% (mm) 6±4 6±5
|DT|max (mm) 10±6 10±6
CoM (mm) 3±2 3±2
Characteristics of the deformation fields
HE 0.15±0.01 0.39±0.06
det(Jac)1% 0.72±0.10 0.5±0.3
det(Jac)99% 1.32±0.09 1.7±0.3
ICEmean (mm) 0.08±0.10 0.8±0.7
ICEstd (mm) 0.2±0.2 1.9±1.5
ICE99% (mm) 0.9±1.2 10±8
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7.5 Discussion
Promising results were found for multimodal and multitemporal registrations. For
the soft tissues and OARs, values found were in agreement with results from other
multimodal studies [213, 214], and comparable to monomodal or quasi-monomodal (CT-
CT/CT-CBCT) studies [87, 221]. In spite of the large deformations between pre- and
pos-treatment images, it was possible to achieve similar registration accuracy as for CT
and MR in treatment position.
The registration of bony anatomy was poorer than for other types of structures. On one
side, the reduced contrast between soft tissue and bone in MR difficulties the delineation
of bones, particularly for complexly shaped structures such as the vertebrae, resulting in
a non-ideal gold-standard. This low contrast also affects the quality of the registrations.
However, the main interest in using MR is not to provide additional information on the
bone anatomy (where CT is more adequate), but rather on the soft tissues. Thus misreg-
istrations of the bones is of reduced importance when considering clinical applications
and, in fact, in regions of higher clinical relevance, such as OAR and soft tissues, DIR
performed in a higher level of accuracy. Nevertheless, the poor registration of the bones
may affect nearby soft tissues so it is of importance to develop DIR strategies that account
for the rigid behaviour of bony anatomy.
CT-MR1 DIR slightly improved the anatomical matching in comparison to a rigid
registration; however, the difference was not clinically significant. One must carefully
tune its DIR registration to avoid introducing errors in this process. Further studies with
a larger patient dataset are necessary to fully understand this additional uncertainty, and
also to validate CT-MR registrations for patients that can not acquire MR1 in treatment
position (i.e., with considerable setup variation between scans).
The FoV clipping was found to limit the quality of the registrations. A clipped body
contour reduces the ability to capture global deformations and generates unrealistic de-
formations within the patient near the edges of the FoV. For example, this was found
to interfere in the registration of the mandible, which was very often clipped in the MR
scans.
7.6 Current status and future work
The work here presented was a first step toward incorporating additional imaging
into the radiotherapy pathway; thus some aspects of the current work were not finished.
Two particular aspects were investigated but not included in this chapter:
1. Only work on registering CT-MR1 with similar positioning was reported in this
thesis. However, a similar optimisation was performed using two datasets where
the MR1 was not acquired in treatment position. These datasets served as training
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sets for the optimization of registration strategies, which differed from the cases
where the patient could be immobilised in the MRI scanner. The most important
conclusion of this study was that the constrains of the registration had to be relaxed
to be able to account for changes in position; however, no quantitative data was
available of this evaluation due to lack of complete delineations from physicians.
2. Unlike the CT-to-CBCT registrations used in the previous chapters, in CT and MR it
was possible to unequivocally identify points and OAR relevant to HN treatments.
The target registration error (TRE) was measured, and analysed using the mean
and root-mean square error of the absolute TRE. The components in the right-left
(RL), anterior-posterior (AP) and superior-inferior (SI) were also assessed separately.
These results were also not reported as complete identification of landmarks was
not concluded by the completion of this thesis. Nevertheless, all the analysis code
was produced and tested.
Traditionally, MRI was used to acquire additional anatomical information, since un-
like CT it provides high contrast in soft tissues. Nowadays MRI technology is rapidly
evolving from anatomical and structural to dynamic, functional and metabolic imaging.
Functional MRI sequences include DCE-MRI, DW-MRI and MRS [199]. The work here
presented focused on anatomical information only, so future work will also focus on
tracking functional information associated with the anatomical scans, with a particular
interest in DW-MRI. DW-MRI measures the diffusion of water in tissue. Water motion
is not random in tissue, but instead modified by flows within conducts and interactions
within the cells and with the extracellular matrix [222]. Movement of the tissue water
molecules between two gradients results in dephasing, depicted as signal loss. This signal
loss will be proportional to the amount of water molecule movement and the strength of
the gradients. By repeating the sequence with different gradients, one can quantify the
observed signal loss using the ADC [201]. There appears to be a correlation between the
ADC values, tumour cellularity and tumour grade. ADC values can be measured before
and during treatment to demonstrate the presence or absence of therapy-related changes
in tumour tissue architecture [199].
Using DIR to map functional information is still a unexplored topic in the literature.
Galban et al. evaluated mid-treatment MR as an early biomarker for outcome, using
a semi-automatic algorithm to propagate contours between time points [223]. A step
forward from this study would be to look at sub-regions of the tumour, which would
also require an accurate one-to-one mapping. Functional acquisitions are acquired co-
registered to anatomical acquisitions, but further corrections may be necessary to deal
with artefacts and patient motion. In the same study functional-to-anatomical DIR is
performed to deal with susceptibility artefacts and patient motion. However, it is probably
more adequate to first correct the functional images using specialised methods for that
purpose as DIR can introduce additional uncertainties [224, 225].
One of our main interests is to use multimodal and multiparametric MR imaging in
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the context of ART applications, which is becoming an increasingly relevant topic with
the advent of the MRI-LINAC [226]. The present study is not ideal to validate the use
of DIR for such applications, as the multiple MRs were not acquired throughout the
treatment. Such a dataset was not available at UCLH or easily available from other col-
laborators. However using a pos-treatment MR results in more challenging registrations,
and therefore MR2 can be considered a surrogate for MR acquired during treatment. This
is however only true when considering the mapping of healthy tissues. Tracking of tu-
mour volumes has to still be properly validated when the MRs are acquired throughout
the course of radiotherapy. However, this is not a trivial matter due to the complexity
of the mechanisms of tumour microscopic response. The challenges in tracking and val-
idating tumour progression are the motivation behind the work presented in chapter 8,
where the concept of using an in vitro cancer model as a controllable and deformable
bio-phantom is explored.
CT-to-MR and MR-to-MR DIR are of interest in radiotherapy for other applications,
such as MR-based treatment planning and estimation of attenuation corrections for
PET/MR scans. MRI-LINAC systems are becoming available in clinical settings, and
synthesising CT from MR is one of the potential applications of CT-to-MR and MR-to-
MR [227]. Quantitative PET reconstruction requires correction for photon attenuations
using an attenuation coefficient map, that is a measure of the electron density (i.e., CT
information) [228].
7.7 Conclusion
In this chapter the use of an open-source DIR algorithm was investigated for the reg-
istration of CT and MR datasets from HN patients. The results founds were preliminary
but promising, which allowed to identify the limitations of current DIR algorithms and
current protocols of MRI acquisition. This was a first step toward incorporating additional
imaging into the radiotherapy pathway.
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A novel artificial cancer mass model
for imaging applications
To raise new questions, new
possibilities, to regard old problems
from a new angle, requires creative
imagination and marks real advance
in science.
Albert Einstein
In this cancer models were investigated as a bio-phantom for multimodal imaging
applications. Tissue engineering techniques were explored to produce living samples
MRI-friendly; the design process of the samples and the initial imaging and characteri-
sation are the focus of this chapter. This chapter, unlike the previous ones, has a more
descriptive character. It describes in detail the exploratory work performed in this topic
to guide future studies.
The work in this chapter resulted in the following output:
• C. Veiga, T. Long, B. Siow, M. Loizidou, G. Royle, and K. Ricketts, “MO-F-CAMPUS-
I-04: Magnetic resonance imaging of an in vitro 3D tumor model,” Med. Phys.
42(6):3579 (2015).
8.1 Introduction to tissue engineering
One of the major obstacles in translating multimodal and functional imaging to routine
clinical practice is the lack of clinical evidence of the benefits of doing so. Even though
numerous benefits of using additional multimodal and multiparametric imaging (partic-
ularly MRI) in radiotherapy have been reported by several research groups, ranging from
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Figure 8.1: Platforms to study cancer and therapies: (a) monolayer cells lines, (b) in vitro 3D cancer models,
(c) xenograft and, (d) clinical trials.
animal ([229–232]) to patient studies ([59, 210, 223, 233]), there has yet to be a translation
from research to routine clinical practice. Additional imaging is costly and poses addi-
tional risks to the patients, so further evidence of the benefits of acquiring it is necessary.
There are several platforms to study cancer and therapies (Figure 8.1). Ground-truth
evidence is gathered in clinical trials, which are performed on a small sample of patients
and require ethics approval. Most of our current knowledge of cancer biology and the
effect of therapeutic treatments outside of clinical trials comes from pre-clinical studies,
from which the two most common models are in vitro monolayer cell lines (2D) and in vivo
animal trials (xenograft). These models attempt to mimic the biological characteristics of
the tumour microenvironment outside the human body. The tumour microenvironment
consists of the cancer cells, which interact dynamically with the surrounding stroma. The
stroma contains non-cancer cells, secreted soluble factors (such as growth factors) and
non-cellular solid material that provides structural support and biomechanical properties,
the ECM. The ECM of connective tissues represents a complex combination of diverse
protein families: collagen, fibronectin, elastin and laminin.
Traditional in vitro systems involve growing cancer cell lines in monolayers in cell
culture (2D). The main advantage of this simple model is to be highly reproducible and
responsive to drugs and radiation [234]. 2D studies contributed greatly to our current
understanding of carcinogenesis and tumour response to treatments [235]. However,
the non-existence of their native microenvironment often does not accurately forecast
a tumour’s in vivo response [236]. This approach lacks essential cancer characteristics:
complex interactions between cancer cells and stromal cells or ECM components, hypoxia
and angiogenesis drivers and architectural characteristics [235].
The most common in vivo model is the xenograft, which consists of injecting human
cancer cells or small fragments from cancer specimens in the laboratory mice (Mus mus-
culus), and allowing the tumour to grow. A great advantage of this method is that both
cancer tissue and surrounding stroma can be transplanted, mimicking the complexity of
the human tumour environment. The main disadvantages of this method are its laborious
nature, the need for animal facilities, ethical approval, and the resulting poor predictions
[234, 237].
As an alternative to animal and patient data, the use of novel artificial cancer masses to
provide evidence of the benefits of additional imaging during radiotherapy is suggested
176
Introduction to tissue engineering
Figure 8.2: The three elements of tissue engineering: cells, matrix (or scaffold) and biochemical and physical
signals. Adapted from [242].
and investigated in this chapter. In vitro tumour models are invaluable systems for study-
ing the dynamic and progressive behaviour of cancer under controlled conditions [238].
3D in vitro models have been used in cancer research as a compromise between the sim-
plicity of 2D cultures and the complexity of mice models. Intermediate 3D models were
firstly developed, known as multicellular tumour spheroids [239] and gel embedding
[240], and are able to mimic limited aspects of the tumour biology. Such models have an
intrinsic limitation in size due to the lack of mechanisms of oxygen transport. Recently
tissue engineered 3D complex tumour models have been built to be biomimetic (both
cell-cell and cell-ECM interactions are reproduced), aiming to accurately replicating the
native in vivo scenario in which they are found [241]. Cells cultured in 3D configurations
differ greatly from cells cultured in 2D monolayers in terms of cell density, ECM synthesis,
cell surface receptor expression, cell contraction, intracellular signalling and metabolic
functions [238]. Three key elements define a tissue engineered structure: the properties of
the cells cultured, the surrounding matrix (that mimics the ECM), and their biochemical
and physical properties (Figure 8.2).
Previous work by the Division of Surgery and Interventional Science (UCL) enabled
the construction of 3D samples that closely mimic colorectal cancer [243]. In chapters 3
and 7 the ability of using DIR to map contours between scans was evaluated, but only
for OARs. Propagation of target volumes is more challenging due to the complexity of
the tumour microscopic structure and of the biological responses that occur as effect of
treatment. A quantifiable and deformable bio-phantom can potentially provide some
insight into this clinical problem. Thus the motivation behind the establishment of a
MRI-friendly model in the context of this thesis was to create a controllable gold-standard
for validating DIR of the tumour progression during radiotherapy treatments. Thus, this
chapter focuses on exploring the concept of an engineered tumour model compatible with
multimodal and sequential imaging studies. This work is inserted in a larger research
interest in the application of the tumoroid model. The main focus of this chapter was
MR imaging; other research interests of the tumoroid research group include treatment
response, dose enhancement studies, and other imaging techniques. My contribution to
the whole project was the theoretical design of the samples, planning of the experimental
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pre-clinical MRI setup and, initial characterisation of the samples in terms of MRI contrast.
Some preliminary work was also performed on CT imaging (section 8.4.3.3), but this was
not prioritised due to the poor tumour contrast characteristic of CT imaging in comparison
with MRI.
The ACM model has the potential to act as a challenging 3D imaging bio-phantom:
(i) The model has shown characteristics similar to those found in vivo tumours.
(ii) The samples are easy to produce, and can be used in imaging and/or treatment
studies without the need of ethics approval.
(iii) The biological characteristics of the tumoroids are controllable and reproducible,
making them a perfect test subject for repetitive and sequential studies.
The use of 3D tumour models as bio-phantom for radiotherapy and medical imaging
applications has so far been poorly explored. Few studies available focus on routine
and clinical imaging modalities using less complex 3D bio-phantom as tool to verify,
for example, nanoparticles as MRI contrast agents [244]. Furthermore, in previous work
conducted within our group gold-nanoparticle concentration was measured on 3D ACMs
using non-destructive X-ray fluorescence technique [245]. The imaging-friendly artificial
cancers can potentially be used for a multitude of high impact applications in radiother-
apy:
• To calibrate imaging acquisitions of different imaging systems, which could be of
commercial interest.
• To provide pre-clinical evidence of the benefits of additional imaging and differ-
ent treatment choices, via multimodal and sequential imaging and treatment, and
correlation with histology studies.
• To further individualise radiotherapy, by deciding on the treatment approach after
testing the efficiency of different treatment modalities in patient-specific artificial
cancer masses.
8.2 Engineering of a tridimensional cancer model
The ACM model developed at the Division of Surgery and Interventional Science
(UCL) consisted of cancer cells seeded in a collagen matrix, which were compressed to
increase the density, and embedded in an uncompressed collagen gel that can contain
sparse fibroblasts and healthy cells. This model had shown a number of characteristics
similar to in vivo cancer masses, such as migration, hypoxia, and release of pro-angiogenic
factors capable of initiating cancer-related angiogenesis [235].
In this section the standard protocol to produce the 3D artificial cancer mass is de-
scribed as an introduction to tissue engineering. It consists of the two main steps: cell
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culture and collagen gel preparation.
8.2.1 Cell culture
The cell line used was the human colon adenocarcinoma cell line (HT29). The cells
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 1000 mg glucose/L,
L-glutamine, NaHCO and pyridoxine HCl (Sigma-Aldrich, St Louis, MO, USA) supple-
mented with 10% foetal bovine serum (FBS) (First Link UK Ltd, Birmingham, UK) and
1% penicillin/streptomycin (P/S) (GIBCO, Invitrogen, Paisley, UK). Cells were maintained
under sterile conditions as 2D monolayers in 100% humidity, 5% CO2 in air at 37◦C in an
incubator.
The medium maintains cells in tissue culture by providing the nutrients the cells
require to stay alive and healthy (amino acids, salts, glucose and vitamins). It must be
changed frequently (at least twice a week) to replace the nutrient levels and remove cell
waste. A standard cell maintenance protocol was followed (Appendix B).
Once the cells are seeded into a flask, they adhere on the bottom surface. The number
of cells increases as the cells undergo mitosis to populate the available space. The term
“confluency” is used to numerically describe this process: x% confluency describes the
situation when x% of the flask surface is covered in cells. Once 100% confluency is reached
the growth eventually stops due to contact inhibition, lower availability of nutrients and
excessive waste. To maintain a healthy cell culture the cells are subcultured before
reaching 100% confluency (between 85-95%). This process is called passaging, which
involves enzymatically detaching the cells from the flask surface, and transferring a
fraction of the cells to new flask(s). A standard cell passaging protocol was implemented
throughout (Appendix C).
An accurate number of cells embedded in the collagen matrix are necessary to assure
reproducibility in manufacturing the bio-phantoms. The number of cells in a cultured
flask can be measured using a haemocytometer and a standard cell counting protocol. The
total number of cells is then re-suspended in the necessary volume of DMEM to quantify
the cell concentration when seeding the collagen matrix (Appendix D). A haemocytome-
ter consists of a counting chamber in a thick glass slide covered with a thin glass coverslip.
The chamber is laser-engraved with a grid of perpendicular lines visible under micro-
scope. The volume of each grid unit is known, so once the chamber is filled with cells
in suspension it is possible to count the number of cells per volume unit. The concen-
tration of the cells should neither be too high or too low, as high concentrations result in
cell overlapping and low concentrations in higher statistical errors. The accuracy of this
manual counting technique ranges from 7.1 to 15.6% [246].
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Figure 8.3: Photo of the mould and plunger system for plastic compression. The mould is placed on top of
the nylon and steel meshes.
Figure 8.4: Photo of the artificial cancer mass after plastic compression, and its dimensions. Courtesy of
Tarig Magdeldin.
8.2.2 Collagen matrix
The ACMs were manufactured following a standard protocol to seed the cancer cells in
collagen hydrogel and applying plastic compression to increase the density (Appendix E).
Collagen hydrogel (rat tail collagen type I, 2.04 mg/ml in 0.6% acetic acid, First Link UK,
Birmingham, UK) is mixed with 10× concentrated minimum essential medium (MEM)
(Invitrogen, Waltham, MA, USA). The solution is neutralised in a drop-wise manner with
sodium hydroxide (NaOH). The solution changes from yellow to bright pink when the
optimum pH level of 7.3 is reached. The cell suspension is then added to the solution. In
the original ACM protocol the collagen is populated with 6.4×106 cells. The final solution
has 4 mL, composed of 3.2 mL of collagen, 0.4 mL of MEM and 0.4 mL of cell suspension.
The thoroughly mixed solution is transferred to a mould and left to incubate at room
temperature for 30 minutes, allowing for gel setting. Once set, the ACM density is
increased by plastic compression (using a mould and plunger as shown in Figure 8.3)
and self-compression. The plastic compression process is repeated from both sides of the
ACM to homogenise the compression within the volume.
The compressed ACMs can then be cut using a sterile surgical blade (Figure 8.4). The
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Figure 8.5: MR relaxation to equilibrium. (a) At equilibrium the magnetisation (M0) is aligned with
the external magnetic field (B0). (b) A 90◦ pulse (B1) is applied for enough time to rotate the M0 into
the x-y plane. (c) With time the magnetisation relaxes to equilibrium. (d) Some time later (t>>T1) the
magnetisation has returned to equilibrium state.
Figure 8.6: Components of the magnetisation in (a) z axis and (b) x-y plane before, during and after the
90◦ RF pulse.
pieces are then embedded in uncompressed collagen, which can be populated with other
cells. The samples are then covered in DMEM and incubated. The medium is removed
and replaced regularly.
8.3 Physics of magnetic resonance imaging
8.3.1 Contrast mechanisms of conventional magnetic resonance imaging
MRI uses the natural properties of the hydrogen atoms, a major constituent of the
human body to generate images of high soft tissue contrast. When a sample is inside the
magnet it acquires a very small magnetic field (“magnetisation”, M0), which aligns with
the strong field of the scanner (B0). Radio-frequency (RF) pulses are used to change the
direction of this magnetisation to the x-y plane, described by the flip angle (α). Following
the RF pulse the system relaxes back to equilibrium: dephase in the x-y plane (signal
decay) and the macroscopic magnetisation realigns with the field [247–249]. Figure 8.5
describes schematically the process of relaxation to equilibrium, which occurs via two
processes at different rates, spin-lattice (T1) and spin-spin (T2) relaxation times. The
components of the magnetisation can be represented graphically (Figure 8.6).
1. T1 relaxation: after the RF pulse, the magnetisation gradually realigns with the
external magnetic field in a time characterised as spin-lattice relaxation time. The
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hydrogen nuclei lose their magnetic energy to the surroundings (the lattice). The
equation for the recovery of Mz following a 90opulse is:
Mz(t) = M0(1 − e−t/T1) (8.1)
2. T2 relaxation: MR signal that is in the x-y plane (Mxy) evolves by decaying away at
an exponential rate defined by the spin-spin relaxation time T2. The rate at which
Mxy is lost is given by:
Mxy = M0e−t/T2 (8.2)
T2 decay is generally shorter than T1 as it governed by more than one effect: (i)
exchange of energy between nearby spins and (ii) presence of nearby magnetic
molecules that perturb and change locally the magnetic field. In real systems the
magnetic field is never perfectly uniform, and the existent inhomogeneities also
accelerate the decay of Mxy. The combined T2 and magnetic field inhomogeneity is
known as T∗2.
T1 and T2 are characteristic of the tissues, but are not constant as they vary with the
strength of the external magnetic field and temperature. For water at 1T both have a
value of 2500 ms [250].
The magnetisation is measured in the x-y plane by detecting the voltage it induces in
a receiver coil. This signal is known as free induction decay (FID) and it decays exponen-
tially to zero since the protons are de-phasing and relaxing back to the equilibrium. In
practical terms the FID is not measured, but rather echoes created from the signal.
8.3.2 Pulse sequences
MR images are produced using a pulse sequence, which is stored in the scanner
computer. The sequence contains the RF pulses and gradient pulses which have carefully
controlled durations and timings. There are two types of pulse sequences: spin-echo (SE)
and gradient echo (GE). The choice of repetition time (TR) and echo time (TE) define the
type of contrast (Table 8.1). Other parameters such as inversion time (TI) and flip angle
(α) are also used to define particular sequences.
SE uses two RF pulses, usually 90◦ and 180◦ pulses, to create an echo which measures
the signal intensity. In such sequences the accelerated T∗2 is reversible by the application
of the 180◦ pulse, that refocuses the spins to form a SE. SE produces the images with
higher quality at the cost of longer acquisition times.
GE uses a single RF pulse followed by a field gradient reversal to generate an echo
without an 180◦ pulse. Like SE sequences, any type of contrast can be generated (Table
8.1), but these are much faster acquisitions. Thus, they are more influenced by field
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Table 8.1: Choice of repetition time (TR), echo time (TE) and flip angle (α) and contrast generated for
spin-echo (SE) and gradient echo (GE) acquisitions. For GE the TR is always short (<750 ms).
SE GE
TE TE
TR Short
(<40 ms)
Long
(>75 ms)
α Short
(<15 ms)
Long
(>30 ms)
Short
(< 750 ms)
T1 N/A Small
(<40◦)
PD T2*
Long
(> 1500 ms)
PD T2 Large
(>50◦)
T1 N/A
inhomogeneities and timing of the parameters such that the amplitude of the gradient
echo is determined by T∗2 decay.
Within the two major families of pulse sequences (SE and GE) there are some well-
known acquisitions. Relevant to this project are the fast low angle shot (FLASH) and
rapid acquisition refocused echoes (RARE). The first is a fast GE with low flip angles, and
the second refers to multiple fast SE.
8.3.3 Measurement of T1 and T2 relaxation times
T1 and T2 are properties of the tissue, and can be measured using imaging. One method
of T1 measurement requires a series of inversion-recovery (IR) sequences with varying
TI. IR starts with a 180◦ inversion pulse that inverts M0, which then starts to recover. A
time is waited after the 180◦ pulse (known as TI) before continuing with the SE imaging
sequence. When the 90◦ pulse is applied some of the signals may still be negative, and
a mixture of positive and negative echoes will be formed. TR must be at least five times
the longest T1 to allow full relaxation between inversion pulses. When this condition is
met, the signal given T1 is extracted by fitting the data to the curve:
Mz = M0(1 − 2e−TI/T1) (8.3)
T2 is measured by using a train of SE sequences to measure the signal intensity at
varying TE. T2 is extracted by fitting the data to the curve:
Mxy = M0e−TE/T2 (8.4)
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8.4 Design of an artificial cancer mass for magnetic resonance
imaging
8.4.1 Design specifications
Ideal ACM samples should provide imaging contrast both in anatomic and functional
sequences; further engineering is necessary to achieve this goal. The specifications desired
for the engineered samples are:
(i) The tumoroids should provide image contrast in different imaging modalities, such
as CT and multiparametric MR.
(ii) The contrast generated should be quantifiable based on its biological properties
(such as cell density, cell viability, etc).
(iii) The tumoroids should be compatible with sequential imaging (i.e, multitemporal).
(iv) Changes in the biological properties of the tumoroids (for example, due to treatment)
should be within the sensitivity of the imaging system.
8.4.2 Biological properties of the samples
8.4.2.1 Cell density
The major limitation of the original model by Nyga et al. was the low cell density of
the ACM, which reduced the generation of MR contrast. The cell density can be increased
by varying three different parameters during the ACM production: cell density, collagen
density and incubation time.
Cell seeding Increasing the number of cancer cells seeded in the collagen matrix is the
most straightforward method to increase the cell density. However, empirically it is found
that when more than 30-50×106 cells were seeded the collagen gel no longer sets properly.
This could be explained due to the large number of cells causing interference during the
collagen fibrillogenesis, and/or non-optimal pH conditions when the high concentration
of cells is added. Additionally, previous studies show that cells growth rate in the ACM
from day 7 to 14 was independent of the initial seeding density (Figure 8.7). For imaging
applications it is desirable for the cell number to be as high and as stable as possible
during the first days of the tumoroid life.
Collagen density The collagen density is increased by plastic compression: as the
water is squeezed out by external pressure, the volume of the construct is reduced which
effectively increases the cell density. The weight and duration of the plastic compression
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Figure 8.7: Cell densities of HT29 measured over 14 days in a partially compressed ACM for different cell
seeding values on each time points. Adapted from [235].
step must be set to maximise the final density of the samples. Brow et al. had found that
significantly extending the plastic compression time did not increase fluid loss but does
reduce the inter-construct variance [251]. Additional weight, however, did increase the
collagen density. Therefore several methods to optimise the plastic compression process
were investigated, which were tested in the laboratory by Tong Long (Division of Surgery
and Interventional Sciences, UCL):
1. Use the original mould (Figure 8.3) and increase the compression time. Parallel
experiments to measure the collagen density as a function of the compression time
were performed, and results similar to Brow et al. were found [251].
2. Design a new mould. Varying the surface could affect the expelling of water and
allow for additional compression. A mould with varying surface was designed,
and smaller surfaces resulted in less compressed constructs. Therefore, the initial
mould was used in the imaging experiments. Additional information on work on
this point can be found in appendix F.
3. Use the available mould and increase the load. The process had to be done in steps
of increasingly external pressure or the construct would loose its integrity. This
allowed to increase the collagen density, defined as the ratio between dry and wet
weight, from 20±3% to 40±2% (Figure 8.8).
The technique chosen to maximise the plastic compression of the samples imaged used
the previously available mould with additional load. The main limitation of this approach
(which will be discussed further on section 8.5.2.2) was the poor reproducibility achieved
with the technique. Following preliminary studies of the samples, a standardised pro-
tocol was followed to attempt to produce reproducible samples. Figure 8.9 presents the
schematic diagram of the protocol followed to ensure higher reproducibility between
samples. The plastic compression maximum height is controlled via a construct of de-
185
A novel ACM model for imaging
Figure 8.8: Collagen density (ratio between dry and wet weight) for different compression times and
additional force (C). Courtesy of Tong Long.
Figure 8.9: Plastic compression with additional constructs for higher reproducibility of the collagen density:
construct of fixed dimension (L) to constrain the compression and additional weight (W).
fined length (L) that stops the compression after that threshold is reached. This constructs
can be 3D printed to customise the size and ensure adequate fitting to the mould. The size
varies between sides being compressed, being longer on the first side (L1 >L2) . A fixed
weight (W) can be added to the top of the plunger to generate the additional compres-
sion. The dimensions and weights were not fully optimised; values of L1=6 mm, L2=4
mm were chosen empirically, and the additional weight was applied manually.
Incubation time Once the gel is set, it should consist of a uniform distribution of
cancer cells in a collagen gel. As the ACM is given time to stabilise, the cancer cells keep
proliferating and start to migrate from the centre, which is hypoxic, forming at the surface
high density clusters. With time, the cells start to detach from the dense collagen and
invade the surrounding stroma (Figure 8.10). This is similar to in vivo behaviour of cancer
invasion. Given time, the cells will contract the collagen gel, eliminate fluid and improve
the mechanical properties [252].
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Figure 8.10: Days (a) 1 (b) 7 (c) 14 and (d) 21 (using at seeding 2×106 cells per ml of gel). The microscopy
images of the sections were taken at 40× magnification. Courtesy of Tarig Magdeldin.
The incubation time should be appropriate for the gel to stabilise; short enough to
reduce the risk of contamination and adequate considering cell proliferation. As seen
in Figure 8.7, tumoroids with very high cell number at seeding become less dense with
time. Due to the high number of cells of our constructs, the tumoroids were incubated
for 24 hours before imaging. This allowed stability of the construct, higher cell density
homogeneity and higher viability of the cells at the time of the imaging sessions.
8.4.2.2 Sample fixation
Fixation is a chemical process by which biological tissues are preserved from decay,
thereby preventing autolysis or putrefaction. Fixation terminates any on-going biochem-
ical reactions, and may also increase the mechanical strength or stability of the tissues.
However, chemical fixation causes the MR properties of biological tissues to be different
from those found in vivo. Moreover, these properties change as fixation time elapses. For
T2 there is a general reduction of signal with time ([253, 254].
Correlating images from fixed and living samples is challenging, and may be affect the
ability to generate MR contrast. Fixation however facilitates the logistics of optimising
samples and imaging protocols. The decision was to perform all the following imaging
experiments with living samples since this was also a necessary condition for sequential
imaging experiments.
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Figure 8.11: (a) Bruker ICONTM MRI scanner system and (b) composition of the coil-holder and its
electronics.
8.4.3 Design of the imaging experiments
8.4.3.1 Magnetic resonance system specifications
The images were acquired at CABI using the ICONTM (Bruker Corporation, Billerica,
MA, USA) MRI scanner. It is a compact small footprint high-performance MRI system
for pre-clinical research and in vivo imaging (Figure 8.11a). The ICONTM operates at a 1
T field strength.
The magnet bore is horizontal and Figure 8.11b shows the system where the RF coil is
embedded. The piece is equipped with a system of flowing water that allows to maintain
the temperature of the samples. The temperature of the water can be selected, measured
and monitored in real-time. This system was set so that the tumoroid is at an ideal
temperature as if inside the incubator (T≈32oC).
8.4.3.2 Experimental setup and sample holder
An optimised setup for MRI takes in consideration two aspects: (i) the size to the
coil should be as small as possible while enclosing the sample and (ii) the filling of the
coil should be maximised (i.e., minimise empty volumes). The tumoroid samples were
cultured in a 7 mL bijou tube (L=38 mm, D=18 mm) that fits inside the smallest RF coil
available (L=40 mm, D=23 mm, as Figure 8.11). The bijou tube was chosen due to its
adequate dimensions, MR-compatible materials and sterile availability.
Since the sample does not fill the whole coil, a sample holder was designed to maximise
the filling, as shown in Figure 8.12 and created using a 3D printer. A small aperture at the
top is included to facilitate the contact between the temperature probe and the sample
(alternatively a non-sticky conductive material could be used as interface between the
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Figure 8.12: Sample holder for MR imaging (a) schematic diagram, (b) 3D sketch and, 3D printed sample
holder inside the holder: (c) frontal and (d) superior views.
tube and probe). Additionally, it provides a guideline for the orientation of the holder
inside the coil. An additional stick exits the bottom of the holder, which can be inserted
inside an available coil hole and screwed for stability, allowing to switch between samples
during the same experiment without moving the holder. The design was iterated a couple
times to ensure appropriate dimensions after 3D printing. Dr. Robert Moss and George
Randall (Department of Medical Physics & Biomedical Engineering, UCL) provided 3D
printing and workshop expertise to finalise the prototypes of the sample holder.
Within the bijou tube, the filling must also be maximised which is done by overfilling
the tube with DMEM. Since the magnet bore is horizontal, the tube must be in horizontal
position as well. Because it is impossible to fully fill the bijou tube (there is always a
residual air gap), a small air bubble is generated inside the tube. When the tube is in
horizontal position this bubble can come in contact with the collagen. The collagen matrix
starts to shrink and loose its integrity when in contact with air. To avoid this the sample
holder hole can be tilted by a small angle to minimise the risk of bubbles coming in contact
with the gel (Figure 8.12).
8.4.3.3 Fiducial markers
Fiducial markers within the samples are necessary to guide image acquisition and are
of particular interest for imaging registration studies as a reference point. An ideal marker
would be irregularly shaped, be positionable such that it clearly identifies where the ACM
is located within the stroma without affecting the tumoroid morphology and biological
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Figure 8.13: Magnetic resonance imaging compatible markers tested: (a) plastic, (b) wood, (c) PinPointr
and (d) Gold AnchorTM.
properties (biocompatible), do not generate any MR signal and/or cause susceptibility
artefacts. If internal, the markers have to be sterile or autoclavable. With the aim of
making the tumoroids friendly for additional imaging modalities as a long-term goal, the
markers would ideally be MR and CT compatible.
Several types of internal and external markers were investigated, both made in-house
or commercially available (Figure 8.13a), simultaneously with the experiments that will
be presented in section 8.5:
• Plastic marker. This marker was made in-house and irregularly shaped. It can
be introduced to the ACM during the plastic compression or to the surrounding
stroma. Polypropylene was used in the preliminary assessment, but a 3D printed
marker made of polylactic acid (PLA) is also a comparable alternative.
• Wood marker. This marker was made in-house and had a pointed shape. It can
be introduced to the ACM during the plastic compression or to the surrounding
stroma.
• PinPointr (Beekley Medical, Bristol, CT). This is a CT/MR image registration exter-
nal marker developed commercially for clinical use. It contains a 1.27 mm diameter
center hole that can be used as landmark for image registration. Due to its large
dimensions and non sterile availability, it had to be attached to the bijou tube (i.e.,
externally to the sample).
• Gold AnchorTM (Naslund Medical, Huddinge, SW). This is a CT/MR image registra-
tion fiducial marker developed commercially for clinical use. It consists of a 0.28×20
mm rod that has two possible configurations (straight or ball shaped). It is normally
introduced in patients using a sterilised needle. However, the Gold AnchorTM sam-
ples available were not sterile and were added to an acelular tumoroid during plastic
compression.
Figure 8.13b shows MR images acquired of the markers. The plastic marker was
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found to be the more adequate for MR-only applications as it was clearly identifiable and
did not generate any visible artefacts in T1, T2 and T∗2 acquisitions. It can also have a
shape fully personalised using a 3D printer. The wood marker had the disadvantage of
absorbing water with time, and therefore it was found to also generate signal, which is
sub-optimal. Its shape was however desirable, as it clearly points towards the ACM. The
PinPointr was found as non-usable, since not only its larger dimensions required a larger
coil (and therefore the setup would be less optimal) but also it generated positive contrast
that saturated the signal, removing the ability to distinguish details within the collagen
samples. Finally, the Gold AnchorTM was used in a ball shaped arrangement, and even
though it was easily identifiable it generated susceptibility artefacts. These artefacts were
however not severe, and due to the high resolution of the system they could be reduced
by using a single strand of the marker in straight configuration. For CT/MR applications
this type of marker is the more desirable, and it was imaged using the X-TEK Real-time
x-ray benchtop µCT (Nikon Metrology UK Ltd, Hertfordshire, UK) (Figure 8.14). The
images were acquired with a resolution of 27×27×27 µm3, and unlike the ICONTM the
samples were placed vertically inside the scanner and therefore no sample-holder system
was necessary for these preliminary acquisitions. Daniel O’Flynn (Department of Medical
Physics & Biomedical Engineering, UCL) was responsible for acquiring the data on this
system. The high attenuation of the markers made them more susceptible to artefacts
during CT reconstruction (Figure 8.14c). However, that can also be minimised by using
the marker in straight configuration. Its sterile availability is also an advantage of this
markers, while its increased cost is a limitation. Simultaneously to the imaging of the
marker, an acellular and 20×106 HT29 cell tumoroid were also imaged. These preliminary
results had no evidence of x-ray contrast of the collagen gels, indicating the need of further
engineering for CT imaging. In summary, a plastic marker is the most efficient for MRI,
while the Gold AnchorTM is more versatile for multimodal applications. Further studies
are necessary to optimise their shape and size, and assess their biocompatibility.
8.4.3.4 Sample transportation and storage
The samples were produced at the Division of Surgery and Interventional Sciences at
the Royal Free Hospital and imaged at CABI, located within the UCL main campus. The
samples had therefore to be transferred and stored for the imaging sessions. At CABI no
incubator equipment was available, and therefore the samples were kept in an oven when
not being imaged. This temperature had to be lower than a normal incubator (≈35◦C)
due to gradients of temperature inside the oven, particularly near its walls.
From the several imaging sessions performed, it was clear that the samples were
very sensitive to high variations in temperature and vibrations during transport. Rapid
changes in temperature resulted in contraction of the collagen and detachment from the
tube, causing the tumoroid to float on top of the medium. This was extremely undesirable,
as it would compromise the stability of the samples and the ability to image them with
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Figure 8.14: (a) X-TEK Real-time x-ray benchtop µCT, and images acquired of Gold AnchorTM: (b)
projection and (c) reconstructed 3D image.
Figure 8.15: Polystyrene box for transport of the tumoroids between the Royal Free Hospital and UCL
main campus.
the optimised setup. To avoid this issue a prototype of a transportation box was designed
and produced in order to minimise the perturbation of the samples during relocation. It
consisted of polystyrene box for temperature isolation, with slots for two samples.
8.4.3.5 Timeline for imaging sessions
Figure 8.16 presents the general timeline followed for the imaging sessions. The
samples were produced approximately 24 hours before the time the MR system was
booked for. The whole process took approximately 2 hours per sample, followed by the
incubation period. In the day following the production, the samples were transported
to CABI using the adequate transportation box. The bijou tube was only fully filled
with medium right before transportation, to minimise the risk of its weight causing the
collagen to migrate to the top of the tube. The imaging sessions lasted, in general, 4 to
5 hours, with T1 and T2 maps being acquired. The first hour is occupied with setup,
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Figure 8.16: Timeline followed in the imaging sessions, from production to imaging experiments to follow-
up studies.
tuning of the RF, scout and localiser acquisitions, and preliminary acquisitions to tune
any parameters deemed necessary. During the imaging, the temperature is stabilised in
a warm water bath. If more than one sample was transported, this sample is stored in
the oven while the first is being imaged. Once the first imaging session is completed, the
two samples switch places. After all images are acquired, the samples stay in the oven
until returned to the Royal Free Hospital. This can be done on the same day if follow-up
studies of the samples are planned.
8.5 Magnetic resonance imaging of the tumoroids
This section describes the several imaging experiments performed with the tumor-
oids. These studies were conducted in chronological order, as in this preliminary work
each session raised different research questions that following experiments attempted to
answer.
8.5.1 Methods and materials
8.5.1.1 Samples description
The tumoroid samples were manufactured by following the standard protocol to seed
cells in collagen hydrogel (described in detail in Section 8.2) that was modified to further
increase the cell density of the construct. The plastic compression process was performed
during 40 seconds, and additional weight was applied after that time. The whole (or
partial) dense ACM was then immersed in a uncompressed collagen matrix. Some of
the samples imaged also contained different types of markers (previously discussed in
section 8.4.3.3).
A total of three sequential imaging studies were performed, with different samples
being imaged sequentially for different aims (Figure 8.17). All the sample were manu-
factured by Tong Long (Division of Surgery and Interventional Science, UCL) as per my
design specifications.
Study I: Two samples with complete compressed constructs were produced: one was
acellular (0M), and the second was seeded with 30×106 HT29 cells (30M). Figure 8.18
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Figure 8.17: (a) Schematic diagram of the samples used for the imaging studies: (a) Study I: acellular and
30×106 cells, (b) Study II: acellular, and (c) Study III: acellular and 20×106 or 40×106 cells.
Figure 8.18: (a) Acellular (0M) and (b) seeded with 30×106 HT29 cells (30M) tumoroid samples. Different
markers were tested with these samples.
shows the two samples before imaging. The aim was to verify the ability of generating
MR contrast with the tumoroids.
Study II: One acellular sample (0M) composed of the two halves of a compressed con-
struct was produced. The aim was to evaluate the MR contrast generated by compressed
collagen in the absence of cancer cells.
Study III: Two types of samples with two halves of compressed constructs were pro-
duced: the first consisted of an acellular portion (0M) and a 20×106 HT29 cells portion
(20M), and the second consisted of an acellular portion (0M) and a 40×106 HT29 cells por-
tion (40M). Each type of sample was produced twice (with the 40M ones being produced
from different collagen neutralisation, and the 20M coming from the same neutralisation
split in half), with the relative positioning of each portion being switched. The aim was to
evaluate the sensitivity of MR acquisitions to changes in biology via measuring changes
in image intensity versus cell seeding density.
194
Magnetic resonance imaging of the tumoroids
8.5.1.2 Data acquisition
The Bruker ICONTM MRI system for pre-clinical research was used to image the
samples. Standard standard T1, T2 and T∗2 sequences were acquired for each sample.
The samples were imaged alive, and kept in the oven at 35◦ when not being imaged.
During the imaging sessions the temperature was monitored and kept above 32◦ to
minimise loss of integrity throughout the imaging sessions.
The 3D printed sample holder described in Section 8.4.3.2 was used from study II
onward. For study I the bijou tube was fitted inside the coil using support material, and
therefore the filling was not fully optimised for this experiment.
8.5.1.3 Measurement of T1 and T2 relaxation times
To measure the T1 and T2 relaxation times, the imaging data is fit to equations 8.3 and
8.4. There are two different ways to process this data: a ROI-based approach, or a pixel-
by-pixel fitting. In the first case the average signal over a ROI is used, while for the second
an histogram of relaxation times is used to find the peaks in T1 (or T2) correspondent to
the different constituents of the sample.
Measured signals differ from the true signal due to the existence of noise. Due to the
Rician properties of the MR noise, Mxy is not measured as decaying to zero but rather to
an offset value. The noise in the images is a systematic factor, rather that just a source
of random variation. The relationship between measured and true signal can be well
approximated using a simple function:
S =
√
S20 + C
2 (8.5)
where S is the measured signal, S0 the true signal in the absence of noise and C the noise-
related constant [255]. C can be estimated by using the mean signal intensity in a region
devoid of true signal.
Therefore, in T2 measurement experiments equation 8.4 is modified to include the
noise properties:
S =
√
(S0e−TE/T2)2 + C2 (8.6)
For T1 measurements another important concept is the efficiency of the IR process.
When the inversion is perfect, the signal at TI=0 should be equal to -M0 [256]. Therefore,
equation 8.3 was modified to include loss of efficiency during the IR process and the effect
of noise.
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Figure 8.19: Comparison between T1 and T2 fitting curves: theoretical vs experimental (considering the
noise).
S =
√
[S0(1 −  × e−TI/T1)]2 + C2 (8.7)
where  represents the efficiency of the inversion recovery process.
The differences between the original equations and the ones used during the fitting of
experimental data can be schematically evaluated in Figure 8.19.
The code to estimate the T1 and T2 relaxation times was implemented in MATLAB
(MathWorks, Natick, MA, USA), using the curve fitting tool (non-linear least squares
method and the trust-region algorithm).
8.5.2 Results and discussion
8.5.2.1 Study I
The aim of this experiment was to evaluate the feasibility of generating contrast with
the tumoroids in standard MR acquisitions, and to generate feedback for next iterations
of the project in terms of experimental setup. The imaging session was split in two halves:
first the acellular tumoroid was used to optimise the setup and to perform some initial
tuning of the imaging parameters. Later it was replaced with the 30M tumoroid to repeat
and improve the acquisitions.
The acellular tumoroid sample was imaged with scout T1, T2 and T∗2 sequences. The
scout T1 and T2 provided evidence of structural information, and were extended to
sequences that measure T1 and T2 relaxometric maps.
T1 contrast was investigated using an IR-RARE sequence with TE=12 ms, TR=10000
ms, and TI={500, 1500, 2000, 2500} ms, with a 20×20 mm2 FoV and resolution of
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Figure 8.20: IR-RARE sequences images of an acellular tumoroid with TI of (a) 500, (b) 1500, (c) 2000,
and (d) 2500 ms (TE=12 ms, TR=10000 ms).
Figure 8.21: T2 MSME images of an acellular tumoroid with a TE of (a) 50, (b) 100, (c) 150, (d) 200, (e)
250, (f) 300, (g) 350 and (h) 400 ms (TR=6000 ms).
0.208×0.208×1 mm3 (Figure 8.20). The images show contrast at the boundaries, but no
apparent signal difference between the dense collagen (internal) and the uncompressed
collagen (external).
T2 maps were assessed using multi-slice multi-echo (MSME) technique with
TE=25:25:400 ms (a total of 16 echoes) and TR=6000 ms, with a 20×20×14 mm3 FoV
and resolution of 0.125×0.125×1 mm3 (Figure 8.21). The images show evidence of con-
trast particularly at the boundaries, and (but less evident) between the dense collagen
(internal) and the uncompressed collagen (external). The air bubbles formed in the un-
compressed collagen generated artefacts particularly in T2 images.
T∗2 scout images were acquired with two FLASH sequences, with the following pa-
rameters: TE=5 ms, TR=400 ms and α=30◦, and TE=40 ms, TR=800 ms and α=30◦, with
a 20×20×14 mm3 FoV and resolution of 0.156×0.156×1 mm3 (Figure 8.22). It is clear that
the air bubbles present in the collagen gel generate severe artefacts in T∗2 images, and
therefore the current tumoroid model was not adequate for T∗2 imaging.
The 30M tumoroid sample was also imaged to measure T1 and T2 relaxation times.
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Figure 8.22: T∗2 FLASH sequences images of an acellular tumoroid with (a) TE=5 ms, TR=400 ms, α=30
◦
and (b) TE=40 ms, TR=800 ms, α=30◦.
Figure 8.23: IR-RARE sequences images of a 30M tumoroid with TI of (a) 205, (b) 500, (c) 1000, (d) 1500,
(e) 2000, (f) 4000, and (g) 6000 ms (TE=12 ms, TR=10000 ms).
T1 maps were assessed using an IR-RARE sequence with TE=12 ms, TR=10000 ms, and
TI={205, 500, 1000, 1500, 2000, 4000, 6000} ms, with a 32×32 mm2 FoV and resolution of
0.333×0.333×1 mm3 (Figure 8.23). T2 maps were assessed using the MSME technique with
the same parameters as the previous sample but a 32×32×14 mm3 FoV and resolution of
0.333×0.333×1 mm3 (Figure 8.24).
In both sequences appears to exist a difference in signal between the dense collagen
and uncompressed collagen, but a striking feature is the “halo” effect at the boundaries
of the ACM. The signal intensity profiles clearly indicate a dip in signal intensity at the
boundaries (Figure 8.25).
This first study showed the ability to generate contrast in the ACM using MRI. How-
ever, the source of the contrast and the origin of the “halo” were uncertain. There are three
possible sources of contrast: cells, compressed collagen, and air bubbles. Air bubbles at
the boundaries could cause apparent contrast, but this possibility was discarded as (i) the
volume of the region was not affected by increasing the TE of the acquisitions and (ii)
that region signal was effectively inverted during the IR. Therefore, either gradients of
collagen or cell density (or combination of both) cause the difference in signal. The “halo”
could be also explained by either, as the collagen is more compressed at the boundaries
and cells tend to migrate from the hypoxic center with time. However, it is more likely
to be collagen generated, as visual inspection of the tumoroids immediately after manu-
facturing shows regions at the boundaries of stronger white colouring. Contact between
collagen and metal, and stronger forces felt at the boundaries during plastic compression
can explain the additional compression of the collagen.
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Figure 8.24: T2 MSME images of a 30M tumoroid with a TE of (a) 50, (b) 100, (c) 150, (d) 200, (e) 250,
(f) 300, (g) 350 and (h) 400 ms (TR=6000 ms).
The acquisitions in this study were purely qualitative and were not adequate for further
quantitative analysis. However, this preliminary study was fundamental to optimise the
setup and imaging acquisitions. The 3D printed sample holder described in section 8.4.3.2
was produced based on the feedback obtained from Study I.
8.5.2.2 Study II
As a result from the previous study, the sample holder described in section 8.4.3.2 was
designed and 3D printed. It was therefore necessary to assess the suitability of the holder,
and if its current dimensions were adequate.
The sample used to test the experimental setup was acellular, and the whole construct
was split and separated in two parts. The portions were immersed in the less collagen,
such that one was on top of the other, and as close to the bottom/top of the surrounding
collagen. This disposition allowed to clearly distinguish the two ACMs (without the
need of fiducial markers) and to evaluate the positioning of the ACMs inside the imaging
FoV to ensure that the regions to image were well positioned inside the coil (i.e., within
volumes of larger signal received). The sample was acellular to facilitate its production
and provide further preliminary results into the mechanism of contrast generation (i.e.,
infer if compressed collagen had different MR properties than uncompressed collagen).
The acellular tumoroid sample was imaged to measure T1 and T2 relaxation times.
T1 maps were assessed using an IR-RARE sequence with TE=12 ms, TR=10000 ms, and
TI={250, 500, 750, 1000, 1250, 1500, 1750, 2000, 4000, 6000, 8000} ms, with a 40×40 mm2
FoV and resolution of 0.42×0.42×1 mm3 (Figure 8.26). T2 maps were assessed using
MSME technique with TE=25:25:3200 ms (a total of 128 echoes), with a 40×40 mm2 FoV
and resolution of 0.25×0.25×1 mm3 (Figure 8.27).
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Figure 8.25: Intensity profile on T1(TI=500 ms) (top row) and on T2 (TE=300 ms) (bottom row) images:
(a) lines in the image where the profile was plotted and (b) intensity profile plot.
Figure 8.26: IR-RARE sequences images of an acellular tumoroid (2×) with TI of (a) 250, (b) 500, (c) 1000,
and (d) 1500 ms, (e) 2000 ms, and (f) 8000 ms (TE=12 ms, TR=10000 ms).
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Figure 8.27: T2 MSME images of acellular tumoroid (2×) with a TE of (a) 100, (b) 200, (c) 400, (d) 800,
(e) 1200, and (f) 2000 (TR=5000 ms).
Unlike in the previous study, the overall morphology of the acellular tumoroid is
similar to that found for the cellular sample used in study I (i.e., reduced intensity within
the ACM, and a darker “halo” at the construct boundaries). The differences between the
results of study I and II regarding the acellular gel indicate the poor reproducibility of the
samples. It is also clear that compressed collagen is one of the sources of the contrast, but
further studies are necessary to evaluate if the cells also contribute to the final intensity.
Therefore, the samples produced for following experiments were produced in a more
reproducible fashion, using the protocol described in Figure 8.9.
Regarding the sample holder prototype, while both ACMs are clearly captured within
the imaging FoV (Figures 8.26 and 8.27) the upper ACM was partially within the volume
where the signal intensity starts to decay, while the region inferior to the bijou tube still
had stronger signal. Therefore design of the holder was afterwards adjusted to reflect
these findings, and a new version was printed for study III.
8.5.2.3 Study III
The aim of this study was to evaluate the role of the HT29 cells into the contrast
generation of the tumoroids. To achieve this goal ACMs of different cell seeding density
(0, 20 and 40 ×106) were imaged.
All the samples were imaged to measure T1 and T2 relaxation times. T1 maps were
assessed using an IR-RARE sequence with TE=12 ms, TR=10000 ms, and TI={250, 500, 750,
1000, 1250, 1500, 1750, 2000, 4000, 6000, 8000} ms, with a 40×40 mm2 FoV and resolution
of 0.42×0.42×1 mm3 (Figure 8.28). T2 maps were assessed using the MSME technique
with TE=25:25:3200 ms (a total of 128 echoes), with a 40×40 mm2 FoV and resolution of
0.25×0.25×1 mm3 (Figure 8.29).
Visual inspection of the imaging data acquired shows that the different samples all
had very similar properties, and the existing differences were not perceptible with visual
inspection. The most interesting aspect to note is the variability between and within
samples. For example, the acellular tumoroid portion of samples 1 and 2 had very differ-
ent properties. Similarly, the samples can have internal features easily distinguishable.
This indicates (a) low reproducibility of the samples production and (b) the existence of
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Figure 8.28: IR-RARE sequences images of the different samples imaged with TI of (a) 250, (b) 1000, (c)
1500, (d) 2000 ms, (e) 4000 ms, and (f) 8000 ms (TE=12 ms, TR=10000 ms).
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Figure 8.29: T2 MSME images of the different samples imaged with a TE of (a) 100, (b) 200, (c) 400, (d)
800, (e) 1200, and (f) 2000 ms (TR=5000 ms).
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gradients of compression within the samples (i.e., non-uniformity).
Using portions of the whole construct may reduce the uniformity of the samples, as
additional handling (such as pinching) may deform and change locally the compression
of the samples. Smaller ACMs were investigated to facilitate parallel biological studies
of the samples, and were in fact adequate regarding the resolution of the MRI scanner.
However, for future characterisation studies it is advisable to use the whole construct
instead.
8.5.2.4 Measurement of T1 and T2 relaxation times
In the previous sections an overview of the experiments and images acquired was
presented in a qualitative fashion. Here a quantitative analysis of the imaging data is
performed, aiming to measure the T1 and T2 relaxation times of the tumour models.
To compute the T1 and T2 the noise of the data was first pre-processed. For T1 maps,
since each TI corresponds to a different acquisition, the signal should be normalised to
the noise level before the fitting. For T2 this is not always necessary as the whole range
of TE is acquired in a train of SE sequences and, therefore, the noise conditions should
be similar. For each dataset the properties of the noise were assessed, and corrected for
when deemed necessary. The noise level was defined as the average noise within a ROI
devoid of true signal. This region had to be properly defined per dataset and acquisition,
as it is usual for non-signal areas to be polluted with signal from other regions.
The relaxations times were calculated using both the ROI and pixel-by-pixel ap-
proaches. Regions of interest were drawn on the images acquired for the different studies
defining the surrounding uncompressed and acellular collagen, and the dense collagen
(populated or not with cells). The samples imaged in study I were not included in this
analysis as the acquisitions were sub-optimal for this purpose. The results obtained for
T1 and T2 relaxation times using the ROI approach can be found in Table 8.2. The quality
of the fittings can be seen in Figure 8.30. Regarding the T1 results, there was a large
variability within similarly designed samples; for example, considering the stroma the
values range within an interval of [2450, 3200] ms. However, the corresponding results for
T2 were stable and reproducible. Considering different types of samples, uncompressed
collagen was clearly different from compressed collagen, but the differences found be-
tween varying cell seeding densities were not significant due to the high variability within
similar samples.
The ROI fitting provides an overall view on T1 and T2 inter-sample variability, but is
an oversimplification due to the existence of clear features within the samples, such as the
“halo” effect (intra-sample variability). Figure 8.31 shows the results for the pixel-by-pixel
approach, which provides a qualitative view into the homogeneity of the samples. It is
therefore possible to use an histogram to describe the distribution of T1 and T2 values
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Table 8.2: T1 and T2 relaxation times for stroma (acellular and uncompressed collagen) and compressed
collagen seeded with 0, 20 and 40 ×106 HT29 cells.
T1 T2
Stroma 0M 20M 40M Stroma 0M 20M 40M
Study II 2430 2140 - - 970 580 - -
Study III
(sample 1) 2600 2460 - 1860 970 810 - 500
(sample 2) 2980 2350 - 2670 970 680 - 680
(sample 3) 3190 2530 2560 - 1020 710 640 -
(sample 4) 3170 2640 2690 - 1000 660 670 -
Mean 2900±300 2400±200 2620±90 2300±600 990±20 690±80 660±20 590±130
Figure 8.30: Fitting of (a) T1 from inversion-recovery sequence and (b) T2 from MSME images for stroma
and acellular compressed collagen (study II). The fitting was done over the average intensity within a
region-of-interest.
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Figure 8.31: (a) T1 and (b) T2 relaxometric maps of the samples imaged in studies II and III.
(Figures 8.32 and 8.33). These figures illustrate the lack of homogeneity and reproducibil-
ity within compressed collagen samples, with values of T1 and T2 ranging over a wide
interval of values. The variability between similar samples imaged at different time points
may be related with the scanner acquisitions, such as temperature fluctuation and/or drift
of the magnetic field. However, the most important effect is the poor reproducibility of
the plastic compression process. A pos-imaging follow-up study of the samples used in
study III showed that the collagen density varied between 10 to 80%, adding evidence of
the poor reproducibility between samples.
Quantifying T1 and T2 allows to not only quantitatively differentiate different tissues,
but also optimise TR and TE for T1 and T2 image acquisition protocols. The highest
contrast achievable between two materials with different T1 is achieved by selecting a TR
such that the absolute difference between the signals (using equation 8.1) is maximum.
The same is true for T2 and choice of TE based on equation 8.2. Figure 8.34 shows this
calculation for the average values found for the uncompressed collagen and 40M sample.
In this case the optimal values for imaging were TR=2580 ms and TE=760 ms.
8.6 Current status and future work
Considering the design specifications of an imaging bio-phantom (identified in section
8.4.1), at the current stage of this project the following progress was achieved:
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Figure 8.32: T1 histograms for (a) stroma (uncompressed collagen), and compressed collagen seeded with
(b) 0, (c) 20×106 and (d) 40×106 HT29 cells.
Figure 8.33: T2 histograms for (a) stroma (uncompressed collagen), and compressed collagen seeded with
(b) 0, (c) 20×106 and (d) 40×106 HT29 cells.
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Figure 8.34: Optimal acquisition values for (a) T1 and (b) T2 contrast for uncompressed collagen and
compressed collagen seeded with 40 ×106 cells.
(i) The tumoroids should provide image contrast in different imaging modalities. The tu-
moroids were engineered to be imageable using T1 and T2 sequences. The current
model was found inadequate in its current state for T∗2 and CT imaging. Other
multiparametric acquisitons (such as DW) were not investigated at this point.
(ii) The contrast generated should be quantifiable based on its biological properties. The non-
homogeneity and poor reproducibility of the samples did not allow to take firm
conclusions on the contrast mechanisms, and the current model does not generate
controllable and quantifiable contrast.
(iii) The tumoroids should be compatible with sequential imaging. The samples were imaged
alive, and the viability of the cells was confirmed via confocal microscopy several
days after the imaging sessions, providing evidence of the suitability of the model
for sequential imaging studies. Further studies are necessary to ensure resistance
to multiple travelling and characterise the biological strain due to transport and
imaging.
(iv) Changes in the biological properties of the tumoroids should be within the sensitivity of the
imaging system. A quantifiable phantom has to be achievable before this specification
can be evaluated, and therefore this aspect is unexplored to this point.
To achieve the design requirements, three lines future of future research were identi-
fied:
1. Sample production: design, reproducibility and engineering.
2. Characterisation and biological properties of the samples.
3. MRI setup.
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8.6.1 Sample production: design, reproducibility and engineering.
The artificial cancer mass bio-phantom needs to be further engineered to be increas-
ingly specialised for imaging applications. The current protocol to produce the samples is
considered reproducible from a tissue engineering point-of-view, but not from a physics
point-of-view. Design needs, possible improvements and other aspects of potential in-
terest for future research that were not further explored in this stage of the project are
discussed in the following paragraphs:
• The non-homogeneity and poor reproducibility is the most important feature to
understand, engineer and characterise. There are several aspects to consider in this
point:
(i) The setting of a collagen gel is dependent on the pH of the solution, and
there is a range where the process is stable. This leads to variability in the
samples produced, as the chemical properties can vary within that interval.
The protocol for neutralisation is not exact, as the base is added on a drop-wise
fashion. Therefore, a step that can be further optimised is the pH neutralisation.
Since there can be variability between batches of collagen, a method to measure
quantitatively the pH in real-time should be investigated and developed.
(ii) The method currently used for plastic compression is clearly not reproducible
and controllable between batches of samples, as seen in the imaging and colla-
gen density studies. The plastic compression introduces gradients of collagen
density that are complex to model theoretically. Other methods to further
compress the gel could be investigated further, such as compressing the tu-
moroids to thin sheets, and rolling the structures. Alternatively, the use of
uncompressed collagen can be explored to remove the uncertainty in matrix
density. However, this also has limitations, such as less similarities with in vivo
tumours, larger number of cells being necessary to increase cell density, and
imaging artefacts caused by air bubbles.
(iii) The possibility of generating heterogeneities and internal features in the bio-
phantoms is unwanted when attempting to quantify the biological properties
behind the contrast generated, but of interest for image registration validation
studies so the possibility of designing samples with internal features is of inter-
est. Therefore, two routes can be followed: design a homogeneous tumoroid,
with controllable cell and matrix densities, or develop other imaging methods
method to quantitatively measure these two quantities and coregister that in-
formation with MR imaging, so that it is possible to correlate signal intensity
with the gold-standard information.
• The process of setting the collagen gel results in the production of air bubbles inside
the matrix, that generate artefacts in MR images. A method to minimise bubble
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production needs be engineered to minimise imaging artefacts.
• Different cell lines have different micro-structure (i.e., size, shape and arrangement
in the matrix) and biological responses. Different cell lines can be used to investigate
how the properties of the underlying microstructure affect the measured MR signal.
• Previous studies showed that when the tumoroid is co-cultured with other types
of cells (e.g., fibroblasts and endothelial cells) the tumour cells showed different
morphology and behaviour than when cultured alone in the collagen gel. When
the ACM is surrounded by collagen gel populated with other cell lines the cancer
cells have slower proliferation than when cultured alone [235]. Acellular gels were
used in the described imaging experiences; nevertheless, imaging of more complex
stroma models is of potential future interest.
• Contrast agents may also be included in the current model to enhance contrast [244,
257]. Ideally the model should be usable without external contrast agents, but it
might be that engineering of the constructs is not enough to achieve the design
specifications and artificial contrast is necessary. Nevertheless, there is a lot of
potential in studying the suitability of different contrast agents using this tumour
model for other applications, such as the development of biomarkers.
8.6.2 Characterisation and biological properties of the samples
Together with improving the reproducibility and controllability of the tumour model,
it is fundamental to understand how the changes in design and the imaging experiments
affect the biological properties of samples. Several points can be highlighted in this topic:
• The tumoroids are living samples, and their micro-structure changes in time due to
cell proliferation and migration. For sequential imaging studies, it is necessary to
understand over time how the cells are distributed in the matrix (morphology), cell
density viability (proliferation), oxygenation cell number over time (hypoxia), etc.
• Imaging experiments are a strain to the cells, as imaging experiments involve spend-
ing several hours in sub-optimal conditions (temperature, atmosphere, vibration
due to transport, etc). The level of that strain must be evaluated and further min-
imised if deemed necessary.
• In the imaging experiments conducted a resolution of a fraction of the mm was
achieved, but this is still 1-2 orders of magnitude above the dimensions of the
cell/matrix (the average diameter of HT29 cells is 11 µm). It is therefore crucial to
investigate other types of imaging common in biology (such as microscopy methods)
and methods to register with medical imaging modalities (CT/MR).
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Figure 8.35: 3D printer cap add-on: the add-on is glued to the cap, and when horizontal stops bubbles from
reaching the collagen matrix.
8.6.3 Magnetic resonance imaging setup
• The experimental setup and sample holder could be further refined:
(i) An additional safety check for the setup protocol was designed its feasibility
was investigated. It was not built as the previous design was proven in most
cases to deal sufficiently with the air bubble issues, but it could also help dealing
with potential migration of the samples within the bijou tube. This consisted of
modifying the bijou cap to stop the residual air bubble from coming in contact
with the collagen (Figure 8.35). This should be made of a polymer material to
be easily manageable, MR-compatible and autoclavable (since it needs to be
sterile). Polymers have a specific temperature (inferior to the melting point) at
which the modulus drops catastrophically, and they loose their physical prop-
erties. The autoclave reaches high pressure and temperatures of 121◦C, which
can be problematic for several polymers used in lab supplies (Figure 8.36). The
bijou container screw cap is made of polypropylene, and has a melting point of
approximately 150◦C. Therefore the add-on could also be made of polypropy-
lene. Other option that facilitates manufacture is PLA, the material used by
the 3D printer, which as a melting point also of approximately 150◦C. The
softening points are higher than the autoclave temperature, but both materials
have a heath deflection temperature considerably lower (approximately 60◦C).
Therefore, both materials were autoclaved for testing purposes, and no major
issues were seen with deformation of the constructs. Different parts can be
glued together using adhesives resistant to water and high-temperatures (i.e.,
autoclavable). Several glues were tested and both the Permatex High-temp
RED RTV silicone and the Evo-Stik Serious Glue were found to be appropriate
for this application.
(ii) The sample holder could be further engineered to maintain the samples in an
ideal atmosphere during imaging (Figure 8.37), minimising the strain to the
cells. The bijou screw cap could be modified to include a filter, allowing a
constant airflow and minimise chance of contamination. The available screw
cap can be drilled to attach a glued filter, and then autoclaved. This filter would
211
A novel ACM model for imaging
Figure 8.36: Heath deflection temperatures under a load of 1.82 MPa for selected polymers. Adapted from
[258].
Figure 8.37: Possible improvements to the sample holder for imaging sessions: the bijou screw cap is
individualised, by drilling holes and adding an appropriate filter to keep its contents sterile. An attachable
device is added to the cap to connect with a 5% CO2, a 2% O2 and a 93% Ar gas cannister. The aseptic
and atmosphere conditions can be therefore maintained during imaging sessions.
have to be waterproof since the tube is filled with medium. An airflow system
can then be added to the cap to connect it with a 5% CO2, 2% O2 and 93% Ar
gas cannister.
• The 1 T MRI system used in this work has its limitations. Thus, using a higher
resolution system (such as the 9.4 T system also available at CABI) might improve
the imaging data extracted. With higher magnetic field both larger sensitivity and
resolution are achievable.
• To estimate the T1 and T2 relaxation times the method used can be sub-optimal
in some cases, particularly when the images contain considerable noise. The non-
linear least squares method assumes Gaussian noise, which is not true for MRI.
To consider the Rician properties of the noise distribution the most appropriate
method is the maximum likelihood fitting. Additionally, other fitting equations are
also suggested in the literature that may be more appropriate [255, 256, 259].
• Other types of imaging modalities that provide complimentary structural/functional
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information should be investigated, such as DW-MRI, magnetic spectroscopy, etc.
8.7 Conclusions
In this chapter the use of artificial cancer masses as a bio-phantom for multimodal and
multitemporal imaging was investigated. The ideal design specifications were presented,
and the investigative work conducted toward the specified goals was presented. An ideal
bio-phantom should be reproducible and controllable, generate quantifiable contrast in
multimodal and multiparametric imaging, and be compatible with sequential imaging.
The preliminary work toward such a bio-phantom, such as design of the samples, de-
sign of the experimental setup and imaging studies were detailed in this chapter. The
tumoroids were shown to be imageable in the current state using standard T1 and T2
MRI acquisitions. CT and T∗2 contrast was not achieved, while more complex MRI se-
quences were not investigated. The main limitation of the current tumour model was the
poor reproducibility and controllability of the properties of the samples, which makes the
contrast generated non-quantifiable.
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Chapter 9
Final remarks
The whole is more than the sum of its
parts.
Aristotle
This thesis has made a contribution to the Medical Physics field as a research effort
focused at using information from different imaging modalities for adaptive radiotherapy
applications. This was a multidisciplinary effort, where radiotherapy physics, imaging,
computing and tissue engineering techniques were used toward the challenging goal of
integrating multiple imaging modalities into the radiotherapy workflow toward improv-
ing patient outcome.
The majority of the work conducted in this project was focused on using DIR as a
tool, and CBCT as the main image-guidance modality. Both IMRT and proton therapy
applications were investigated, and the work conducted was focused on the HN and
lung cohorts. For the studies focused on HN malignancies, the applications investi-
gated included the geometric validation of deformations for multiple DIR algorithms,
the assessment of the uncertainty in dose recalculation using a CBCT-based dCT, and
the uncertainty in dose summation resulting from the properties of the underlying de-
formation fields. The dCT method was shown to be a good interim solution to repeat
CT and a superior alternative to the direct use of current CBCT imaging technology for
dose calculation, all in the context of ART; for proton therapy treatments the associated
uncertainties of the method were in general higher than for IMRT. The ability of using
DIR to co-register multimodal and multitemporal data in the HN region was also inves-
tigated; the results found were promising and the limitations of current algorithms and
data acquisition protocols were identified. Following the work done on the HN cohort,
a clinical workflow for lung adaptive proton therapy was proposed and evaluated, both
in terms of technical and clinical parameters. This work was the first clinical evaluation
of proton-gantry CBCT, and demonstrated the usefulness of image-guidance in this type
of radiotherapy treatments. It is clear that there is still a lot of work to be done before
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these methods and techniques become part of widespread clinical routine; however, the
evidence gathered in this thesis and other publications shows that there is evidence to
start translating these techniques to controlled clinical research settings. A first important
point to refer is the whole problematic of DIR validation and lack of perfect gold stan-
dard to ascertain the uncertainties associated with the workflows. While throughout this
thesis methodologies to bypass this issue were suggested, the lack of a true gold standard
(particularly for dose summation) remains unanswered. Additionally, a lot of work has
to be done to improve DIR algorithms to more accurately describe the real deformations
that occur in the patient anatomy. CBCT is also a modality with its own limitations, and
research effort should be done in the direction of improving its quality to become closer
to CT imaging.
The use of novel artificial cancer masses as a novel platform to study the benefits of
additional imaging during radiotherapy was explored. An existing artificial cancer mass
model was extended to generate samples that were MRI friendly. The tumoroid model
was shown to be image-able in its current state in standard T1 and T2 MRI acquisitions.
In spite of the efforts to measure its relaxometric properties, the reproducibility and
controllability of the samples were inadequate, which caused the contrast generated to
be non-quantifiable. The work presented in this topic was the first exploratory work on
using tissue engineering techniques for medical imaging; therefore there is a large scope
of possible improvements and understanding of the current model.
IGRT and ART are topics of high relevance in clinical radiotherapy, and the work
conducted in this thesis is a step toward understanding the applicability and limitations
of different computational methods in clinical routine. It is clear that there is a lot of work
still to be conducted before ART is implemented in a cost-efficient, accurate, optimised,
automatic and widely available fashion; therefore, this is an area where research efforts
are still needed.
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Clinical indicators of replanning
Table A.1 presents the values found for under/over-ranges statistics using the dCT
method and acquiring a new rCT, for all the patients included in this study. Similarly,
Table A.2 shows the variation in DVH statistics from the planning values calculated using
the dCT method (DdCT-WET and DdCT) and acquiring a new rCT.
Table A.3 is a breakdown of the analysis of the clinical indicators obtained for dCT and
rCT, specifying the limitations of each particular dataset, correct predictions and false
negatives/positives in detections.
C
linicalindicators
ofreplanning
Table A.1: Changes in WET between planning (pCT) and verification scans (dCT and rCT) per treatment field.
WETunder>3mm(%) WETover>3mm(%) WETunder-95%(mm) WETover-95%(mm)
PT# Field dCT rCT ∆ dCT rCT ∆ dCT rCT ∆ dCT rCT ∆
1 LPO1 14.7 28.3 -13.6 10.4 14.3 -3.9 6.9 6.4 0.5 4.1 4.0 0.1
LPO2 18.9 26.6 -7.7 12.3 18.7 -6.4 34.9 16.4 18.5 19.8 15.8 3.9
2 RPO1 0.6 0.1 0.5 0.0 0.0 0.0 50.2 54.1 -3.9 27.0 24.6 2.4
RPO2 0.9 0.0 0.9 0.0 0.0 0.0 57.9 61.8 -3.9 29.6 25.2 4.3
3 RPO 0.0 0.0 0.0 0.0 0.0 0.0 76.9 50.5 26.4 48.0 41.4 6.6
PA 0.0 0.0 0.0 0.0 0.0 0.0 57.1 57.1 0.0 47.1 44.1 3.0
4 PA 0.1 0.0 0.1 0.0 0.0 0.0 33.3 34.7 -1.4 15.6 10.6 5.1
RPO 0.0 0.0 0.0 0.0 0.0 0.0 61.8 52.5 9.3 19.1 11.0 8.1
5 PA 0.0 0.0 0.0 0.0 0.0 0.0 47.3 24.6 22.7 8.9 7.2 1.7
LAO 0.0 0.0 0.0 0.0 0.0 0.0 17.5 15.7 1.8 8.1 5.4 2.8
6 PA 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 2.7 2.3 1.3 1.0
LPO 0.0 2.8 -2.8 0.0 1.8 -1.8 6.9 0.8 6.1 3.5 1.1 2.5
7 PA 0.0 0.5 -0.5 0.0 0.0 0.0 62.8 68.9 -6.1 10.7 11.0 -0.3
RPO 0.1 0.4 -0.2 0.0 0.0 0.0 59.2 73.3 -14.1 9.3 11.6 -2.4
8 ASO 0.3 0.0 0.3 0.0 0.0 0.0 26.8 41.9 -15.1 10.3 21.4 -11.0
PA 0.0 0.0 0.0 0.0 0.0 0.0 60.0 41.4 18.6 15.0 25.3 -10.3
9 PA 0.0 0.0 0.0 0.0 0.0 0.0 50.3 7.2 43.1 8.8 3.7 5.1
LPO 0.0 0.0 0.0 0.0 0.0 0.0 68.6 17.1 51.5 9.6 5.2 4.4
10 PA 0.0 1.2 -1.2 0.0 1.3 -1.3 5.0 0.0 5.0 3.0 0.0 3.0
LPO 0.0 1.0 -0.9 0.0 0.8 -0.8 11.0 0.8 10.2 4.6 0.0 4.5
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11 AP 0.0 0.0 0.0 0.0 0.0 0.0 8.5 29.2 -20.7 4.1 8.5 -4.4
RPO 0.0 1.2 -1.1 0.0 0.0 0.0 15.0 14.7 0.3 5.8 7.5 -1.7
12 PA 0.0 0.0 0.0 0.0 0.0 0.0 19.2 39.7 -20.5 5.4 9.3 -3.9
RPO 0.0 0.0 0.0 0.0 0.0 0.0 31.9 48.2 -16.4 8.3 10.5 -2.2
13 PA 0.2 0.0 0.2 0.0 0.0 0.0 14.8 33.8 -18.9 10.5 16.0 -5.5
LPO 0.0 0.0 0.0 0.0 0.0 0.0 35.1 43.4 -8.3 15.5 17.6 -2.1
14 PA 0.8 0.7 0.1 0.0 0.0 0.0 39.0 42.2 -3.1 19.5 26.4 -6.9
LPO 1.2 2.2 -1.0 0.0 0.0 0.0 42.6 37.5 5.1 22.9 30.7 -7.8
15 PA 0.0 0.1 -0.1 0.0 0.0 0.0 24.9 26.6 -1.7 6.5 9.1 -2.6
RPO 0.0 0.3 -0.3 0.0 0.0 0.0 59.0 27.7 31.3 8.5 8.4 0.1
16 RPO 3.2 2.2 1.0 1.9 1.1 0.8 9.2 5.8 3.4 5.1 3.6 1.5
LAO 0.7 1.9 -1.3 0.0 0.0 0.0 11.4 5.2 6.2 5.7 3.1 2.7
17 LPO1 0.0 0.3 -0.3 0.0 0.4 -0.4 18.0 15.2 2.8 7.0 8.8 -1.8
LPO2 0.1 0.5 -0.4 0.0 0.3 -0.3 19.1 12.6 6.5 16.8 16.8 0.0
18 AP 1.4 0.2 1.1 0.0 0.0 0.0 2.8 1.0 1.7 2.6 1.5 1.0
RAO 2.6 0.0 2.6 1.8 0.0 1.8 2.1 1.6 0.5 1.8 1.6 0.1
19 PA 0.0 0.0 0.0 0.0 0.0 0.0 6.1 28.7 -22.6 3.3 6.0 -2.7
RPO 0.0 0.0 0.0 0.0 0.0 0.0 18.8 46.6 -27.8 6.6 7.6 -1.1
20 RPO1 0.9 0.0 0.9 0.0 0.0 0.0 27.0 40.7 -13.6 17.0 13.9 3.1
RPO2 1.0 0.0 1.0 0.0 0.0 0.0 30.8 39.8 -9.0 17.1 13.2 3.9
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Table A.2: Variation in DVH statistics from planning to verification doses: dCT range-corrected and recalculated doses (DdCT-WET and DdCT), and rCT recalculated dose (DrCT).
PTV ∆V95%(%) iCTV ∆V99%(%) Heart ∆Dmax(Gy) Heart ∆V45Gy(%) Cord ∆Dmax(Gy)
PT# DdCT-WET DdCT DrCT DdCT-WET DdCT DrCT DdCT-WET DdCT DrCT DdCT-WET DdCT DrCT DdCT-WET DdCT DrCT
1 -3.0 -1.4 -3.1 -9.4 -10.7 -2.8 6.2 6.2 13.8 0.0 0.0 0.0 2.5 2.5 2.5
2 -0.3 -0.2 -0.6 -7.4 -6.3 -7.5 -1.4 -0.7 -0.8 5.6 5.5 9.8 6.9 6.5 3.6
3 -4.8 -5.7 -0.3 -27.4 -27.1 -13.4 0.0 -0.2 -0.4 -0.1 -0.2 -0.1 -0.2 0.0 1.3
4 0.1 0.0 -0.1 0.3 -0.6 -1.3 -0.3 -0.3 -0.1 -4.6 -4.6 -1.1 -4.2 -4.3 -0.2
5 -1.8 -1.1 -0.7 -1.4 -0.8 -0.6 -0.2 0.2 -0.1 0.5 0.8 1.0 -1.2 0.8 1.1
6 -0.2 -0.1 -0.3 0.2 0.0 0.2 3.4 5.4 9.4 0.0 0.0 0.0 3.0 3.3 1.0
7 -0.1 -0.4 -0.9 -3.6 -4.6 -7.4 -1.4 -1.1 -0.4 -0.3 -0.2 0.5 2.8 3.2 4.1
8 -1.0 -0.7 -3.2 -4.7 -3.0 -13.5 0.3 -0.1 -0.5 3.2 3.1 9.7 1.3 1.3 0.3
9 0.6 0.5 0.1 -2.0 -5.7 -0.2 -0.4 -0.5 -0.6 0.5 0.8 0.1 0.1 0.0 0.5
10 0.0 0.2 -0.6 0.4 -1.2 0.9 -0.5 -0.2 -0.1 -0.2 0.1 0.1 2.2 2.2 2.9
11 -0.2 0.0 -0.2 0.0 0.1 2.2 -0.5 0.3 -0.7 0.5 0.5 2.2 5.7 6.8 7.3
12 -0.2 -0.3 -0.1 0.2 0.0 -0.2 24.8 20.9 18.0 0.0 0.0 0.0 7.2 7.3 5.6
13 0.5 0.7 -0.1 3.1 1.4 -3.7 0.1 0.1 0.7 0.1 0.1 1.9 -2.0 -1.5 1.5
14 -0.6 -0.7 -0.8 -4.8 -7.4 -6.0 -0.9 -0.3 -0.2 0.7 0.9 1.2 -0.1 0.0 1.9
15 -0.1 0.0 -0.6 -5.8 -5.7 -1.0 -0.2 0.3 0.7 1.1 1.1 1.1 1.9 1.9 1.2
16 -0.7 -0.1 -0.1 1.4 1.4 1.9 2.9 1.5 1.8 -1.2 -0.8 0.6 10.9 11.4 4.9
17 -0.9 -0.1 -12.5 0.6 0.1 -5.0 -0.2 0.1 0.3 -0.7 -0.7 1.2 1.4 1.5 2.6
18 -0.9 -0.3 -0.1 -0.3 -0.6 0.2 -0.2 0.1 0.0 1.9 2.4 0.8 -7.4 -6.0 5.1
19 -0.2 0.1 0.0 0.6 -0.2 -1.3 1.9 2.3 0.8 0.0 0.0 0.0 1.1 1.2 1.5
20 -1.3 -1.2 -1.4 0.1 -2.6 -3.1 -0.8 1.4 -0.3 0.5 0.9 0.9 11.6 11.6 3.2
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Table A.3: Summary of the results obtained for clinical indicators extracted per patient for dCT and rCT: properties/limitations of the datasets, and analysis of the clinical indicators (correct
predictions and false positives/negatives).
PT corrected Properties and limitations of the Analysis of clinical indicators
# dCT (Y/N) dataseta Correct detections False negatives/positives
1 Y -dCT corrected for atelectasis;
-Differences in positioning be-
tween rCBCT and rCT (scapula)
-Significant under-ranging: WETunder-95% >10
mm (both fields)
-Significant over-ranging: WETover-95% >15 mm
(LPO2 field)
-2D WET difference maps: consistentb
-Dose to oesophagus: Dmax from 50 Gy to 71/71/68
Gy for DdCT-WET/DdCT/DrCT
-DVHs: loss of coverage and increase dose to oe-
sophagus
-Overestimation of loss of iCTV coverage: ∆V99%=-9/-
11/-3% for DdCT-WET/DdCT/DrCTc
2 Y -dCT corrected for tumour ero-
sion
-Differences in positioning be-
tween rCBCT and rCT (deforma-
tion of external contours)
-Significant over-ranging: WETover-95% >15 mm
(both fields)
-2D WET difference maps: consistent
-iCTV coverage: ∆V99%=-7/-6/-8% at
DdCT-WET/DdCT/DrCT)
-Dose to cord: Dmax from 45 to 52/52/49 Gy for
DdCT-WET/DdCT/DrCT)
-Dose to heart: V45Gy from 25% to 31/31/35% for
DdCT-WET/DdCT/DrCT)
-DVHs: loss of coverage and increase dose to
heart/cord
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3 Y -dCT corrected for lung reinfla-
tion
-Cropped contours (RPO field)
-Significant over-ranging: WETover-95% >15 mm
(both fields)
-2D WET difference maps: consistent
-iCTV coverage: ∆V99%=-27/-27/-13% for
DdCT-WET/DdCT/DrCT
-DVHs: overestimation of loss of coverage
4 N -Cropped contours (RPO field) -2D WET difference maps: consistent
-DVHs: no major changes
-Overestimation of over-ranging:
WETover-95%=15.6/10.6 (PA field) and 19.1/11.0
(RPO field) for dCT/rCTd
5 N -2D WET difference maps: consistent
-DVHs: no major changes
6 N -DVHs: no major changes -2D WET difference maps: inconsistent
7 N -Differences in positioning be-
tween rCBCT and rCT (position-
ing of pacemaker wires)
-iCTV coverage: ∆V99%=-4/-5/-7% for
DdCT-WET/DdCT/DrCT
-DVHs: loss of iCTV/PTV coverage
-Overestimation of loss of iCTV coverage: ∆V99%=-
27/-27/-15% for DdCT-WET/DdCT/DrCT
-2D WET difference maps: inconsistent
8 Y -dCT corrected for tumour
shrinkage
-Poor image quality (large
patient)
-2D WET difference maps: consistent
-DVHs: loss of iCTV/PTV coverage
-Overestimation of over-ranging:
WETover-95%=10.3/21.4 (ASO field) and 15.0/25.3
(PA field) for dCT/rCT
-Underestimation of loss of iCTV coverage: ∆V99%=-
5/-3/-14% for DdCT-WET/DdCT/DrCT
-Underestimation of dose to heart: V45Gy from
22% to 25/25/31% for DdCT-WET/DdCT/DrCT)
-DVHs: underestimation of dose to heart
9 N -Differences in positioning be-
tween rCBCT and rCT (scapula)
-2D WET difference maps: consistent (LPO field) -2D WET difference maps: inconsistent (PA field)
-Overestimation of loss of iCTV coverage:
∆V99%=-2/-6/0% for DdCT-WET/DdCT/DrCT
-DVHs: Overestimation of loss of iCTV coverage
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10 N -Differences in positioning be-
tween rCBCT and rCT (deforma-
tion of external contours)
-Differences in positioning between rCBCT and
rCT (deformation of external contours)
-2D WET difference maps: consistent
-DVHs: no major changes
11 N -2D WET difference maps: consistent
-Dose to cord: Dmax from 30 to 36/37/37 Gy for
DdCT-WET/DdCT/DrCT
-DVHs: no major changes
12 N -Differences in positioning be-
tween rCBCT and rCT (misalign-
ment external contours)
-2D WET difference maps: consistent (PA field)
-Dose to heart: Dmax from 1 to 26/22/19 Gy for
DdCT-WET/DdCT/DrCT
-DVHs: no major changes
-2D WET difference maps: inconsistent (RPO
field)
13 N -Differences in positioning be-
tween rCBCT and rCT (position-
ing of airways)
-2D WET difference maps: consistent
-Significant over-ranging: WETover-95% >15 mm
(LPO fields)
-DVHs: no major changes
-Underestimation of over-ranging:
WETover-95%=10.5/16.0 (PA field)
-Different predictions of tumours coverage
(∆V99%=+3/+1/-4% for DdCT-WET/DdCT/DrCT).
14 Y -dCT corrected for tumour
shrinkage
-Significant over-ranging: WETover-95% >15 mm
(both fields)
-2D WET maps: consistent
-iCTV coverage: ∆V99%=-5/-7/-6% for
DdCT-WET/DdCT/DrCT
-DVHs: loss of iCTV/PTV coverage
15 N -Cropped contours (RPO field)
-Differences in positioning be-
tween rCBCT and rCT (misalign-
ment external contours)
-Dose to heart: V30Gy from 10 to 14/14/14% for
DdCT-WET/DdCT/DrCT
-DVHs: increase in heart dose
-2D WET difference maps: inconsistent
-Overestimation of loss of iCTV coverage:
∆V99%=-6/-6/-1% for DdCT-WET/DdCT/DrCT
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16 N -Differences in positioning be-
tween rCBCT and rCT
-2D WET difference maps: consistent
-Dose to cord: Dmax from 35 to 46/47/40 Gy for
DdCT-WET/DdCT/DrCT
-DVHs: right shift of iCTV/PTV DVH curves
17 N -Cropped contours (LPO field) -2D WET difference maps: consistent
-Significant over-ranging: WETover-95% >15 mm
(LPO2 field)
-DVHs: no major changes
-Different predictions of tumours coverage iCTV
∆V99% =0/0/-5%)
18 N -2D WET difference maps: consistent
-DVHs: no major changes
19 N -Differences in positioning be-
tween rCBCT and rCT (scapula)
-DVHs: no major changes -2D WET difference maps: inconsistent
-Underestimation of over-ranging: WE-
Tover>3mm was 18.8/46.6% for dCT/rCT
(RPO field)
20 Y -dCT corrected for tumour
shrinkage
-Change in tumour density
-2D WET maps: consistent
-DVHs: target coverage loss
-Underestimation of loss of iCTV coverage:
∆V99%=0/-3/-3% for DdCT-WET/DdCT/DrCT
-Overestimation of dose to cord: Dmax from 27 to
39/39/30 Gy for DdCT-WET/DdCT/DrCT
a Only differences in setup that are in beam path are described.
b Consistency in 2D WET maps refers to similar topology of under/over-range location.
c Differences in ∆V99% are reported as false positives/negatives; however if the DVH curves did not show the same behaviour this was not considered a
failure of the method. ∆V99% was found to be a sensitive parameter. Such cases were highlighted in italic font.
d Large discrepancy in WETover-3mm/WETunder-3mm were reported as false positives/negative; however if the 2D WET maps were consistent this was not
considered a failure of the method. WETover-3mm/WETunder-3mm were found to be quite sensitive parameters. Such cases are were highlighted in italic font.
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Appendix B
Cell maintenance protocol
Material
• pipettes (5 and 10 mL)
• 75cm2 flask(s)
Reagents
• DMEM + 10% FBS + 1% P/S
• phosphate buffed saline (PBS)
Protocol
1. Warm up the reagents in a water bath (≈37◦).
2. Prepare all the material needed in the hood.
3. Remove the cells from the incubator and view cultures with a microscope to assess
the degree of confluency and confirm the absence of bacterial and fungal contami-
nants.
4. Pipette the entire medium from the flask.
5. Add ≈12 mL of fresh medium to the flask.
6. Ensure all cell surface is covered by the medium, and return the sample to the
incubator.
Cell maintenance protocol
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Appendix C
Cell subculture protocol
Material
• pipettes (5 and 10 mL)
• 75cm2 flask(s)
Reagents
• DMEM + 10% FBS + 1% P/S
• 1× Trypsen-ethylenediaminetetraacetic acid (EDTA)
• PBS
Protocol
1. Warm up the reagents in a water bath (≈37◦).
2. Prepare all the material needed in the hood.
3. Remove the cells from the incubator and view cultures with a microscope to assess
the degree of confluency and confirm the absence of bacterial and fungal contami-
nants.
4. Pipette the entire medium from the flask.
5. Wash the cells with 10 mL of saline solution, PBS. Do not pour directly on the cell
surface. PBS washing removes any remaining medium and associated proteins that
can neutralise the detaching enzyme. Repeat if there are any vestiges of the medium
left.
Cell subculture protocol
6. Add 3 mL of Trypsin-EDTA, a detaching enzyme. Although most cells will detach
in the presence of trypsin alone the EDTA is added to enhance the activity of the
enzyme. Ensure the whole surface is covered.
7. Leave in the incubator for 5 minutes.
8. Meanwhile, add 12 mL of medium to the flask(s) the cells are going to be passaged
to.
9. Examine the cells using an inverted microscope to ensure that all the cells are
detached and floating. The side of the flasks may be gently tapped to release any
remaining attached cells.
10. Add 7 mL of medium and gently mix with the pipette. The medium neutralises
the Trypsin, that when in contact with the cells for too long starts breaking the
membranes and killing them. The ratio of Trypsin:medium should always be at
least 2:1.
11. Transfer a fraction of the final solution (10 mL) to the new flask(s). At least 10% of
the original detached population must be passaged.
12. Store the flasks in the incubator, ensuring that the solution is homogeneously dis-
tributed in the surface.
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Appendix D
Cell counting protocol
Material
• haemocytometer
• pipettes (5 and 10 mL)
• Gilson pipettes (P20, P1000)
• universal tube (20 mL)
Reagents
• cell suspension
Protocol
1. Follow steps 1-11 of Protocol C to prepare the cell suspension.
2. Transfer the cell solution into a tube, and centrifuge (1500 rpm for 5 minutes). Do
not forget to balance the weight with a tube filled with approximately the same
volume of water.
3. Pipette the entire medium from the tube. Avoid disturbing the cell pellet by tilting
the tube slightly while removing all the media.
4. Re-suspend the cells in a fixed volume of medium (V=4-6 mL, depending on con-
fluence of the flask initially). Gently mix with the pipette, ensure the solution is
homogeneous.
5. Remove 10 µL from the solution and flood the haemocytometer chamber using a
Gilson pipette.
Cell counting protocol
Figure D.1: Squares of the haemocytometer used in cell counting.
6. Count in the microscope the number of cells in 4 of the 9 of the large squares of the
grid (Figure D.1). Average the number of cells counted (Ncount).
7. The total number of cells in suspension is given by:
Ncells = Ncount × Chaem × V (D.1)
Chaem is the conversion factor of the haemocytometer, and is the inverse of the
volume of each of the large squares. For the haemocytometer used in this work it
corresponded to a conversion factor of 104.
Example: If Ncount=250 and V=5 mL, then the solution contains a total of:
Ncells = 250 × 104 × 5 = 12.5 × 106 cells (D.2)
A dilution factor of the solution may also have to be considered if the cell suspension
was diluted in other volume, such as Trypan blue. Trypan blue is a vital stain used
to selectively colour dead tissues or cells blue, and is commonly used to check the
viability of the cells.
8. Centrifuge again the cell solution (1500 rpm for 5 minutes).
9. Pipette the entire medium from the tube.
10. Re-suspend the cells in the desired volume of medium (Vsuspension). For tumoroid
preparation, the amount of cells desired must be diluted in 0.4 mL of medium.
Considering that we want to include a total of Ntumoroid cells in the collagen gel, the
volume to re-suspend the cells in (Vsolution) is calculated by:
Vsolution =
0.4 mL
Ntumoroid
×Ncells (D.3)
Example: To produce a 4 mL gel with 6.4×106 cells using the previous example
solution (Ncells=12.5×106), the cells have to be re-suspended in:
Vsolution =
0.4 mL
Ntumoroid
×Ncells = 0.4 mL6.4 × 106 × 12.5 × 10
6 = 0.78 mL (D.4)
Note: HT29 cells by gravity action start to deposit at the bottom of the container
with time. Carefully re-suspend the solution (mix gently) before using it in any step
of the process. This ensures a homogeneous distribution of cells in solution.
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Appendix E
Collagen matrix preparation protocol
Material
• universal tube (20 mL)
• Petri dish
• ice container
• syringes (1 mL)
• needles (21 g)
• pipettes (2 mL and 5 mL)
• pipette tips (20 µL and 1 mL)
• Pasteur pipette
• autoclaved bag: mould and plunger, filter paper, glass slide, nylon meshes, steel
meshes, tweezers
• surgical scalpel
Reagents
• 10×MEM
• DMEM + 10% FBS + 1% P/S
• 1M and 5M NaOH (filtered and sterile – do not use if prepared more than 6 months
ago)
• cell suspension (Appendix D)
• collagen Type I
Collagen matrix preparation protocol
Figure E.1: Mould preparation for tumoroid production: filter paper, glass slide and mould. The plunger
should not be inside the mould at this point (it is in the figure just to be indicative of the orientation of the
mould). All the equipment must be autoclaved.
Protocol
1. Prepare all the materials in the hood. Store the collagen and the universal tube
inside an ice container.
2. Prepare the syringes for the pH neutralisation. Add a small volume (≈0.2 mL) of 5M
NaOH to one, and a larger volume (≈0.5 mL) of 1M NaOH to the other. Properly
identify each of the syringes by its content.
3. Prepare the mould (Figure E.1).
4. Pipette 0.4 mL of 10×MEM into the universal tube.
5. Pipette 3.2 mL of collagen type I solution into the universal tube. When handling the
collagen it is important to not introduce any air bubbles. Pour the collagen gently
against the tube wall, and mix the tube gently to ensure a homogenous yellow
colour throughout.
6. Neutralise the solution by adding 5M NaOH (filtered) dropwise into the collagen-
MEM solution until the colour changes from yellow to pink, and back to a light
orange. Keep the tube inside the ice container as much as possible.
7. Neutralise the solution by adding 1M NaOH dropwise into the collagen-MEM
solution until the colour changes from yellow to bright pink. Take care not to
over-neutralise the solution as the gel will not set otherwise.
8. Pipette 0.4 mL of cell suspension into the neutralised collagen solution. Mix gently
with the pipette tip, and by gently shaking the tube.
9. At this stage, take care that the collagen gel has already begun to set. Transfer the
4ml solution into the mould using the Pasteur pipette. To avoid bubbles do not
overfill the pipette and/or dispose of all its contents in one go. Always leave the last
drop on the pipette to check the gel setting.
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Figure E.2: Preparation of the meshes for tumoroid production: filter paper, steel mesh and nylon mesh.
All the equipment must be autoclaved.
10. Allow the collagen solution to become a gel by leaving for 30 minutes at room
temperature.
11. Prepare the material for plastic compression (Figure E.2). Place the steel mesh on
top of the filter paper and place the nylon mesh above the steel mesh. Always hold
the meshes in the corner to avoid contamination.
12. After the 30 minutes, place the meshes arrangement on top of the mould, and flip
over. From the side gently lift the glass slide, and hold the apparatus as a with both
hands from the sides. Only touch the meshes in the corner to avoid contamination.
Place the weight of the plunger (175g) within its slot for 30 seconds to compress the
gel.
13. Repeat compression on the other side of the gel.
14. Cut up the gel inside the Petri dish into 2 equal pieces (by eye). Place media on top
of the gels and store in the incubator.
15. Follow steps 4 to 8 to create an acellular hydrogels. Use 0.4 mL of DMEM instead of
cell suspension in the solution. Divide the acellular mixture into 2 containers, and
then place a piece of the ACM) within the hydrogel. Return to the incubator.
16. After the gels sets (≈20 minutes), place 1 mL of media directly on top and return to
the incubator. The media should be changed every 2 days.
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Appendix F
Mould re-design
The possibility to re-design the mould used to compress the gel was investigated for
two main reasons. First, the plastic compression process had to be optimised to achieve the
highest density, and the effect of the varying surface in absorbing water out was important
to be understood. Secondly, the samples produced with the old mould had anisotropic
dimensions, and a more suitable geometry was desired to maximise imaging contrast
due to system resolution. The aim of this experiment was to (i) evaluate if differences in
surface area negatively affect the plastic compression process and (ii) measure the final
volume and collagen density of the samples.
Different mould re-design strategies were considered (Figure F.1). All of the proposed
designs required new plunger(s), and had its own pros and cons.
1. New mould with two holes of varying surface. The main advantage of this design
is its simplicity and similarity with the old mould. It requires a new mould to be
made for the purpose of testing.
2. Modify old mould by adding a metal filler. The advantage of this method is to use
something already available, and just modify it to meet the testing needs. The cost
associated with building is therefore smaller. The simplest way to attach the filler
to the main body is using autoclave tape. However, several deficiencies occur with
this design. First, inserts have to be mounted and adhered to the main body before
autoclaving, adding risk to metal expansion and consequent difficulty in removing
the inserts later (the current mould can be split in two parts, which makes this a
solvable issue). The fillers would have to be made of heavy stainless steel, and tape
may not be strong enough to hold everything in place, making difficult the handling
of the device during plastic compression.
3. Design a mould with varying surface. The main advantage of this design is its
versatility; it could be used for a wide range of applications apart from imaging.
Therefore, it is more suitable as an end-point hardware, instead of a test equipment.
The additional material necessary will significantly increase its weight. Ergonomy
Mould re-design
is also reduced, as flipping might be difficult with the extras. To reduce problems
with autoclaving and expansion, the mould could open and close. Screws would
allow the system to be stable in any position chosen.
A simple experiment was designed to assess the usefulness of the mould re-design.
Moulds of different surface areas were used to prepare acellular collagen gels of different
dimensions. Since the main aim of this experiment was to check if the surface area
will affect the effectiveness of the plastic compression, and therefore exact optimum
radius cannot be predicted without knowing the compression achievable, design (a) was
manufactured since it was easy and fast to produce. It was built in aluminium because
of the easiness to handle this metal and it contained 2 circular holes with different radius
(8 and 12 mm). A circular shape was chosen to make the manufacture easier, since holes
could be easily drilled in the bulk material (Figure F.2). The values chosen for the hole size
were such that the surface area was approximately halved (and therefore height doubled).
This mould could not be autoclaved and was only used to produce non-aseptic sam-
ples. Two acellular tumoroids were prepared and compressed using the two holes of the
re-designed mould. The values of density measured (ratio between dry and wet weight)
were 2.19% and 1.91% for the larger and smaller surfaces, respectively. This provides
evidence that reducing the surface area impacted the final density of the construct, and
therefore in the imaging experiments described in this thesis the previously available
mould with additional load was used.
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Figure F.1: Mould re-design suggestions: (a) new mould with two holes of varying surface; (b) modifying
old mould by adding a metal filler; and (c) new mould with varying surface.
Figure F.2: Re-designed mould. Built in aluminium, it consisted of two circular holes with different radius
(8 and 12 mm).
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